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Abstract 
 
Toll-like receptor (TLR) signalling represents the first line of defence against 
infection. TLRs respond to recognition of pathogens by activating transcription 
factors such as NFκB and the interferon regulatory factors (IRF)s to induce pro-
inflammatory cytokines and IFNs. Whilst many of the components of the TLR signal 
transduction pathways have been identified, a full understanding of these complex 
regulatory systems remains to be delineated. This thesis probes the molecular, cellular 
and physiological roles of a protein termed evolutionary conserved signalling 
intermediate in toll (ECSIT) in innate immune signalling pathways.   ECSIT was 
initially described as a TRAF6 interacting protein that bridged the TLR signalling 
intermediate TRAF6 to MEKK1 and downstream activation of NFκB. Subsequent 
data revealed an important developmental role for ECSIT in the BMP signalling 
pathway based on the embryonic lethal phenotype in the ECSIT knockout mouse. 
Other studies have indicated an important role for ECSIT in bacterial killing during 
infection via the production of mitochondrial reactive oxygen species (mROS). To 
date no information on the human orthologue of ECSIT (hECSIT) has been available. 
In this study we describe novel functional roles for hECSIT in TLR signalling. 
Through use of knockdown studies and a humanised animal model we demonstrate 
that hECSIT negatively regulates innate immune signalling pathways despite its 80% 
sequence homology to mECSIT. We show that phosphorylation, ubiquitination and 
processing of hECSIT leads to an inhibitory C-terminal form that contains both E3 
ligase and DUB activity. We also demonstrate that hECSIT can independently target 
and regulate the ubiquitination of TRAF6, TRAF3 and RIP1 in TLR4/IL-1R, TLR3 
and TNF-α signalling, respectively. These findings identify hECSIT as a novel 
regulator of innate immune signalling and highlight a sophisticated evolutionary 
difference between two highly conserved proteins. 
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1.1 The Mammalian Immune System 
 
The mammalian immune system systematically eradicates infection through the 
cooperation of two components of immunity, innate and adaptive. The innate immune 
system consists of evolutionary conserved pattern recognition receptors (PRRs) that 
detect infection of micro-organisms and activate adaptive immunity. The adaptive 
immune system uses randomly generated, clonally expressed receptors with limitless 
specificity to clear infections (Medzhitov and Janeway, 1997). It is the combination of 
these two systems that make mammalian immunity extremely efficacious. 
PRRs detect the presence of microbial infection to activate the appropriate innate 
immune response (Akira et al, 2006). The elements of the innate immune system 
comprise of anatomical, humoral and cellular barriers to infection. Anatomical 
barriers include the skin, internal epithelial layers acting as physical barriers to 
infection and mucosal layers which provide protection against inhaled or ingested 
micro-organisms. Secretery fluids such as saliva, tears and sweat all act as deterrents 
for microbial infection. If these barriers are compromised in any way infection may 
occur which leads to acute inflammation. Humoral factors play important roles in the 
inflammatory process and they are constitutively present at the site of infection. The 
complement system is an important component of the innate immune system and can 
lead to enhanced vascular permeability, recruitment of phagocytes and lysis of 
bacteria (Morgan et al, 2005). 
The initiation of the inflammatory response results in the recruitment of many 
immune cells via the secretion of various chemo attractants. Neutrophils, 
macrophages, dendritic cells (DCs) and natural killer cells are recruited to the site of 
infection during inflammation. These immune cells serve as a link between adaptive 
and innate immunity by phagocytosing and presenting antigens to T and B cells of the 
adaptive immune system via the antigen presenting molecules MHC class I and II. 
Activation of the adaptive immune system relies on signals from the innate immune 
system in order to initiate the clonal expansion of antigen specific B and T cell 
lymphocytes which direct antibody and cellular immune responses. 
The innate and adaptive immune systems are ideal partners because of the 
differing strategies they employ to recognize infection which provides complementary 
advantages and disadvantages to the host (Palm and Medzhitov, 2009). Adaptive 
Chapter 1 General Introduction 
_____________________________________________________________________ 
13 
 
immunity uses random, diverse, clonally expressed receptors produced via somatic 
recombination of genes and therefore is highly effective in specifically targeting 
immune responses towards the infection which spares the surrounding uninfected host 
tissues. The innate immune system uses germ line encoded receptors to recognize 
invariant features of typical classes of microbes and is extremely efficient at 
distinguishing self from non-self (Janeway CA Jnr, 1989). However the non-clonal 
activation of the innate immune system has the potential to cause significant damage 
to self-tissues resulting in immunopathology, which is seen in autoimmune diseases 
such as arthritis, colitis and Lupus. As a result cells of the innate immune system are 
not able to detect every possible antigen; instead they have evolved to recognize 
highly conserved structural components of microbes that are not found in mammalian 
cells. These highly conserved structures are referred to as Pathogen Associated 
Molecular Patterns (PAMPs). It is the receptors of the innate immune system that 
recognize these PAMPs and trigger the first immune response to infection (Palm and 
Medzhitov, 2009). 
 
1.2 Pattern Recognition Receptors 
 
1.2.1Toll like Receptors 
Toll like receptors were the first PRRs to be identified and as a result have become the 
best characterized PPRs (Akira et al, 2006). TLRs are type 1 transmembrane proteins 
that contain leucine rich repeats that mediate recognition of PAMPs, a transmembrane 
region and a cytosolic Toll-IL1/R (TIR) domain that activates downstream signaling 
pathways. TLRs are expressed on the cell surface or associated with intracellular 
vesicles such as the endoplasmic reticulum, endosomes, lysosomes and 
endolysosomes (Blasius and Beutler, 2010).  To date 10 and 12 functional TLRs have 
been identified in human and mouse, respectively. Each TLR detects specific PAMPs 
derived from micro-organisms such as bacteria, viruses, mycobacteria, fungi and 
parasites. The different ranges of PAMPs recognized by TLRs are summarized in 
Table 1.1. TLR1, 2, 4, 5 and 6 are localized on the cell surface and largely recognize 
microbial membrane components whereas TLR3, 7, 8 and 9 are expressed within 
intracellular vesicles and recognize viral nucleic acids (Blasius and Beutler, 2010).  
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Upon TLR activation a specific set of adaptor proteins are recruited. These TIR 
domain containing proteins initiate downstream signaling events that lead to the 
production of pro-inflammatory cytokines, type 1 IFNs and chemokines (Kawai and 
Akira, 2010).  Currently there are five known TIR adaptor proteins, myeloid 
differentiation primary response protein 88 (MyD88), MyD88 adaptor like (MAL), 
TIR domain containing adaptor protein inducing IFN-β (TRIF), TRIF related adaptor 
molecule (TRAM) and sterile A and HEAT-armadillo motifs (SARM). The specific 
response elicited by each TLR depends on the recruitment of a single, or a specific 
combination of TIR domain containing adaptor proteins. MyD88 is utilized by all 
TLRs, with the exception of TLR3, and the IL-1R to transmit signals culminating in 
NFκB and MAP kinase activation.  TLR3 and TLR4 use the adaptor TRIF to activate 
a MyD88-independent pathway leading to the activation of NFκB and IRF3 and the 
induction of type 1 IFNs. It is on this basis that signaling through TLRs can be 
separated as MyD88-dependent or MyD88-independent.  
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Receptor Ligands Origin of ligands 
TLR1 
 
Tri-acyl lipopeptides 
Soluble factors 
Bacteria, mycobacteria  
Neisseria meningitides  
TLR2 
 
 
 
 
 
 
 
 
 
 
 
Lipoprotein/lipopeptides 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan 
A phenol-soluble modulin 
Glycoinositolphospholipids 
Glycolipids 
 Porins 
Zymosan 
Atypical LPS 
Atypical LPS 
LPS 
HSP70 
A variety of pathogens  
Gram-positive bacteria  
Gram-positive bacteria   
Mycobacteria   
Staphylococcus epidermidis   
Trypanosoma cruzi  
Treponema maltophilum  
Neisseria   
Fungi   
Leptospira interrogans  
Porphyromonas gingivalis 
Porphyromonas gingivalis  
Host  
TLR3 Double-stranded RNA Virus  
TLR4 LPS 
Taxol 
Fusion protein 
Envelope proteins 
HSP60 
HSP60 
HSP70 
Type III repeat extra domain A of 
fibronectin 
Oligosaccharides of hyaluronic acid 
Polysaccharide fragments of heparan 
sulfate 
Fibrinogen 
Gram-negative bacteria   
Plant   
RSV   
MMTV  
Chlamydia pneumoniae   
Host   
Host   
Host   
Host  
Host  
Host  
TLR5 Flagellin Bacteria  
TLR6 Di-acyl lipopeptides Mycoplasma  
TLR7 Imidazoquinoline 
Loxoribine 
Bropirimine 
Sigle-stranded RNA 
Synthetic compounds  
Synthetic compounds   
Synthetic compounds  
Virus 
TLR8 Imidazoquinoline 
Sigle-stranded RNA 
Synthetic compounds 
Virus 
TLR9 CpG DNA Bacteria  
TLR10 N.D. N.D. 
TLR11 Uropathogenic E.coli strains  
Profilin-like molecule 
Uropathogenic bacteria 
Table 1.1 Toll-like receptors and their ligands   
N.D.: not determined       (Adapted from Akira and Takeda, 2004) 
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1.2.2.1 MyD88 dependent signalling 
 
MyD88 contains a C-terminal TIR domain which enables it to bind to TLRs and 
an N-terminal death domain (DD) which allows MyD88 to bind other DD-containing 
proteins such as the IL-1 receptor associated kinases (IRAKs) (Dunne et al, 2009). 
TLR2 and TLR4 use MAL as an additional adaptor protein to recruit MyD88. 
Activated MyD88 interacts with IRAK4 which recruits and activates IRAK1 through 
phosphorylation. IRAK1 then phosphorylates itself and leads to the activation of 
TRAF6 (Moynagh, 2009) IRAK1 and 4 are also regulated by the Pellino protein 
family. The stimulation of IL-1R/TLR results in the interaction between Pellinos and 
IRAK1. This results in the phosphorylation of the Pellinos by IRAK which activates 
their E3 ligase activity and the subsequent ubiquitination of IRAK1 (Butler et al, 
2007). TRAF6 is oligomerized and ubiquitinated following activation by IRAK1. 
Ubiquitinated TRAF6 then recruits the transforming growth factor-β (TGF-β) 
activated kinase (TAK1) complex which is made up of TAK1 and its associated 
adaptor proteins TGF-β binding proteins  TAB1,2,3 (Mendoza et al, 2008) and the 
recently described TAB4 (Prickett et al, 2008). Activated TAK1 can then activate the 
inhibitor of Iκb kinase (IKK) complex, p38, c-jun N-Terminal kinase (JNK) and the 
Mitogen Activated Protein Kinase (MAPK) (Wang et al, 2001). The IKK complex 
consists of IKK-α and IKK-β, the two catalytic subunits and the regulatory subunit, 
Nuclear Factor Kappa B Essential Modifier (NEMO). NEMO is associated with 
TRAF6 and is capable of binding ubiquitin chains for stability of the IKK complex 
(Crosetto et al, 2006). The IKKs directly phosphorylate members of the inhibitory IκB 
family which normally sequester NFκB in an inactive form in the cytoplasm (Vi et al, 
1998). The phosphorylation of the IκB proteins represents a signal for 
polyubiquitination followed by their degradation by the 26S proteasome which 
enables the release of NFκB and its subsequent translocation to the nucleus 
(Medzhitov et al, 1997).  While most TLRs use the MyD88 signaling pathway, TLR3 
exclusively uses the MyD88-independent pathway. Interestingly TLR4 utilizes the 
MyD88-dependent and independent pathways to induce type 1 IFNs. 
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1.2.2.2 MyD88 Independent signalling  
 
TLR4 is the only TLR that can activate both the MyD88 dependent pathway and 
MyD88 independent pathway (Kawai et al, 1999). TLR4 activates both pathways by 
using four different adaptor proteins. Upon activation of TLR4 by its ligand LPS, it 
initially recruits Mal and MyD88, Mal localizes to the plasma membrane where it 
interacts with phosphatidylinositol 4,5-bisphosphate (PIP2) and serves as a bridge 
between MyD88 and TLR4 (Barton and Kagan, 2009). MyD88 then recruits IRAKs 
and TRAF6 to activate the TAK1 complex that results in the early phase activation of 
NFκB and MAP kinases (Kawai and Akira, 2010). TLR4 is then endocytosed and 
delivered to intracellular vesicles to form a complex with its other two adaptors TRIF 
and TRAM. TRAM, like MAL, acts as a bridge between TLR4 and TRIF. TRIF then 
recruits the protein kinases TBK1 and IKKε which catalyze the phosphorylation of 
IRF3 leading to the induction of type 1 IFNs (Barton and Kagan, 2009).  
TLR3 is the only TLR that is completely MyD88 independent and activation of 
TLR3 results in the recruitment of TRIF and subsequent activation of the kinases 
TBK1 and IKKε (Fitzgerald et al, 2003).  TRAF3 also functions in the TLR3 pathway 
to link TRIF and TBK1 (Saha et al, 2006). Receptor interacting protein 1 (RIP1) is 
also an important adaptor protein in TLR3 signaling and has been shown to be critical 
in the activation of NFκB by TLR3 via its interaction with TRIF (Meylan et al, 2003). 
Pellino 1 has also been implicated in TLR3 signalling via RIP1. Pellino1 E3 ligase 
activity is required for the ubiquitination of RIP1 to facilitate the downstream 
activation of NFκB. Pellino 1 deficient mice were shown to have impaired NFκB 
activation in response to TLR3 stimulation (Chang et al, 2009). MyD88 dependent 
and independent signalling is summarized in Figure 1.1. 
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Figure 1.1 MyD88 dependent and Independent signalling 
 
TLR4 engagement by LPS results in the recruitment of MYD88 and the rapid assembly of a large 
multiprotein complex at the cytoplasmic face of the plasma membrane. Complex formation results in 
TRAF6 activation and K63 ubiquitination of cIAP proteins, which enhances their K48-specific 
ubiquitin ligase activity towards TRAF3. Proteasomal degradation of TRAF3 results in cytoplasmic 
translocation of the MYD88-associated multiprotein complex, thereby allowing activation of TAK1, its 
downstream MAPKs and the eventual induction of pro-inflammatory cytokines and chemokines. 
Activated TLR4 also translocates to an endosomal compartment, and this is accompanied by the 
recruitment of TIR domain-containing adaptor protein inducing IFN-β (TRIF), TRAF3 and other 
proteins. Unlike the MYD88 complex, the TRIF-assembled complex does not contain cIAP and its 
formation results in the activation and K63 ubiquitination of TRAF3. This causes the activation of 
TBK1 and IKKε, which phosphorylate interferon regulatory factor 3 (IRF3) to induce the type I IFN 
response. TRIF-dependent signalling also leads to the activation of NFκB, JNK and p38, albeit with 
slower kinetics than MyD88 signalling (Adapted from Newton and Dixit, 2011). 
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1.2.2NOD like Receptors  
Nucleotide-binding oligomerization domains like receptor (NLR) proteins are a 
family of proteins with a wide range of functions in innate immune signaling. The 
NLR receptors are grouped based on their shared Nucleotide binding domain (NBD) 
and a leucine rich repeat (LRR) domain (Flavell et al, 2011). Two well-studied 
receptors in the NLR family that function in the antimicrobial response are NOD1 and 
NOD2. NOD1 and NOD2 are cytosolic receptors that recognize distinct building 
blocks of peptidoglycan, a polymer that consists of glycan chains cross linked via 
short peptides (Fritz et al, 2006). Both NOD1 and NOD2 are highly expressed in 
epithelial cells and antigen presenting cells such as Neutrophils, macrophages and 
dendritic cells (Kanneganti et al, 2007).  NOD2 expression is induced in response to 
TLR ligands such as LPS and by inflammatory cytokines such as TNF-α, IL-17 and 
IFN-γ (Flavell et al, 2011). NOD1 and NOD2 have been implicated in the recognition 
of different bacterial species such as Helicobacter Pylori (Viala et al, 2004), 
Clostridium difficile (Hasegawa et al, 2011), Legionella Pneumophilia (Berrington et 
al, 2010), Listeria monocytogenes (Boreca et al, 2007) and Staphylococcus. Aureus 
(Travassos et al 2005).  
 In contrast to the NOD proteins other members of the NLR group form 
signaling complexes which are known as ‘Inflammasomes’. The formation of an 
inflammasome results in the activation of Pro-Caspase 1 and the subsequent 
processing of Pro-IL1β and Pro-IL18 for secretion of their mature forms (Flavell et al, 
2011). The activation of the inflammasome is a two-step process. The first signal is 
required to activate the transcription of the genes encoding the precursor forms of 
IL1β and IL18 and is usually provided by TLR and NFκB signaling. The second 
signal is required for inflammasome assembly. However much debate still exists on 
the second signal. Danger signals such as mitochondrial DNA and mitochondrial ROS 
from defective mitochondria have been proposed as signals for IL-1 processing 
(Nakahira et al, 2011; Zhou et al, 2011) The inflammasome NLRs that function as 
sensors of exogenous and endogenous PAMPs and DAMPs include NLRP1, NLRP3, 
NLRC4 and AIM2 (Sutterwala et al, 2007).  
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1.2.3 RLRs (RIG-I like receptors) 
The RIG-I like receptors are a family of DExD/H box RNA helicases that 
function as intracellular sensors of PAMPs within viral RNA. The RLRs signal to 
downstream IRF transcription factors to drive type 1 IFN production (Gale et al 
2001). To date 3 RLRs have been discovered, RIG-I (Retinoic acid inducible gene 1), 
Mda-5 (Melanoma differentiation associated factor 5) and LGP2 (Laboratory of 
genetics and physiology 2). RLR expression is normally maintained at low levels in 
the cell. However upon IFN exposure and after viral infection the level of RLR 
expression is greatly increased (Kang et al, 2001). RIG-I and Mda5 recognize dsRNA 
viruses and their activation leads to the production of type 1 IFN. LGP2 is a helicase 
that can detect dsRNA but is unable to transmit a downstream signal and has been 
shown to function as a negative regulator of RIG-I and Mda5 (Thompson and 
Locarnini, 2007). 
RIG-I and Mda5 induce type 1 IFN production in response to viral infection via a 
common adaptor protein known as mitochondrial anti-viral signaling protein 
(MAVS).  The interaction of RIG-I and Mda5 with MAVS facilitates the recruitment 
of the RLRs to Mitochondria associated membranes where they initiate the 
downstream signaling events to form the MAVS signalosome to drive IFN production 
(Hiscott et al, 2006).  TRAF3 binds to the TRAF interacting motif (TIM) which is 
found in the Proline rich region of MAVS and recruits the IRF3 activating kinases 
TBK1 and IKKε (Hacker et al, 2006). More recently it has become evident that RLR 
signaling can be separated into two signaling pathways that results in IFNβ production 
and IL-1 and IL-18 maturity. The latter pathway results in the binding of RIG-I  to the 
adaptor ASC to activate Caspase 1 (Poeck et al 2010). 
Like TLR signaling, RLR signaling pathways are tightly regulated by a number 
of different mechanisms to prevent aberrant IFN production that can lead to immune 
toxicity or immune disorders. Post-translational modifications such as ubiquitination 
or deubiquitination of RLR pathway components are major regulators of the pathway. 
RNF135 is an ubiquitin ligase that interacts with RIG-I but not Mda5 (Oshiumi et al, 
2009). It is has been shown to mediate the conjugation of K63 linked polyubiquitin 
chains within its CARD domain at K154, K164 and K172 during viral infection. This 
modification has also been shown to stabilize the RIG-I and MAVS interaction to 
induce IFN production (Gack et al, 2008). RNF125 is another ubiquitin ligase that 
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utilizes the E2 enzyme UbcHSc to ligate K48 linked ubiquitin chains onto RIG-I, 
Mda5 and MAVS to initiate proteasomal degradation (Arimoto et al, 2007). RIG-I 
signaling is also negatively regulated by the ubiquitin editing enzyme A20 via its C-
terminal domain (Lin et al, 2006).  TRAF3 activity is also tightly regulated in RLR 
signaling. The E3 ligase Triad3a targets TRAF3 for degradation via K48 
ubiquitination during viral infection (Wakhaei et al, 2009).  TRAF3 is also regulated 
by OTUB1/OTUB2 (Li et al, 2010), DUBA (Kagayaki et al, 2007) and the IFN 
inducible gene FLN29 (Mashima et al, 2005) in an ubiquitination dependent manner. 
More recently the ubiquitin binding protein NEMO has been shown to negatively 
regulate RIG-I signalling when it is linearly ubiquitinated by the Linear Ubiquitin 
Assembly Complex  (LUBAC) (Belgnaoui et al, 2012).  
 
1.3 TNFR1 Signalling  
 
Inflammation is an essential component of innate immunity and the host response 
to infection. In response to viral or bacterial infection innate cells produce potent pro-
inflammatory cytokines such as TNF-α and IL-1ß which trigger the inflammatory 
response (Serhan et al, 2008).  TNF-α initiates a complex cascade of signaling events 
that lead to the induction of proinflammatory cytokines, cell proliferation, and 
differentiation or programmed cell death (Chen and Goeddel, 2002). The binding of 
TNF to its receptor TNFR1 leads to association of TNF-R1 associated death domain 
protein (TRADD) (Hsu et al, 1995) with the receptor complex  followed by 
recruitment of FAS associated death domain protein (FADD), TRAF2 and RIP1 (Hsu 
et al, 1996). Whilst FADD can trigger activation of Caspase 8 leading to cell 
apoptosis (Wilson et al, 2009), TRAF2 and RIP1 mediate the activation of NFκB and 
MAP kinase in response to TNF-α (Karin and Gallagher, 2009). The K63 and linear 
ubiquitination of RIP1 facilitates the recruitment of IKK complexes (Ea et al, 2006) 
and subsequent activation of NFκB. However this model has been challenged in a 
recent study that revealed RIP1 is not required for activation of NFκB in response to 
TNF-α (Wong et al, 2010).  The TNF pathway is heavily dependent on ubiquitination 
and until recently it was thought that K63 and K48 ubiquitination were the two 
linkages that regulated the pathway. Recent reports now show linear ubiquitination of 
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TNF components as a critical step in the activation of NFκB by TNF-α (Tokunaga et 
al, 2009; Tokunaga and Iwai, 2012; Ikeda et al, 2011) 
 LUBAC is recruited to the TNFR via ubiquitin chains that are attached to 
components of the TNFR1 signalling complex such as RIP1 and NEMO (Lo et al, 
2009). The recruitment of LUBAC results in the stabilization of the TNFR1 signalling 
complex (Haas et al, 2009) LUBAC consists of three components, the heme oxidized 
IRP2 ubiquitin ligase-1 (HOIL-1), HOIL-1 interacting protein (HOIP) and the newly 
characterized SHANK associated RH-domain interacting protein (SHARPIN) (Dixic 
et al, 2011; Iwai et al, 2011;Walczak et al, 2011). LUBAC is currently the only known 
E3 ligase that promotes the synthesis of head-to-tail linear linked chains and can use 
multiple E2 conjugating enzymes, such as UbcH5, E2-25 and UbcH7, to generate 
head-to-tail ubiquitin conjugates (Kirisako et al, 2006). HOIP has been shown to be 
the major contributor to LUBAC binding to ubiquitin chains (Haas et al, 2009) 
whereas SHARPIN and HOIL-1 mediate the ubiquitination of NEMO to activate the 
IKK complex and NFκB (Dixic et al, 2009). It has been suggested that ubiquitination 
of cIAPs, following TNF stimulation, leads to recruitment of LUBAC and linear 
ubiquitination of components of the TNFR complex leading to persistent activation of 
NFκB and inhibition of TNF induced cell death (Haas et al, 2009). The importance of 
the LUBAC complex in the TNF pathway has been highlighted through the use of 
HOIL-IL and SHARPIN knockout mice (Togunaka et al, 2009; Gerlach et al, 2011; 
Ikeda et al, 2011). However a mouse lacking all 3 LUBAC components has yet to be 
described and we thus await a full understanding of the function of the LUBAC 
complex in the TNF pathway. K11 polyubiquitination has also been described in TNF 
signaling (Dynek et al, 2010), which suggested that K11 linked chains play a role in 
signal transduction as well as degradative signals  in cell cycle regulation (Kirkpatrick 
et al, 2000). The E3 ligase cIAP1 facilitates the K11 linked ubiquitination of RIP1 in 
TNFR1 signalling (Dynek et al, 2010).  
As mentioned the activation of the TNFR1 can also lead to programmed cell 
death. Ligand binding to the TNFR triggers the assembly of the death-inducing 
signaling complex (DISC) (Guicciardi and Gores, 2009). Recruitment of the adaptor 
FAS-associated DEATH domain protein (FADD) or TNFR1 associated DEATH 
domain protein and Caspase 8 leads to DISC formation. Caspase 8 is activated and the 
death domain signal is amplified by the subsequent proteolytic activation of the 
downstream effector caspases 3 and 7 which culminates in apoptotic death (Wertz et 
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al, 2011). In the presence of cIAP proteins TNFR1 predominantly activates canonical 
NFκB and MAPK proinflammatory and cell survival whilst the absence of cIAP 
proteins transforms TNF-α into a pro-apoptotic ligand (Bertrand et al, 2008). In the 
absence of cIAPs RIP1 is not ubiquitinated and can associate with FADD and Caspase 
8 to form a secondary death promoting signalling complex that dissociates from the 
receptor (Peterson et al, 2007). Alternatively and independently  of Caspase 8 activity, 
non-ubiquitinated RIP1 can bind to RIP3 to promote programmed necrosis or 
necroptosis (Vandenabeele et al, 2010). This form of cell death relies on the kinase 
activity of RIP1 and RIP3 (Cho et al, 2009). 
Like TLR signalling the TNFR1 pathway is also heavily regulated in a 
ubiquitin-dependent manner. A20 participates in a negative feedback loop to attenuate 
TNF-α induced NFκB activation (Krikos et al, 1992). The A20 signalling complex 
targets RIP1 for deubiquitination and degradation in a unique system via two different 
domains. A20 first removes K63 chains from RIP1 via its OUT DUB domain and 
promotes the addition of K48 chains on RIP1 via its zinc-finger-4 motif (Wertz et al, 
2004). A20 carries out its dual ubiquitin editing function via its interaction with the 
A20 complex proteins, Tax1bp1, RNF11, Itch and the ABIN-1. RNF11 is required for 
the association between RIP1 and A20 and interacts with Tax1bp1 and A20 in a TNF-
α dependent manner (Shembade et al, 2009). An important PPxY motif in RNF11 is 
required for the formation of the A20 signalling complex and for termination of NFκB 
signalling. ABIN-1 was initially described in a yeast-2-hyrid screen as an A20 
interacting protein (Heyninck et al, 1999). ABIN-1 serves as an adaptor molecule 
between A20 and NEMO to facilitate its deubiquitination (Mauro et al, 2006). 
Similarly to the A20 complex the DUB CYLD has been shown to form a complex 
with the A20 complex protein Itch, through critical PPxY motifs  to negatively 
regulate the TNF pathway via the deubiquitination and K48 ubiquitination of TAK1 
(Ahmed et al, 2011). CYLD has also been shown to deubiquitinate RIP1 (Vucic et al, 
2011). However the exact role of CYLD in RIP1 deubiquitination remains unclear as 
CYLD deficient cells have revealed no difference in TNF-α induced RIP1 
ubiquitination (Zhang et al, 2006). However CYLD has been shown to be required for 
programmed necrosis (O’Donnell et al, 2012). Also CYLD deubiquitinates linear 
ubiquitin chains and may play a role in regulating LUBAC (Haas et al, 2009). A 
schematic representation of the TNF pathway is summarised in Figure 1.2. 
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Figure 1.2 TNFR1-elicited signalling pathways.  
A. In response to TNF-stimulation, RIP1 is recruited to TNFR and forms a membrane associated 
complex I with TRADD, TRAF2/5 and cIAP1/2, which in turn leads to polyubiquitination of RIP1 and 
pro-survival NFκB activation. B. when RIP1 is not ubiquitinated by A20 or CYLD, deubiquitination of 
RIP1 leads to the formation of cytosolic DISC with FADD and caspase-8. Activation of caspase-8 in 
DISC leads to apoptosis induction. During apoptosis, RIP1 is cleaved and inactivated by caspase-8. C. 
In conditions where caspases are blocked or cannot be activated efficiently, RIP1 binds to RIP3 leading 
to necrosis. (Adapted from Murakami, 2011). 
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1.4 NFκB 
  
In innate immune signaling NFκB is activated via two distinct pathways 
termed the Canonical or Classical NFκB pathway or the non-canonical or non-
classical pathway. The canonical NFκB pathway is activated by most TRAF 
dependent signaling pathways whereas the non-canonical pathway relies on activation 
by a set of TNFRs such as CD40 and BAFFR and the Lymphotoxin-β-receptor 
(LTβR).  The classical NFκB pathway regulates the expression of a number of target 
genes that function in immune responses, cell survival and inflammation. The non-
canonical pathway is mainly involved in the in the regulation of lymphoid organ 
development, adaptive immune responses and B-cell survival (Bonizyei et al, 2004). 
 The NFκB family of transcription factors consists of NFκB1 (p50 and its 
precursor p105), NFκB2 (p52 and its precursor p100), p65, c-Rel and Rel-B, all of 
which contain an N-terminal Rel homology domain (RHD) which mediates homo and 
heterodimerization as well as sequence specific DNA binding. p65, c-Rel and Rel-B 
also contain a C-terminal transcription activation domain (TAD) whereas p52 and p50 
subunits do not and rely on other factors to positively regulate transcription (Hayden 
and Ghosh, 2008). Rel-B preferentially dimerizes with p100 and its processed form 
p52 (Senfitleben et al 2001). P65 and c-Rel heterodimerize with p50 (Karin et al, 
2000).  
 The inhibitors of NFκB, the IκB proteins sequester IκB dimers in the 
cytoplasm of resting cells. The IκB proteins consist of IκB-α, IκB-β and IκB-ε (Karin 
et al, 2009). The IκB proteins are characterized based on the presence of multiple 
ankyrin repeats that mediate binding to NFκB dimers. A number of post-translational 
modifications at different sites on the dimers including phosphorylation and 
acetylating further modulate DNA binding and transcriptional activities (Perkins, 
2006). The three major IκBs undergo signal-induced proteasomal degradation 
(Hoffman, 2002). IκB-α is degraded in response to pro-inflammatory stimuli such as 
LPS and TNF-α. Following degradation and subsequent translocation of the NFκB 
dimers a negative feedback loop induces de novo synthesis of IκB-α to enter the 
nucleus and associate with de-acetylated p-65: p50 dimers and shuttle them back into 
the cytoplasm (Chen et al, 2001). The degradation of the IκB proteins is an essential 
step in the activation of NFκB and is facilitated by the IKK complex as described 
previously. 
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1.5 MAP Kinases  
MAPK pathways exist in all eukaryotic cells, regulating cellular activities 
from proliferation, differentiation, development and transformation to apoptosis. 
There are 3 extensively studied groups of mammalian MAPKs including the Extra 
Cellular Signal-Regulated Kinase (ERK), JNK/SAPK and p38 MAPK. In general, 
ERK1 and ERK2 are activated in response to growth factors and phorbol esters and 
function in regulating meiosis, mitosis, and post-mitotic processes in differentiated 
cells (Jonhson and Lapadat, 2002). The JNK and p38 kinases are more responsive to 
stress stimuli such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock 
and are involved in cell differentiation and apoptosis (Chen et al, 2009). Each family 
of MAPKs is composed of a set of three evolutionarily conserved kinases, which are 
activated in series: a MAPK, a MAPKK (MAPK kinase) and a MAPKKK (MAPKK 
kinase). To date, at least 14 MAPKKKs, 7 MAPKKs, and 12 MAPKs have been 
identified in mammalian cells (Widmann et al, 1999). Stimuli from outside the cell 
initiate the cascade in which MAPKKK phosphorylates and activates a dual-
specificity protein kinase (MAPKK) that, in turn, phosphorylates and activates a MAP 
kinase. MAPK signalling is summarised in Figure 1.3. 
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Figure 1.3 MAP Kinase Activation by innate immune receptors  
Activation of TLRs, IL-1R and TNFR initiate the MAPK cascade in which MAPKKK phosphorylates 
and activates a dual specificity protein kinase (MAPKK) that, in turn. Phosphorylates and activates a 
MAPK. The MAPK cascade is determined by the substrate selection. (Adapted from Symons et al, 
2006) 
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1.6 Interferon Regulatory Factors (IRFs) 
 
 The activation of PRR pathways can also lead to the activation of the 
Interferon regulatory factors (IRFs) family of transcription factors.  To date nine IRFs 
have been identified in humans (Taniguchi et al, 2001). IRFs are involved in the 
regulation of cell cycle, apoptosis and tumour suppression; however they are best 
known for their roles as drivers of type 1 IFN expression that is essential in the innate 
anti-viral response (Honda et al, 2006).  
 IRF3 and IRF7 to date have been the most intensely studies members of the 
IRF family and have key roles in initiating the transcription of the type 1 IFNs, IFN-α 
and IFN-β in response to viral infection.  Activation of IRF3 and IRF7 is mediated by 
the phosphorylation of C-terminal serine residues by the two IKK related kinases 
TBK1 and IKKε (Fitzgerald et al, 2003).  IRF3 primarily activates the IFN promoter 
in tandem with other transcriptional factors such as NFκB. Once IFN-β is produced it 
subsequently activates the IFN pathway which results in the formation of IFN-
stimulated gene factor 3 (ISGF3). ISGF3 in turn induces the expression of IRF7 
which is then subject to phosphorylation in a similar manner to IRF3 (Moynagh, 
2005).  Plasmacytoid Dendritic cells (pDCs) are specialized at producing extremely 
high levels of type 1 IFNs in response to viral challenge (Liu et al, 2005). pDCs are 
unique in expressing high basal levels of IRF7 and this facilitates high induction of 
type 1 IFNs following stimulation of TLR7, 8 and 9 (Honda, 2005).  
 
 
1.7 Ubiquitination 
  
Ubiquitination is a post-translational modification that results in the 
attachment of 8kDa ubiquitin proteins, in a variety of lengths and conformations to 
regulate cell signaling (Picart and Fushmann, 2004). The process of ubiquitination is 
now recognized as an important regulator of processes such as cell cycle progression, 
apoptosis, cell proliferation, signal transduction and DNA damage responses (Taylor 
and Jobin, 2005). Ubiquitination occurs in a three step process catalyzed by three 
different enzymes E1, E2 and E3. The E1 enzyme first activates the ubiquitin 
molecule by covalent attachment to the ubiquitin moiety via a thiol-ester bond. The 
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activated ubiquitin can then be transferred to an E2 ubiquitin conjugating enzyme. 
The E2 enzyme-ubiquitin complex can then interact with an E3 ubiquitin ligase that 
facilitates the transfer of the ubiquitin protein to a lysine residue on the target protein. 
There are 2 known E1 enzymes that activate ubiquitin molecules for virtually all 
mammalian ubiquitination events. Approximately 38 E2 enzymes are predicted to 
exist and over 600 E3 ligases (Ye and Rape, 2009). E3 ubiquitin ligases confer 
substrate specificity to the ubiquitin reaction by binding to and transferring the 
ubiquitin molecule to the substrate protein. The ubiquitination process is summarized 
in Figure 1.4. 
 Ubiquitination can occur in multiple forms including mono- and 
polyubiquitination. Mono-ubiquitination occurs when a single ubiquitin protein is 
attached via its C-terminal glycine residue to a lysine residue of a target protein. 
Polyubiquitination occurs when ubiquitin chains are formed by the sequential 
attachment of ubiquitin proteins to other ubiquitin molecules resulting in the 
formation of ubiquitin chains (Terzic et al, 2007). Ubiquitin contains 7 lysine residues 
(K6, K11, K27, K29, K33, K48 and K63) that can be targeted for further 
ubiquitination with the lysine linkage being important for dictating the function of the 
polyubiquitination process.  Furthermore N-terminal amino group of ubiquitin can 
also be targeted by the C-terminal glycine of another ubiquitin thus forming distinct 
linear chains (Komande et al, 2009).   
K48 polyubiquitin chains facilitate proteasomal degradation to terminate 
signaling whereas K63-linked chains regulate the activation of pro-inflammatory 
signaling (Zhou et al, 2003). More recently ubiquitin linkages such as K11 (Vucic et 
al, 2010) and K27 (Zotti et al, 2011) and linear ubiquitination (Ikeda et al, 2011), 
(Gerlach et al, 2011) have been highlighted as important linkages in the regulation of 
innate immune signaling.  
 The removal of ubiquitin residues from substrate proteins is another important 
regulatory process and is carried out by a number of de-ubiquitnating (DUBs) 
enzymes. DUBs are cysteine metalloproteases that hydrolyze the amide bond after the 
glycine 76 residue of ubiquitin (Glickman, 2002). There are approximately 100 DUBs 
encoded in the human genome (Skaug and Chen, 2009), subdivided into five families 
based on specific structural domains: ubiquitin C-terminal hydrolases (UCHs), 
ubiquitin-specific proteases (USPs), ovarian tumorproteases (OTUs), Josephins, and 
JAB1 ⁄MPN⁄MOV34 metalloenzymes (JAMMs) (Nijman et al, 2009). The UCH, 
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USP, OUT, and Josephin. DUBs are cysteine proteases, whereas JAMMs are zinc 
metalloproteases (Cope et al, 2002). 
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Figure 1.4 Ubiquitination system 
 
Ubiquitination of a target protein is carried out by an enzymatic cascade comprised of E1, E2 and E3. 
E1 is a ubiquitin activating enzyme, activated ubiquitin is then transferred to a conjugating enzyme, E2, 
which in conjunction with an E3 ligase conjugates ubiquitin onto a lysine residue of the target protein. 
Poly-ubiquitin chains can be formed on target proteins by addition of subsequent ubiquitin proteins 
through one of seven lysine residues on the ubiquitin itself. (Adapted from Taylor and Jobin, 2005) 
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1.8 TRAF Proteins 
  
TRAF proteins function as adaptors in innate immune signaling pathways and 
mediate responses to a large range of innate receptors such as TLRs, RLRs and 
TNFRs. Apart from their role as signaling adaptors TRAF proteins also serve as E3 
ligases, a function which is extremely important for downstream signaling events and 
the activation of NFκB and the IRFs. TRAF1 and TRAF2 were initially identified 
based on their interaction with TNFR2 and their C-terminal region (TRAF domain) 
became the hallmark feature of the TRAF family (Rothe et al, 1994). Most TRAFs 
with the exception of TRAF1 share a N-terminal domain that consists of several zinc 
finger domains and an N-terminal RING domain. The RING domain is a common 
domain found in many E3 ubiquitin ligases and RING domain mediated protein 
ubiquitination has emerged as a key mechanism in TRAF dependent signal 
transduction (Bhoj and Chen, 2009). TRAF proteins can generate both K48 and K63 
linked ubiquitin chains however to date only the direct generation of K63 chains by 
TRAF proteins in conjunction with the E2 enzyme Ubc13-UeV1a has been 
demonstrated in vitro (Zeng et al, 2009). Currently there are seven known proteins in 
the TRAF family, TRAF1-7 with TRAF3 and TRAF6 being especially relevant for 
the present study. 
  
1.8.1 TRAF3 
TRAF3 was originally described as a CD40 receptor interacting protein but 
unlike TRAF2, 5 and 6 it inhibits CD40-mediated activation of NFκB (Chen et al, 
1995). Pattern recognition via different receptors such as TLRs and cytoplasmic RLRs 
results in the production of type 1 IFNs. Both receptor families use TRAF3 in order to 
induce the production of IFN-α and IFN-β. The TIR adaptors Myd88 and TRIF 
interact with TRAF3 to activate IRF3 and IRF7 to facilitate the transcription of IFN-α 
and IFN-β (Kawai and Akira, 2008).  
TLR4 activation by LPS leads to the TRIF dependent K63 ubiquitination of 
TRAF3 in the endosome thus triggering  activation of TBK1 and IKKε and resulting 
in phosphorylation and activation of  IRF3 (Hacker and Karin, 2006). Mutational 
analysis of the TRAF3 RING domain resulted in loss of TRAF3 ubiquitination and its 
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ability to induce type I IFNIFN (Tseng et al, 2009). TRAF3 is also an important 
adaptor protein in TLR3 signaling. This was highlighted in a recent study that 
revealed a loss of function mutation in patients (R118W) which resulted in impaired 
IFN production to viral infection (Perez de Diego et al, 2010). In addition to TLR 
signaling TRAF3 also plays a role in RLR induced IFN production. Following ligand 
stimulation of RIG-I or Mda5 TRAF3 binds directly to MAVS which results in K63 
linked ubiquitination of TRAF3 and subsequent recruitment of the IRF3 activating 
kinase TBK1 (Paz et al 2011). 
 The activation of TLR4 results in the degradation of TRAF3 which is 
facilitated by the K48 ubiquitination of TRAF3 by cIAP1. When TRAF3 is degraded 
it releases TAK1 and the MAP kinase pathway is activated (Tseng et al, 2009).The 
ability of TRAF3 to positively regulate IFN production and negatively regulate P38 
and JNK activation is attributed to the compartmentalisation of the activated TLR 
complex. TRAF3 dependent activation of the IFN response is initiated by signaling 
complexes that are assembled by the adaptor TRIF at an endosomal location. 
Signaling complexes assembled by MyD88 are located at the plasma membrane. In 
the endosome TRAF3 is able to positively regulate the production of type 1 IFN 
however at plasma membrane locations TRAF3 negatively regulates MAP kinase 
signaling by sequestering TAK1 (Barton et al, 2009).  
 In addition to the negative regulation of the MAP kinases TRAF3 also 
functions as a negative regulator of non-canonical NFκB activation. TRAF3 is 
constitutively bound to NIK in resting cells. Following stimulation of the non-
canonical pathway TRAF3 is degraded which results in the accumulation of NIK 
(Xiao et al, 2004). The increase in free NIK results in its autophosphorylation leading 
to IKK-α activation and the processing of p100 (Cheng et al, 2008). This mechanism 
has been highlighted in TRAF3 -/- B-cells which contain high levels of NIK and 
exhibit constitutive p100 processing which can be rescued in a TRAF3 NIK double -/- 
(Gardam et al, 2008).  Further investigation also revealed a role for cIAPs and TRAF2 
in the regulation of NIK by TRAF3. These roles were first highlighted in experiments 
showing that  over expression of cIAP leads to NIK degradation and this was 
dependent on the RING domain and the TRAF2 interacting motif of cIAP 
(Verfolomeev et al, 2007).  This suggested that TRAF2-dependent cIAP activation is 
required for NIK ubiquitination. It was later shown that TRAF3 acts a molecular 
bridge between cIAP and NIK (Vallabhapurapu et al, 2008) facilitating persistent K48 
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ubiquitination and degradation of NIK in unstimulated cells. Following stimulation of 
the cell with LPS cIAP1 is K63 ubiquitinated by TRAF2, causing cIAP1 to promote 
K48 ubiquitination and degradation of TRAF3 Newly synthesized NIK is then no 
longer able to interact with the cIAP-TRAF2 complex and is free to 
autophosphorylate and activate the IKK complex and trigger non-canonical activation 
of NFκB (Zarnegar et al, 2008).  
 
1.8.2 TRAF6 
 
TRAF6 is one of the most divergent members of the TRAF family sharing 
only a 30% sequence homology of its C-terminal TRAF domain with TRAFs 1-5. 
TRAF6 is an essential activator of the IKK complex and JNK in Toll/IL-1R signaling. 
It is a well characterized E3 ubiquitin ligase, is activated following oligomerization 
and promotes activation of TAK1 (Ninomiya-Tsuji et al, 1999). TRAF6 utilizes the 
E2 ubiquitin conjugating enzyme Ubc13-Uev1a to catalyze the formation of K63 
linked polyubiquitin chains on target proteins (Kenny et al, 2007). TRAF6 has also 
been reported to play a role in TRIF mediated activation of NFκB (Sasai et al, 2010). 
However other studies have concluded that TRAF6 is dispensable for TLR3 signalling 
(Jiang et al, 2004). Such a discrepancy in relation to the role of TRAF6 may be due to 
cell specific roles for TRAF6 and/or functional redundancy of TRAF6 with other 
members of the TRAF family (Sato et al, 2003). TRAF6 has also  been implicated in 
mitochondrial reactive oxygen species production (mROS) via its E3 ligase activity 
(West et al, 2011). Like TRAF3, TRAF6 is heavily regulated in a ubiquitin dependent 
manner. Following pathway activation TRAF6 is subject to regulation by 
deubiquitinating enzymes such as A20, Cezanne and OTUB1/2 (Dixit and Harhaj, 
2012).  
As previously discussed A20 can regulate TNF-induced NFκB activation via 
its interaction with RIP1 however A20 can also regulate TRAF6 through 
deubiquitination. A20 removes K63 chains from TRAF6 via its N-terminal domain 
resulting in the inhibition of signal transduction (Boone et al, 2004). This is further 
highlighted in A20-deficient MEF cells that exhibit persistent LPS induced TRAF6 
ubiquitination (Shembade et al, 2010). In a similar manner the deubiquitinating 
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activity of the A20 like proteins  Cezanne (Evans et al, 2001)  and OTUB1/2 (Li et al, 
2009) also facilitate the removal of K63 chains from TRAF6 to inhibit signaling.  
 
1.9 Evolutionary Conserved Signalling intermediate in Toll (ECSIT) 
 
 In 1999 Kopp et al used murine TRAF6 as a bait in a yeast two-hybrid screen 
and reported the identification of a novel interacting protein  termed ECSIT.  Murine 
ESCIT was shown to positively regulate NFκB via an interaction with TRAF6 which 
enhanced the processing of MEKK1. Furthermore, over expression studies showed 
that mECSIT alone, can induce the activation of NFκB, whilst a dominant negative 
mutant inhibited NFκB activation by IL-1R and TLR pathways. The authors also 
demonstrated that Drosophila ECSIT (dECSIT) had a role in the insect immune 
system. dECSIT was found to bind to dTRAF6 and induce the production of 
antimicrobial peptides, defensin and attacin, therefore demonstrating that ECSIT is 
evolutionary conserved. 
To further characterize the physiological role of mECSIT in innate immune 
signaling, null mutant mice were generated (Xiao et al, 2003). However Ecsit -/- 
embryos died in utero due to the absence of mesoderm formation, a phenotype that 
mirrored the Bmpr1-/-.  The deletion of mECSIT prevented the expression of Bmp 
target genes and blocked embryonic development at the beginning of gastrulation. 
The resulting study demonstrated that ECSIT is an important intermediate of Bmp 
signaling. The embryonic lethality of mECSIT -/- mice prevented further 
characterization of the in vivo role of ECSIT in innate immunity. In an attempt to 
further understand the role of ECSIT Xiao et al used a complementary approach to 
knock down the expression of ECSIT using short hairpin RNA. From this it was 
revealed that suppression of endogenous mECSIT resulted in impaired LPS induced 
NFκB activation. 
 In addition to these described roles in TLR and BMP signaling pathways a 
subsequent report described a mitochondrial role for ECSIT. Vogel et al showed that 
a 45kDa splice variant of ECSIT contains an essential N-terminal targeting signal that  
recruits ECSIT to the mitochondria where it interacts with the chaperone NDUFAF1 
to facilitate the assembly and stabilization of the mitochondrial complex I. Complex I 
is one of five enzymatic complexes that are part of the oxidative phosphorylation 
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system, important for the generation of ATP from NADH and FADH2 (Janssen et al, 
2006). Knock down of ECSIT by siRNA resulted in decreased NDUFAF1 and 
complex I protein levels (Vogel et al, 2007). 
A more recent study  further implicated mECSIT as an important mediator of reactive 
oxygen species (ROS) production from the mitochondria in response to TLR1, 2 and 
4 activation (West et al, 2011). Upon stimulation of the surface receptors TLR1, 2 and 
4, production of mitochondrial ROS (mROS) was triggered. This was mediated by the 
interaction of TRAF6 and mECSIT signaling at the surface of the mitochondria. 
These data was supported by an earlier study that identified a role for ECSIT in 
oxidative phosphorylation complex I assembly in the mitochondria (Nouws et al, 
2010).  It was also noted that mECSIT had no role mROS production in response to 
endosomal TLR ligands and TNF-α. The role of ECSIT has mainly been described in 
the context of the mitochondria and contains an N-terminal mitochondria localization 
sequence which is required for its positive role in mitochondrial ROS production. 
Furthermore constructs lacking this N-terminal localization sequence exhibit a 
dominant negative effect and inhibit mitochondrial ROS production during TLR 
signalling (West et al, 2011). However no other information on different functional 
protein domains has been shown.  
To date no characterization of hECSIT has been reported. The hECSIT gene 
had subsequently been cloned by the Molecular Immunology lab in NUI Maynooth  
and preliminary characterization of its role in TLR signaling had been undertaken. 
Human and murine forms of ECSIT share a sequence homology of 80% (Figure 1.5). 
Interestingly hECSIT was shown to negatively regulate TLR-induced activation of 
NFκB and this was associated with its ability to decrease the level of ubiquitinated 
TRAF6 (Nezira Delagic PhD thesis, 2011). This contrasted with the earlier described 
positive role of mECSIT in the NFκB pathway. Functional differences between 
evolutionary conserved protein are not without precedent with many observed 
differences between murine and human immune systems including differential 
expression of some TLRs (Masters and Hughes, 2004) and specificity for exogenous 
ligands including the TLR7/8 ligand CpG. 
  This thesis aims to build on the earlier findings from this lab and further 
investigate the role of hECSIT in innate immune signalling pathways.  
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Figure 1.5 An alignment of the amino acid sequences of human and murine ECSIT 
 
Sequence identity is represented by black shading and sequence similarity by grey shading. 
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1.10 Project Aims 
 
 
 
The specific aims of this study were to: 
 
• Explore the molecular basis to the effects of  hECSIT in innate immune 
signalling pathways 
• Characterise the regulatory pathways that control hECSIT function 
• Characterise the role of hECSIT in TNF- signalling 
• Characterise the role of  hECSIT in anti-viral signalling 
• Generate hECSIT knock-in mouse to characterise the physiological role of 
hECSIT  
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2.1 Materials 
 
2.1.1 Reagents 
 
Reagents Supplier 
Agar Sigma 
Agarose Promega 
Agarose, low melting point Sigma 
Ampicillin Sigma 
APS Sigma 
Bovine serum albumin (BSA) Sigma 
Bradford reagent dye Bio-Rad 
Bromophenol blue Sigma 
Chloroform Sigma 
Clonables™ 2X Ligation Premix Merck 
Coomassie Blue (G250) Sigma 
Cycloheximide (CHX) Sigma 
DAB (3,3'-Diaminobenzidine) Vector Labs 
DAPI (4',6-Diamidino-2-Phenylindole) Sigma 
DEPC (diethylpyrocarbonate)-treated water Ambion 
D-galactosamine (D-Gal) Sigma 
DMEM (Dulbecco's Modified Eagle's medium) Invitrogen 
DMSO (dimethyl  sulfoxid) Sigma 
DNA ladder & Loading dye Promega 
dNTPs (deoxyribonucleotide triphosphates) Promega 
DTT (dithiothreitol ) Sigma 
E.coli - TOP10 competent cells Invitrogen 
EDTA (ethylenedia~nine tetra-acetic acid) Sigma 
Ethanol Sigma 
Ethidium bromide Sigma 
FBS (fetal bovine serum) Invitrogen 
Formalin solution Sigma 
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Glacial acetic acid Merck 
Glycerol Sigma 
Glycine Sigma 
GoTaq® Green Master Mix Promega 
HEPE (hydroxyeicosapentaenoic acid) Sigma 
Hoechst 33342 Sigma 
hydrochloric acid (HCl) Merck 
Hydrogen peroxide solution (H2O2) Sigma 
Igepal Sigma 
Imidazole Sigma 
Isopropanol Sigma 
IPTG (isopropyl β-D-1 thiogalactopyranoside) Sigma 
Kanamycin Sigma 
Lipofectamine 2000 Invitrogen 
Lysogeny broth (LB) Sigma 
Magnesium Chloride Sigma 
Methanol BDH 
Microlon 96-well plates Greiner 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
Protech 
Ni-NTA (nickel-nitrilotriacetic acid) Resin Qiagen 
NF-κB IRDye Labelled Oligonucleotides Licor Biosciences  
OptiMEM Invitrogen 
PBS (Phosphate buffered saline) Oxoid 
Penicillin / Streptomycin / Glutamine Invitrogen 
PMSF (phenylmethylsulfonyl fluoride) Sigma 
Polybrene Sigma 
Prestained molecular weight marker  Invitrogen 
Protease inhibitor mixture Roche 
Protease inhibitor mixture (EDTA free) Roche 
Protein A/G-agarose Santa Cruz 
Protogel National Diagnostics 
Puromycin Sigma 
Random primers Invitrogen 
Restriction enzymes NewEngland 
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RNase Zap Ambion 
SDS (sodium dodecyl sulphate) Sigma 
siRNA Pellino3 specific Ambion 
siRNA Lamin a/c Ambion 
Skim milk powder Sigma 
Sodium chloride (NaCl) Sigma 
Sodium hydroxide (NaOH) Sigma 
Sodium orthovanadate (Na3VO4) Sigma 
Sodium Phosphate (Na3PO4) Sigma 
Sulphuric acid (H2SO4) Sigma 
Synthetic oligonucleotides MWG Biotech 
Taq polymerase Invitrogen 
TEMED (N, N, N′, N′-tetramethylethylenediamine) Sigma 
TMB (3, 3’, 5, 5’-Tetramethylbenzidine liquid substrate ) Sigma 
TNFα R&D Systems 
Tris-base Sigma 
Tris-HCl Sigma 
Trypsin/EDTA Invitrogen 
Tween-20 Sigma 
Z-VAD-FMK (benzyloxycarbonyl-valine-alanine-aspartate-fluoromethyl ketone) 
Promega. 
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2.1.2 Buffers 
 
 
Buffer  Composition  
PBS 2.7mM KCl, 1.5mM KH2PO4, 137mM NaCl, 
 8mM Na2HPO4, pH 7.4  
TBS (Tris buffered saline) 25mM Tris, pH7.4, containing 0.14M NaCl. 
Blocking Buffer 1X TBS, 0.1% (v/v) Tween-20 with 
 5 % w/v nonfat dry milk or 5% w/v BSA 
Cell lysis Buffer 20 mM Tris-HCl, pH 7.4, 150 mM NaCl,  
 0.2% (v/v) Igepal, 10% (w/v) glycerol, 50 mM  
 NaF,1 mM Na3VO4, 1 mM DTT, 1 mM PMSF, 
 complete protease inhibitor cocktail (Roche, mini)  
EMSA Buffer-A  10 mM HEPES pH 7.9, 10 mM KCl,  
 1.5 mM MgCl2; shortly before use add: 0.5 mM 
DTT  
 and 0.5 mM PMSF 
EMSA Buffer-C  20 mM HEPES pH 7.9, 420 mM NaCl,  
 1.5 mM MgCl2, 0.2 mM EDTA, 25% (w/v) glycerol; 
 shortly before use add: 0.5 mM PMSF 
EMSA Buffer-D 10 mM HEPES pH 7.9, 50 mM KCl, 0.2 mM  
 EDTA, 20% (w/v) glycerol; shortly before use add:  
 0.5 mM PMSF and 0.5 mM DTT 
In Vitro Binding Buffer 20 mM Tris-HCl, pH 7.4, 150 mM NaCl,  
 0.2% (v/v) Igepal, 10% (w/v) glycerol  
 and complete protease inhibitor cocktail 
Laemmli sample buffer  62.5 mM Tris-HCl, pH 6.8, 10% (w/v) glycerol, 
(1x Concentrations) 2% (w/v) SDS, 0.7 M β-mercaptoethanol , 
 0.001% (w/v) bromophenol blue 
Qiagen native lysis buffer 50 mM NaH2PO4.H2O, 300 mM NaCl 
 10 mM Imidazole, 10mM β-mercaptoethanol 
Qiagen native wash Buffer 50 mM NaH2PO4.H2O, 300 mM NaCl, 
20 mM Imidazole 
Qiagen native elution Buffer 37.5 mM NaH2PO4, 225mM NaCl,  
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250 mM Imidazole 
SDS running Buffer 25 mM Tris, 192 mM glycine, 0.1% SDS. 
SOC medium  2% peptone, 0.5% Yeast extract, 10mM NaCl,  
(Super Optimal broth with  2.5mM KCl, 10mM MgCl2 , 10mM MgSO4,  
Catabolic Repressor 
medium) 
20 mM Glucose 
Reagent diluent for  ELISA 0.1% (w/v) BSA, 0.05% (v/v) Tween in TBS 
Transfer Buffer 25 mM Tris, 192 mM glycine, 20% methanol 
TAE  40 mM Tris base, 0.1% (v/v) glacial acetic acid,  
(Tris-acetate-EDTA)  Buffer 1 mM EDTA 
TBE 89 mM Tris Base,89 mM Boric Acid,  
(Tris-Borate-EDTA) Buffer 2 mM EDTA 
TE (Tris-EDTA) buffer 10 M Tris-HCl, 1 mM EDTA pH 8.0, 
 
2.1.3 Antibodies 
Antibodies Supplier 
 
β-actin Sigma 
  
ECSIT 
ERK 
MyBiociences 
Cell Signalling 
FLAG M2 Sigma 
His-HRP (horseradish peroxidase) Sigma 
HA-Tag (6E2) Cell Signalling  
IκB-α Santa Cruz 
JNK Cell Signalling 
Myc-Tag (9B11) Cell Signalling  
P38 Cell Signalling 
  
Phosho-ERK Cell Signalling                               
Phosho-IκB-α Cell Signalling                               
Phosho-JNK Cell Signalling    
Phosho- p38 Cell Signalling    
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RIP1 Transduction Labs 
  
  
PARP (Poly-ADP-ribose- polymerase) Cell Signalling 
IKK-β Cell Signalling 
TRAF6 Santa Cruz 
TRAF3 
TAK1                                                                                         
Santa Cruz 
Santa Cruz
Phospho-IKK-α/β Cell Signalling 
Secondary Antibodies： Supplier 
Anti-mouse / rabbit-HRP Cell Signalling 
IRDye 800CW Goat Anti-Rabbit Licor Biosciences 
IRDye 680 Goat Anti-Mouse Licor Biosciences 
IRDye 800CW Donkey Anti-goat Rockland 
 
 
2.1.4 Cells 
 
Cells Description 
HEK293T Human embryonic kidney cells 
HeLa Human epithelial carcinoma cell line 
U373-MG 
THP1  
MEF 
Human glioblastoma-astrocytoma, epithelial-like cell line 
Human acute monocytic leukemia cell line 
Murine Embryonic Fibroblasts 
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2.1.5 Animals 
Humanised ECSIT mice and their wild-type littermates were bred at the animal 
facility at the Institute of Immunology, National University of Ireland Maynooth. 
Genotyping was performed by PCR analysis of genomic DNA from ear punches as 
described in 2.2.. Mice were housed in standard rodent cages, enriched with cardboard 
housing and nesting material. The animals were kept at room temperature (22 – 24°C) 
in a 12hr light/dark cycle (lights on at 8:00 a.m.) with ad libitum access to food and 
water. All mice were used under the guidelines of the Irish Department of Health, and 
all procedures were approved by the research ethics committee of the National 
University of Ireland Maynooth. 
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2.1.6 Gifts 
 
Cell lines: 
 
 HEK293 cells and HEK293 stably expressing TLR4 or TLR3 - Prof. Douglas 
T. Golenbock (The University of Massachusetts Medical School, Worcestor, 
Massachusetts 01605, USA). 
 
Constructs: 
 
 pFR-luciferase Gal4 reporter construct – Dr. Andrew Bowie (Trinity College 
Dublin, Ireland) 
 NF-κB-luciferase reporter construct – Prof. Luke O’Neill (Trinity College 
Dublin, Ireland) 
 HA-tagged Ubiquitin wild type – Dr. Jim Johnson (University of Queens, 
Belfast Northern Ireland) 
 FLAG Tagged cIAP1 – Dr Mikihiko Naito (National Institute of Health 
sciences, Tokyo, Japan) 
 FLAG Tagged TAK1-KD – Dr Daniel O’Toole (NUIG, Galway, Ireland) 
 FLAG Tagged TAK1-K158a/ TAK1-K209a – Dr Jianhua Yang (Baylor 
College of Medicine, Texas, USA) 
 Myc-tagged C-Terminal truncated hECSIT/ N-terminal truncated hECSIT – 
Dr Daniel O’Toole (NUIG, Galway, Ireland) 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 HEK293, U373, HeLa and THP1 cells  
 
The parental human embryonic kidney HEK293 cells, HEK293 cells that 
stably express the TLR3 / TLR4 receptors, U373 and HeLa cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM), which was supplemented with 10% 
(v/v) foetal bovine serum (FBS), penicillin (100 µg/ml) and streptomycin 100 µg/ml. 
G418 (500 µg/ml) was used to select for  stably transfected TLR cell lines. Cells were 
maintained in a 37ºC humidified atmosphere with 5% CO2. Cells were passaged every 
2 to 3 days using 1% (w/v) Trypsin/ethylenediaminetetraacetic acid (EDTA) solution 
in phosphate-buffered saline (PBS).  THP1 cells were grown in RPMI supplemented 
with 10% (v/v) FBS and penicillin (100 µg/ml) and streptomycin 100 µg/ml and 
passaged every 3 to 4 days.  
 
 
2.2.1.5 MEF Cells 
 
For the preparation of primary MEFs ECSIT+/-mice were intercrossed to produce 
ECSIT +/+ ,+/- and -/- embryos. Mouse breeder pairs were set up and the following 
morning female mice were checked for copulatory plugs to indicate day zero. At day 
13.5, pregnant mice were euthanized according to standard protocols. The uterus 
containing the embryos was dissected from the mouse and placed in a sterile Petri 
dish. Embryos were individually removed from the uterus and placed in a Petri dish 
containing sterile PBS in a laminar flow hood. The head and all soft tissues from each 
embryo were removed. Heads were retained for genotyping the embryos. The 
remaining embryo carcasses were minced using a scalpel and placed in 50ml falcon 
tube containing 1.5ml of trypsin (1X) and 0.5ml H20. The suspension was incubated 
at 37 degrees for 10 min, mixed using a pipette and incubated again at 37 for 10 min. 
DMEM (12 ml) was then added to each tube. Tissue clumps were removed and the 
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contents of each tube were transferred to an individual T75 cell culture flask. MEF 
cells were passaged every 3-4 days. 
 
2.2.2 Site directed mutagenesis 
 
Primers incorporating desired mutations were designed and the following 
considerations were applied in  primer design : 
 Both of the primers contained the desired mutation and annealed to the 
complementary sequences on opposite strands of the plasmid. 
 Primers were between 25 and 45 bases in length, with a melting temperature of < 
75oC. 
 
The following formula was used for estimating the Tm of the primers: 
 
                              Tm =81.5 + 0.41(%GC) - 675/N - % mismatch 
 
Where N is the primer length in bases. 
 
 The desired mutation (insertion or deletion) was in the middle of the primer with 
approximately 10-15 bases of unaltered sequence on both sides. 
 The primers usually terminated in one or more C or G bases. 
 
 Pfu Turbo, a high fidelity DNA polymerase which amplifies longer targets 
more efficiently than other enzymes, was used for PCR amplification using the 
following conditions: 
 
Reagent                                                                                                 Volume 
 
Template 50 ng plasmid DNA                           1 µl 
10X Pfu Buffer                   5 µl 
Primers (125ng)                   1 µl each 
dNTP mix (10 mM each)        1 µl 
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Pfu Turbo                    1 µl 
PCR-grade water                   to 50 µl 
 
Each reaction was initially heated to 94oC for 5 min. This was followed by 22 cycles 
of 94oC for 30 s, a target-specific annealing temperature (Ta) for 30 s and an 
elongation phase of 72oC for 7 min,. Samples were then incubated at 72oC for 10 min. 
 
2.2.3 Propagation of DNA 
2.2.3.1 Rapid transformation of competent cells 
 
 TOP10 chemically competent E.coli were used for propagation of plasmids 
and for the cloning of ligation reaction products. 100-400ng of plasmid or 70 % of a 
ligation reaction product were added to 5 µl or 50 µl of TOP10 cells, respectively. 
DNA and the cells were mixed gently with a pipette and incubated on ice for 30 min. 
The plasmids were allowed to enter the bacterial cells by heat shocking the mixture at 
42oC for 60 seconds. The cells become permeable to allow easy entry of the plasmid 
and cooling on ice for 2 min makes the cells once again impermeable. The 
transformed cells were then incubated in 1 ml Luria Bertoni (LB) broth (1% (w/v) 
tryptone, 0.5% (w/v) yeast extract, 85 mM NaCl) at 37oC on a shaker at 220 rpm for 1 
h. An aliqout of the mix (50-100 µl for plasmid propagation; 1 ml for cloning of 
ligation reaction products) was then plated out on LB agar plates (LB broth with 1.5% 
(w/v) agar) containing 100 μg/ml ampicillin. Plates were inverted and incubated 
overnight at 37oC. Plates were then stored at 4oC for up to four weeks. 
 
2.2.3.2 Small scale preparation of DNA from E. coli 
 
LB broth (2 ml) containing ampicillin (50 µg/ml) was inoculated with a single 
transformed E coli colony from an agar plate. The culture was incubated overnight at 
37oC shaking at 220 rpm. Small plasmid preparations were made using the Qiaprep 
Spin Miniprep kit from Qiagen Inc. The bacterial cells were centrifuged at 9000 rpm 
for 3 min and the supernatant was discarded and the plasmid DNA was extracted as 
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outlined in the manufacturer’s handbook. DNA was quantified using a Cary 
spectrophotometer. After diluting the DNA appropriately in Tris-EDTA (TE) buffer, 
pH 8.0, (10 mM Tris-HCl, 1 mM EDTA) the absorbance of the solution was measured 
at 260 nm and 280 nm. All samples used had an optical density OD260/OD280 ratio in 
the range of 1.7 to 1.9. Ratios below 1.7 or above 1.9 indicated RNA or protein 
contamination, respectively. The concentration was calculated using the formula: 
 
  µg/ml DNA = 50 µg/ml/OD260 x (OD260 measured) x (dilution factor)  
 
2.2.3.3 Large scale preparation of DNA from E. coli 
 
A starter culture of LB broth (2 ml) containing ampicillin (50 μg/ml) was 
inoculated with a single transformed E.coli colony and incubated at 37oC with shaking 
at 220 rpm for 6-8 h. This was then added to a larger volume of LB broth (100 ml) 
containing the relevant antibiotic and incubated at 37oC overnight with shaking at 220 
rpm. Large plasmid preparations were made using the Qiagen high speed plasmid 
midi kit from Qiagen. The bacterial cells were centrifuged at 3000 rpm for 40 min and 
the supernatant was discarded and the plasmid DNA was extracted as outlined in the 
manufacturer’s handbook. DNA was quantified as outlined in Section 2.2.4.2. 
2.2.4 Transient transfection 
2.2.4.1 Transfection of cells for luciferase reporter assay  
 
HEK293-TLR3 and -TLR4 cells were seeded in 96-well plates and allowed to 
adhere for 24 h to approximately 50% confluency. Cells were transfected using 
Lipofectamine 2000. For each well to be transfected, 25 µl of OptiMEM (Invitrogen) 
was mixed with the DNA. DNA mixes were made up for the appropriate luciferase 
construct as outlined in section 2.2.6. Lipofectamine 2000 (0.4 µl) was diluted in 
OptiMEM (25 µl/sample) and the reaction was mixed gently and left at room 
temperature for 5 min. After the incubation, the Lipofectamine/OptiMEM solution 
was added to the DNA/OptiMEM mix (total volume 50 µl/well to be transfected) and 
the combined reaction was mixed gently and incubated at room temperature for 20 
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min. The transfection mixture was then added to each well and mixed gently by 
tapping the side of the plate. Each sample was transfected in triplicate. 24 h after 
transfection the cells were treated as indicated and supernatants were removed, cell 
lysates were generated and used to measure luciferase activity. 
 
 
2.2.4.2 Transfection of cells for Western Blot analysis 
 
 HEK293T cells were seeded in 6-well plates. Cells were grown for 24 h to 
approximately 70% confluency. For each well of a 6-well plate to be transfected, 
DNA (amount depending on individual assays as outlined in relevant sections) was 
diluted in OptiMEM (250 µl) (Invitrogen) and mixed gently. Lipofectamine 2000 (4 
µl) was then diluted in OptiMEM (250 µl) and incubated at room temperature. After 5 
min incubation, the diluted DNA was combined with the diluted Lipofectamine 2000, 
mixed gently, and incubated at room temperature for 20 min. 1 ml of medium was 
removed from each well before adding the DNA-Lipofectamine complexes (500 µl). 
For co-immunoprecipitation studies, constructs encoding potential interacting partners 
were transfected at a ratio 1:1; for ubiquitin studies 1 μg of each construct was used; 
for degradation studies a number of different ratios were utilised. After 24 h, cell 
lysates were generated for co-immunoprecipitation studies (section 2.2.8) or  
ubiquitination studies (section 2.2.9) To determine protein concentration the Bradford 
method was used as outlined in section 2.2.16 and lysates were analysed using SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) (section 2.2.7). 
 
2.2.5 Luciferase Assays 
HEK293-TLR3 or -TLR4 cells were seeded in 96-well plates (200 µl 
DMEM/well) and grown for 24 h. All transfections were performed using 
Lipofectamine 2000 transfection reagents (as described in section 2.2.4.1). Details of 
the constructs transfected are given below. 24 h post-transfection, the medium was 
removed from the cells and reporter lysis buffer (100 µl, Promega) was added to each 
well using a multi-channel pipette. The plate was then wrapped in aluminum foil and 
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placed on a rocking platform for 30 min at room temperature before being placed at -
80oC for a minimum of 1 h. After thawing at room temperature, aliquots (40 µl) of 
each were assayed for firefly luciferase activity using firefly luciferase substrate (40 
µl, Promega), while Renilla luciferase activity was assayed using coelenterazine (0.1 
µg/ml in PBS). Luminescence was monitored with a Glomax microplate luminometer 
(Promega). 
 
2.2.5.1 NFκB assay 
 
To measure activation of the NFκB pathway, cells were transfected with 
NFκB -regulated firefly luciferase reporter plasmid (80 ng), constitutively expressed 
Renilla-luciferase reporter construct phRL-TK (20 ng) and varying amounts of 
expression constructs (detailed in figure legends). The total amount of DNA was 
maintained at 200-250 ng using pcDNA3.1. 
 
2.2.5.2 IRF3 assay 
 
To measure the activation of IRF3, cells were transfected with pFR-Luc (60 
ng), the trans-activator plasmid pFA-IRF3 (IRF3 fused downstream of the yeast Gal4 
DNA binding domain, 30 ng), phRL-TK (20 ng) and varying amounts of expression 
constructs (Outlined in figure legends). The total DNA concentration was maintained 
at 210 ng using pcDNA3.1. 
 
2.2.5.3 IRF7 assay  
 
To measure the activation of IRF7, cells were transfected with pFR-Luc (60 
ng), the trans-activator plasmid pFA-IRF7 (IRF7 fused downstream of the yeast Gal4 
DNA binding domain, 25 ng), phRL-TK (20 ng) and varying amounts of expression 
constructs (Outlined in figure legends). The total DNA concentration was maintained 
at 210 ng using the pcDNA3.1.  
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2.2.6 siRNA Studies 
 
Pre-designed siRNA targeting hECSIT was purchased from Ambion Inc. 
(target sequence: 5’-GGTTCCTTTGCCCAAAGACTT-3’), while Lamin a/c siRNA 
was used as a control, also purchased from Ambion.  
 
2.2.6.1 Transfection of siRNA for knockdown studies 
 
HEK293 TLR4, TLR3, HeLa or U373 cells were seeded in 6-well plates. Cells 
were grown for 24 h to approximately 70% confluency. hECSIT-specific siRNA (30 
nM) or Lamin a/c control siRNA, , were diluted in OptiMEM (250 µl) mixed gently 
and incubated for 5 min, Lipofectamine 2000 (4 µl) was also diluted in 250 µl of 
OptiMEM per sample, the reaction was mixed gently and left at room temperature for 
5 min. After the incubation, the Lipofectamine/OptiMEM solution was added to the 
OptiMEM-siRNA mix (total volume 500 µl per well to be transfected) and the 
combined reaction mixed gently and incubated at room temperature for further 20 
min. 500 µl sample was then added to each well and mixed gently by rocking the 
plate back and forth. Cells were incubated for 48 h prior to analysis for the expression 
of hECSIT by Western Blotting. 
2.2.6.2 Transfection of siRNA for luciferase assays 
 
HEK293 TLR3 or TLR4 cells were seeded in 96-well plates. Cells were grown 
for 24 h to approximately 50% confluency. To determine the effect of hECSIT-
specific siRNA on the activation of NFκB, IRF3 and IRF7, DNA mixes were made up 
for the appropriate luciferase construct as outlined in section 2.2.6. The appropriate 
amount of hECSIT or Lamin a/c control siRNA (for a final concentration of 10 nM 
per well) was diluted in OptiMEM (25 µl) and mixed gently with the DNA. 
Lipofectamine 2000 (0.4 µl) was diluted in OptiMEM (25 µl) per sample, the reaction 
was mixed gently and left at room temperature for 5 min. After the incubation, the 
Lipofectamine/OptiMEM solution was added to the DNA-siRNA mix (total volume 
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50 µl per well to be transfected) and the combined reaction mixed gently and 
incubated at room temperature for 20 min. Samples (50 µl) were added to each well 
and mixed gently by tapping the side of the plate. Cells were incubated for 24 h prior 
to overnight treatment with ligands. 48 h post-transfection supernatants were collected 
and stored at -20ºC, while cell lysates were generated and assayed for luciferase 
activity as outlined in section 2.2.5. 
 
2.2.7 Western Blot Analysis 
2.2.7.1 Preparation of Samples 
 
Cytosolic extracts were added to 4x sample buffer (0.125 Tris-HCl pH 6.8, 20% (w/v) 
glycerol, 4% (w/v) SDS, 1.4 M β-mercaptoethanol and 0.0025% (w/v) bromophenol 
blue) and boiled for 5-10 min prior to loading. For analysis of whole cell extracts, 
10% of total lysate was boiled for 5-10 min before loading. 
 
2.2.7.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 SDS-PAGE was conducted according to the method of Laemmli (Laemmli, 
1970), as modified by Studier (Studier, 1973). Samples and appropriate prestained 
(26.6-180 kDa) protein markers were loaded into separate wells. Electrophoresis was 
performed at 80 V through a 5% SDS polyacrylamide stacking gel and then through a 
10% SDS polyacrylamide resolving gel at 80 V for 1.5-3 h, depending on the size of 
the proteins being electrophoresed. 
 
2.2.7.3 Immunoblotting 
 
Following separation by electrophoresis, the proteins were transferred 
electrophoretically to nitrocellulose membranes in a Hoefer TE 70 Semiphor semi-dry 
transfer unit at 90 mA for 1.5 h or a Thermo Fisher Wet transfer unit using Whatmann 
and nitrocellulose pre-soaked in cold transfer buffer (25 mM Tris Base, 0.2 M glycine 
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and 20% (v/v) methanol) for 10 min. Following transfer, non-specific binding was 
blocked by incubating the nitrocellulose membranes at room temperature for 1 h (or 
overnight) in TBS (20 mM Tris-HCl pH 7.5, containing 0.05% (v/v) Tween 20 and 
0.5 M NaCl) containing 5% (w/v) skimmed milk powder. The membranes were then 
washed 3 times for 10 min each in TBS prior to incubation at 4oC overnight with the 
primary antibodies diluted in TBS containing 5% (w/v) skimmed milk powder. The 
membranes were subsequently subjected to 5 x 10 min washes in TBS prior to 
incubation with secondary antibody (1:5000 dilution) specific for the primary 
antibody in question (anti-rabbit or anti-mouse) in Odyssey Blocking Buffer (Licor, 
Bioscience) for 1 h in the dark at room temperature. The membranes were then 
washed a further 5 times for 10 min each in TBS in the dark. The immunoreactive 
bands were detected using Odyssey Infrared Imaging System from Licor Biosciences 
or E.C.L chemiluminescence, according to the instructions of the manufacturer. 
 
 
1o antibody   Dilution     2o  antibody* 
β-Actin   1:10000           mouse 
c-Myc     1:2000            mouse 
ECSIT    1:1000            rabbit 
Flag    1:2000                       mouse 
HA    1:1000            mouse 
TRAF3                                    1:200                                    mouse 
TRAF-6              1:500            mouse 
RIP1                                        1:1000                                  mouse 
Ubiquitin               1.500            mouse 
p-IκB-α                                    1:500                                    mouse 
IκB-α                                       1:500                                    rabbit 
p-P65                                      1:500                                      rabbit 
P65                                         1:1000                                    rabbit 
p-IKK-α/β                              1:750                                      rabbit 
IKK-α/β                                 1:1000                                    rabbit 
PARP                                     1:1000                                    rabbit 
p-JNK                                    1:500                                      rabbit 
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JNK                                       1:1000                                    rabbit 
p-P38                                    1:500                                       rabbit 
P38                                       1:1000                                     rabbit 
p-TAK1                               1:500                                       rabbit 
TAK1                                  1:1000                                     rabbit 
 
 
* All Licor secondary antibodies were used at a dilution of 1:5000. HRP-linked 
secondary antibodies were used at a dilution of 1:1000   
2.2.8 Co-Immunoprecipitation (Co-IP) 
2.2.8.1 Co-immunoprecipitation analysis of over expressed proteins 
 
HEK293T cells were transfected with Lipofectamine 2000 as previously 
described in section 2.2.5.2 at a 1:1 ratio of expression constructs. Cell extracts were 
generated on ice or at 4oC according to the following experimental strategy. Cells 
were first washed with pre-chilled PBS (1 ml) then lysed with pre-chilled 250μl co-
immunoprecipitation (Co-IP) lysis buffer (50 mM Tris-HCl, pH 7.5, containing 150 
mM NaCl, 0.5% (w/v) igepal and 50 mM NaF, with 1 mM Na3VO4, 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease 
inhibitor mixture (leupeptin (25 µg/ml), aprotinin (25 µg/ml), benzamidine (1 mM), 
trypsin inhibitor (10 µg/ml)) for 30 min on a rocking platform at 4oC. Lysates were 
scraped into pre-chilled 1.5 ml microcentrifuge tubes and centrifuged at 12,000 g for 
10 min at 4oC. Supernatants were removed to fresh tubes (10% of sample was retained 
for whole cell lysate analysis) and incubated for 30 min with mouse or rabbit 
immunoglobulin (Ig) G (1μg) (depending on the host species of the primary antibody) 
and Protein A/G agarose beads (10 μl) on a rotator at 4 oC. Samples were centrifuged 
at 1000 g for 5 min at 4oC to pellet beads with non-specific protein and supernatants 
were removed to fresh pre-chilled tubes. Samples were incubated overnight with 
primary antibody (2 μg). The following day Protein A/G agarose beads (20-30 μl) 
were added to each sample and they were again incubated at 4oC for ~ 6 h / overnight. 
The subsequent day samples were centrifuged at 8000 g for 1 minute. The beads were 
washed with CoIP lysis buffer (500 μl) and subject to re-centrifugation. This step was 
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repeated five times. The supernatant was then removed  and 40 μl of 2 x sample 
buffer (0.125 M Tris-HCl, pH 6.8, containing 20% (w/v) glycerol, 4% (w/v) SDS, 1.4 
M β-mercaptoethanol and 0.0025% (w/v) bromophenol blue) was added to the 
columns for 30 min at RT. Samples were centrifuged at 16000 g for 2 min, to elute 
immunocomplexes and subsequently boiled at 100oC for 5-10 min and analyzed using 
SDS polyacrylamide gel electrophoresis and western blotting (section 2.2.7). 
 
 
2.2.8.2 Co-immunoprecipitation analysis of endogenous proteins 
 
For analysis of endogenous protein interactions, cells were stimulated for 
various times with TNF-α (50ng) or LPS (100ng/ml) or IL-1 (10ng/ml) or Poly (I:C) 
(25ug/ml). Cells were then lysed for immunoprecipitation and western blotting 
analysis as described above. 
2.2.9 Analysis of Ubiquitinated proteins 
2.2.9.1 Analysis of Ubiquitination of over expressed proteins 
 
HEK293T cells were co-transfected with HA-tagged ubiquitin wild type (1 
μg) and 1 μg of various expression constructs encoding different proteins (as outlined 
in figure legends) using Lipofectamine 2000. The following day cells were harvested 
in 200µl of RIPA buffer (1M Tris HCl Ph 7.4, containing 5M NaCl, 20% IgePal , 
10% (w/v) sodium deoxycholate, 20% (w/v)  SDS with , with 1 mM Na3VO4, 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease 
inhibitor mixture (leupeptin (25 µg/ml), aprotinin (25 µg/ml), benzamidine (1 mM), 
trypsin inhibitor (10 µg/ml)) on ice for 40 mins. Lysates were then centrifuged at 
12,000g for 10 mins and transferred to fresh tubes. 20µl of 10% (w/v) SDS was added 
to each sample followed by incubation at 95ºC for 5 mins to remove any associated 
proteins from the ubiquitinated protein of interest. 10% of sample was retained for 
whole cell extract analysis. Samples were then incubated overnight with primary 
antibody (2µg) in 1.5ml of RIPA buffer. Samples were then co-immunoprecipitated as 
described in section 2.2.8.. 
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2.2.9.2 Analysis of ubiquitination status of endogenous proteins 
 
HeLa or U373 cells were seeded (density) in cell culture 10cm petri dishes. 
The following day cells were stimulated with the appropriate ligand for various time 
points. Cells were then lysed as described in section 2.2.9. Samples were co-
immunoprecipitated using the appropriate antibody and analysed by Western 
immunoblotting using an anti-ubiquitin antibody.  
   
2.2.10 In vitro Ubiquitination Assay 
 
Recombinant TRAF3 or TRAF6 was incubated with recombinant hECSIT or C-
terminal hECSIT in the following reaction mixture:  
 
E1     50 ng     
 
E2 UbcH13/Uev1a   400 ng 
 
Ubiquitin Recombinant  2 μg 
 
MgCl2     2 mM 
 
ATP     2 mM 
 
Protease Inhibitor (EDTA free) 
- 1 tablet in 2ml dH2O   1:10 
 
TRAF3/6 Recombinant                     500ng 
 
ECSIT Recombinant    500 ng   
 
dH2O      to 30 μl 
 
Reactions were incubated at 37ºC for 2 h and terminated by addition of 10 μl 4 x 
SDS-PAGE sample buffer (0.125 M Tris-HCl, pH 6.8, containing 20% (w/v) glycerol, 
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4% (w/v) SDS, 1.4 M β-mercaptoethanol and 0.0025% (w/v) bromophenol blue). 
Samples were boiled for 5-10 min, resolved by SDS-PAGE and subsequently 
analysed by Western immunoblotting (section 2.2.7) using anti-ubiquitin antibody. 
 
2.2.11 Lentiviral shRNA Infection 
 
2.2.11.1 Lentiviral production 
 
HEK293T cells were seeded in a T75 flask (15 ml DMEM/flask) and grown 
for 24 h to approximately 70% confluency. The cells were transfected as described in 
section 2.2.4.2. The DNA mixture contained packaging plasmid (5µg), envelop 
plasmid (5µg) and the hECSIT-shRNA (10 μg) (Sigma). shRNA hECSIT sequences 
were as follows: 
 
• shRNA hECSIT A7  
5’-CCGGGCCCTTTGAGTGTACAGCAAACTCGAGTTTGCTGTACA  
CTCAAAG GGCTTTTTG -3’ 
 
• shRNA hECSIT A8   
 5’-CCGGCCCTCGATTCATGAACGTCAACTCGAGTTGACGTTCA  
TGAATCGAGGGTTTTTG -3’ 
 
 
A control shRNA was also used in the transfection. It was a non-targeting shRNA 
vector that activates the RNA-induced silencing complex (RISC) and the RNAi 
pathway, but does not target any human or mouse genes. The short-hairpin sequence 
contains 5 base pair mismatches to any known human or mouse gene. To remove the 
transfection reagent, the media was changed 24 h post-transfection and replaced with 
fresh high serum (30%) growth media. The cells were then incubated for 24 h. The 
media containing lentivirus were harvested ~ 48 h post-transfection and transferred to 
a polypropylene tube for storage at -20°C. The media was replaced with fresh high 
serum (30%) growth media and the cells were incubated for further 24 h. The virus 
was harvested one more time and after the final harvest the packaging cells were 
discarded. 
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2.2.11.2 Lentiviral infection 
 
U373 cells were seeded at 2 x 105 cells/ml in T75 flasks or culture dishes 
(10ml/dish DMEM). The following day virus was added to cells (1:1 virus DMEM). 
Polybrene (8 μg/ml) was added to improve transduction efficiency. The flasks were 
incubated at 37oC. The media was removed 48 h post-infection and replaced with 
fresh growth media containing puromycin (5 μg/ml) to select for cells transduced with 
shRNA. The polyclonal populations of cells were cultured for 2 days and hECSIT 
expression was determined. 
 
2.2.12 EMSA  
 
EMSA was used to detect the presence of DNA-binding proteins in nuclear extracts. 
NFκB infrared dyes labeled oligonucleotides were purchased from Licor Biosciences. 
 
2.2.12.1 Preparation of sub-cellular nuclear fractions 
 
Following treatment cells were washed in PBS and resuspended in 1ml buffer A. 
Following centrifugation at 4ºC (21,000g for 10 min) supernatant was removed and 
cells were lysed in 20µl of Buffer A containing 0.1% (v/v) IgePal for 10 min on ice. 
Lysates were centrifuged at 21,000g for 2 minutes. Supernatants constituted cytosolic 
fractions and were stored at -200C.The remaining pellets were resuspended in 20µl of 
Buffer C and incubated on ice for 15’. Samples were then centrifuged at 21,000g for 
10 min.The supernatants, constituting nuclear extracts  were then transferred to 75µl 
of Buffer D. A Bradford assay was used  to determine protein concentration and 
nuclear extracts were assayed for NFκB DNA binding activity as outlined in the 
following section. 
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2.2.12.2 EMSA Reaction 
 
 
Nuclear extracts (5µg protein) were incubated with the following reaction mix: 
 
10x Binding buffer                                                                                                2µl 
 
Poly (dI-dC) concentration                                                                                   1µl                                                                  
 
1% NP40                                                                                                               1µl 
 
NFκB Oligo                                                                                                          1µl 
  
Nuclear extract                                                                                                      5ug 
 
Water                                                                                                                     to 20ul 
 
 
NFκB consensus oilgonucleotide: 
 
     5’-AGTTGAGGGGACTTTCCCAGGC-3’ 
 
     3’-TCAACTCCCCTGAAAGGGTCCG-5’ 
 
 
Underlined nucleotides indicate binding sites for NFκB.  
 
 
For competition assay unlabeled oligonucleotide containing the consensus NFκB 
sequence was added for 20 min prior to the addition of the IRDye labeled 
oligonucleotides. Incubations were performed in the dark for 1h at room temperature.  
Orange loading dye (2µl) was added to each sample and subjected to native gel 
electrophoresis on 5% acrylamide gels that had been pre-run for 30 min at 90V. Gels 
were then removed from glass plates and visualized using a Licor scanner. 
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2.2.13 ELISA 
Cell supernatants were collected and stored at -20ºC until ELISA analysis. 96-well 
NUNC maxisorb plates were coated with the appropriate capture antibody and 
incubated overnight at room temperature with gentle agitation. Plates were washed 
three times with wash buffer (PBS with 0.05% (v/v) Tween-20) and dried by inverting 
the plates on tissue paper. Plates were blocked for 1 hour with PBS containing 1% 
(w/v) BSA. Plates were again washed three times and dried. Samples or standards 
(100µl) diluted in reagent diluent were added to each well. Standard concentration 
ranged from 0-2000pg/ml. Plates were incubated with samples and standards for 2h 
and were then washed three times. Detection antibody (100µl) (biotinylated) was 
diluted in reagent diluent was added to each well. Again plates were incubated for 2h 
and then washed. Streptavidin-HRP conjugate (100µl) was then added to each well. 
The plates were then incubated in the dark for 20 min and then the wash step was 
repeated. An aliquot (100µl) TMB solution was added to each well and again plates 
were incubated in the dark for 20 min. 50µl of H2S04 was used to stop the reaction and 
the absorbance measured at  450nm using a ELx800TM microplate reader with Gen5 
Data analysis software. The concentrations of cytokine in each sample were 
extrapolated from a standard curve that related absorbance to standard concentration. 
Standard samples were assayed in duplicate to generate the standard curve, while all 
samples were assayed in triplicate. 
2.2.14 PCR Based Genotyping 
 
PCR Amplification was performed on genomic DNA using GotoTaq DNA 
polymerase and specific primers to detect heterozygous/homozygous conventional 
Ecsit mice. 
 
4192_62: CCATTTGCTGGAGTCTGTTCC 
 
4192_63: AAATTCAGCACCTACATGGCAG 
 
Control Primers: CD79B Control Allele  
 
1260_1: GAGACTCTGGCTACTCATCC 
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1260_2: CCTTCAGCAAGAGCTGGGGAC 
 
Flpe Transgene Primers:  
 
1307_1: Flpe_as_GGCAGAAGCACGCTTATCG 
 
1307_2: Flpe_s_GACAAGCGTTAGTAGGCACAT 
 
PCR Reaction: 
 
Genomic DNA                                                                                                       2µl 
  
5X Buffer                                                                                                              5µl 
 
MgCl2                                                                                                                                         2µl 
 
Primers (5µM)                                                                                                       1µl  
 
dNTP mix (10nM each)                                                                                        1µl 
 
GotoTaq                                                                                                               0.15µl 
 
PCR-grade water                                                                                                 to 25µl 
 
 
For each target the samples were initially heated to 95ºC for 5’. This was followed by 
35 cycles at 95ºC for 30s, at 60ºC for 30s and 72ºC for 1’. Samples were then 
incubated at 72ºC for 10’ and stored at 4ºC. The PCR products were subjected to 
electrophoresis on a 1% (w/v) TAE agarose gel, containing ethidium bromide 
(5µg/ml). 
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2.2.15 Agarose Gel Electrophoresis 
Agarose gels were prepared by suspending agarose in TAE (0.5X). This was then 
heated in a microwave until the agarose had completely dissolved. The solution was 
allowed to cool before Ethidium Bromide (5µg/ml) was added and the agarose was 
poured into the gel tray. Following solidification, agarose gels were covered and 
electrophoresed in TAE (1X). Samples were run simultaneously with molecular size 
markers with the range of the marker chosen to suit the particular sample size. Gels 
were electrophoresed at 100V for 30’. Nucleic acids were visualized under ultraviolet 
light (UV) (254nm) and images were acquired using the SynGene Gbox gel 
documentation system (Frederick, MD, USA).  
 
2.2.16 Isolation of RNA and cDNA synthesis 
 
2.2.16.1 Isolation of total RNA 
 
Total RNA was extracted from cells using Trizol reagent as per manufacturer’s 
instructions. The amount of isolated RNA was quantified by measuring the 
absorbance at wavelengths of 260nm and 280nm on a spectrophotometer, where an 
absorbance of 1 unit at 260nm is 40µg/ml. Pure RNA preparations have OD260/280 
ratio of 1.8-1.9. Extracted RNA was stored at -80ºC.  
 
 
2.2.16.2 Synthesis of first strand cDNA from messenger RNA (mRNA) 
 
The Bioline Bioscript cDNA synthesis kit was used for generating full length first 
strand cDNA from total cellular RNA. RNA (2µg) was placed in nuclease free 
microcentrifuge tubes with 1µl (0.5µg/µl) of random primers and water to 13µl and 
incubated at 70ºC for 10’. The mixture was then chilled on ice and centrifuged briefly.  
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The following components were then added: 
 
Bioscript Enzyme                                                                                     0.5µl 
 
5X Bioscript Enzyme Buffer                                                                   5µl 
 
Water                                                                                                       to 20µl 
 
The reaction mixture was then incubated at 42ºC for 1h followed by 10 min at 72ºC. 
Generated cDNA was stored at -20ºC for long-term storage. 
 
2.2.17 Real Time PCR 
A 25µl real-time PCR reaction was prepared in each optical tube as follows:  
 
Template                                                                                                       4µl 
 
SYBR green master mix (2x)                                                                      10µl 
 
Primers (4mM)                                                                                            2.5µl each 
 
PCR Grade water                                                                                          to 25µl 
 
For each target the samples were initially heated to 95ºC for 15min for pre-
denaturation. This was followed by 40 cycles at 95ºC for 30s, at 57ºC for 30s and at 
72ºC for 45s. The PCR was conducted in a Applied Biosystems Step One PLUS real 
time PCR instrument. Integration of the fluorescent SYBR green into the PCR product 
was monitored after each annealing step. Amplification of one specific product was 
confirmed by melt curve analysis where a single melt curve peak eliminated the 
possibility of primer dimer association. For melt curve analysis to be performed the 
products were heated from 60ºC to 95ºC after the 40 cycles. The relative 
quantification of target gene expression was evaluated using the ∆CT method. The 
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∆CT value was determined by subtracting the HPRT CT value for each sample from 
the target CT value. Fold change in the relative gene expression of each target was 
determined by calculating the 2-∆CT. 
2.2.18 PBMC Isolation 
 
Buffy coat blood packs from healthy donors were obtained from the Irish blood 
transfusion service. Buffy coats were diluted 1:1 with sterile PBS and transferred to a 
culture flask. 15ml of Lympho- prep was added to each of 3 Falcon tubes (50 ml). 
35ml of the diluted blood was then layered slowly over the Lympho-prep at an angle. 
Falcon tubes were then centrifuged at 400 x g for 25 mins. Using a Pasteur pipette the 
top plasma layer of PBMCs were removed from each of the 3 tubes into a new 50 ml 
Falcon tube. The cells were then washed in PBS and centrifuged again at 800 x g for 
10 mins. Cells were then resuspended in RPMI media and counted. 
 
2.2.19 Sample preparation for mass spectrometry analysis 
 
The indicated gel bands were first washed with deionised water (2 x 10 min) and the 
Coomassie Blue-stained band of interest was excised from the gels and placed into 
siliconised 1.5 ml Eppendorf tubes. The gel plug was then destained, desalted and 
washed as follows: Gel plugs were first washed with water and then with 50mM 
NH4HC3/acetonitrile 1:1 (v/v) for 15 min at 370C. The liquid was removed and 
enough acetonitrile was added to cover the gel plugs. Acetonitrile was removed and 
the gel plugs were rehydrated in 50mM NH4HCO3.  After 5 min, an equal volume of 
acetonitrile was added. After 15 min of incubation all the liquid was removed and the 
gel plug was then dehydrated in 100% acetonitrile. The acetonitrile was removed and, 
the gel plug was then dried down for 30 min using a Heto type vacuum centrifuge 
from Jouan Nordic A/S (Allerod Denmark). Individual gel plugs were then rehydrated 
in enough digestion buffer (1mg of trypsin in 20ml of 50mM NH4HCO3) to cover the 
gel plug. More digestion buffer was added if all the initial volume had been absorbed 
by the gel pieces. The samples were then incubated at 370C for a period  4 h – 
overnight. The peptides generated by tryptic digestion were recovered by removing 
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supernatants from the digested gel plug. Further recovery was achieved by adding 
30% acetonitrile/ 0.2% trifluroacetic acid to the gel plugs for 10 min at 370C with 
gentle agitation. The resulting supernatants were added to the initial peptide recovery 
following trypsin digestion. Exhaustive peptide recovery was achieved through the 
addition of 60% acetonitrile/0.2% trifluotoacetic acid to each plug for 10 min at 370C 
with gentle agitation. Supernatants were added to the peptide pool and the sample 
volume was reduced until dry through vacuum centrifugation. Samples were 
resuspended in 15ml of ultra-pure ddH2O and 0.1% formic acid for identification by 
ion trap LC/MS (Liquid Chromatography/ Mass Spectrometry) analysis. 
The mass spectrometric analysis of peptides was carried out in the Proteomics 
Suite of the National University of Ireland, Maynooth with a Model 6340 Ion Trap 
LC/MS apparatus from Agilent Technologies (Santa Clara, CA). Excision, washing, 
destaining and treatment with trypsin, was performed by the above optimised method. 
Separation of peptides was performed with a nanoflow Agilent 1200 series system, 
equipped with a Zorbax 300SB C18 5mm, 4mm, 40 nl precolumn and a Zorbax 
300SB C18 5 mm, 43mm x 75mm analytical reversed phase column using HPLC-
Chip technology (Staples et al., 2009). The mobile phases utilized were A: 0.1% 
formic acid, B: 50% acetonitrile and 0.1% formic acid. Samples (5ml) were loaded 
into the enrichment column at a capillary flow rate set to 4ml/min with a mix of A and 
B at a ratio 19:1 (v/v).Tryptic peptides were eluted with a linear gradient of 10-90% 
solvent B over 15 min with a constant nano pump flow rate of 0.60ml/min. A 1min 
post time of solvent A was used to remove sample carry over. The capillary voltage 
was set to 2000 V and the flow and the temperature of the drying gas was 4ml/min 
and 3000C, respectively. For protein identification, database searches were carried out 
with Mascot MS/MS Ion search (Matrix Science, London, UK). 
  
2.2.20 Mitochondrial ROS measurement  
Human PBMCs were isolated as outlined in section 2.2.18. Cells were plated at a 
density of 2 x 105. The following day cells were transfected with hECSIT specific 
siRNA as outlined in section 2.2.4.2. 48 hours after transfection cells were stimulated 
with LPS for 6hrs. Cells were then washed 3 times with warm PBS and stained with 
MitoSox (Invitrogen) at a final concentration of 2.5µM in OptiMEM for 30 minutes. 
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Cells were washed in PBS 3-5 times and cells were removed from plates resuspended 
in PBS containing 1% FBS and analysed by flow cytometry in the FL3 region.  
2.2.21 DUB-Glo Protease Assay 
DUB activity of recombinant full length hECSIT and C-terminal ECSIT was 
measures using the Promega DUB-Glo Protease Assay system. 50μl of DUB-Glo 
reagent was added to each well of a white 96-well plate containing 50μl of water, 
control or test sample.  Samples were then mixed using a plate shaker at 300–500rpm 
for 30 seconds. Samples were then incubated at room temperature for 10-60 minutes. 
Luciferase measurements were then recorded using a luminometer plate reader after 
10 min, 30 min and 60 min to determine DUB activity. 
 
2.2.22 Statistical Analysis  
Statistical analysis was performed using the Two-tailed Student’s t-test where 
indicated. All statistical analysis was performed using the Prism 5 GraphPad software. 
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3.1 Introduction 
 
Bacterial or viral infection leads to the activation of TLRs. Activation of these 
receptors leads to downstream signalling cascades within the cell that culminates in 
the activation of transcription factors such as NFκB and the IRFs, leading to 
production of pro-inflammatory cytokines and type 1 IFN. TLR4 has perhaps been the 
most widely study TLR and can initiate two signalling events know as the MyD88 
dependent and MyD88 independent signalling pathways with the former resulting in 
activation of NFκB and the latter leading to the production of type 1 IFN. Other 
endosomal TLRs,, such as TLR3 respond to viral nucleic acids to produce type 1 IFN. 
TLRs are crucial for the eradication of infection however tight regulation of these 
signalling pathways are required to prevent damage and  the manifestation of severe 
auto-immune conditions such as lupus and different types of cancer. Many regulators 
exist in the cell and serve to inhibit TLR pathways via the targeting of critical 
intracellular signalling adaptors such as TRAF6. TRAF6 ubiquitination leads to 
recruitment of TAK1 and the IKK complex which in turn phosphorylates IκB-α and 
activates NFκB. The creation of TRAF6 deficient mice revelaed the importance of 
TRAF6 in innate immunity. TRAF6 deficient mice have a severe deficiency in NFκB 
activation in response to IL-1β and LPS (Lomaga et al, 1999).  
As discussed mECSIT was initially described as a  TRAF6 interacting protein 
that bridged the latter to MEKK1 during TLR signalling. Overexpression of ECSIT 
was also demonstrated to activate NFκB whereas a truncated form of mECSIT, 
lacking the N-terminus, displayed dominant negative effects and strongly inhibited 
NFκB. Subsequent generation of an Ecsit  knockout  mouse revealed an embryonic 
lethal phenotype which resulted in death at E7.5 (Xiao et al, 2003). This phenotype 
was attributed to impaired mesoderm development and Bone Morphogenetic protein 
(BMP) signalling. The embryonic lethality of Ecsit -/- mice  prevented further analysis 
of the in vivo role of Ecsit. In an attempt to further analyse the role of ECSIT Xiao et 
al used shRNA to knockdown the expression ECSIT. Knockdown of mECSIT 
resulted in impaired LPS induced NFκB activation. Survival of Ecsit +/- mice allowed 
for more detailed analysis of ECSITs functional role in vivo and identified mECSIT 
as a key signalling adaptor in mROS production during TLR signalling (West et al, 
2011). Engagement of TLR4 and TLR2 results in recruitment of TRAF6 to the outer 
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mitochondrial membrane to facilitate the ubiquitination of mECSIT and subsequent 
production of mROS as demonstrated by reduced levels of mROS production in 
Ecsit+/- mice and TRAF6-/- mice. Surprisingly however, Ecsit+/- mice showed no 
deficiency in NFκB activation in response to TLR2 and TLR4. A mitochondrial role 
for murine ECSIT in the generation of ROS was of special interest considering an 
earlier report showing  ECSIT to be an important regulator of mitochondrial complex 
1 assembly during oxidative phosphorylation (Vogel et al, 2009). 
To date there have been no published studies on the role of the human 
ortholog of ECSIT in TLR biology. The host laboratory for this thesis has previously 
cloned hECSIT and demonstrated functional differences between the murine and 
human forms of ECSIT. Over-expression studies suggested that hECSIT negatively 
regulates NFκB and this was associated with deubiquitination of TRAF6. The first 
section of this thesis aimed to further probe the regulatory role of hECSIT in IL-
1R/TLR4 signalling and determine the mechanisms by which hECSIT is regulated 
and how it exerts its regulatory effect in these pro-inflammatory signalling pathways.  
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3.2 Results  
3.2.1 Knockdown effect of hECSIT on LPS induced NFκB activation and mROS 
production 
Previous work carried out in the author’s host laboratory had identified hECSIT as a 
negative regulator of IL-1R/TLR4 signalling. These findings were mostly based on 
overexpression studies and the present study commenced with a characterisation of 
the effects of hECSIT knockdown on these pathways. U373 cells were initially 
transfected with control or ECSIT-specific siRNA and knockdown of hECSIT 
expression was confirmed by Western blotting (Fig. 3.1A). These cells were 
subsequently treated with LPS for various times. Knockdown of hECSIT with siRNA 
resulted in increased phosphorylation of IκB-α and more pronounced degradation of 
IκB-α in response to LPS espcially at longer time points post stimulation (Figure 
3.1A). We next looked at activation of NFκB by characterising the binding of nuclear 
extracts to an oligonucleotide containing the NFκB recognition motif. U373 cells 
were transduced with lentiviral particles containing control or hECSIT-specific 
shRNA and cell lines were selected for stably integrated shRNA constructs. hECSIT 
expression was suppressed in cells stably expressing hECSIT shRNA (Fig. 3.1B). 
Cells were stimulated with LPS for the indicated times and nuclear extracts were 
assayed for NFκB oilgonucleotide binding. LPS induced a time dependent increase in 
the binding of nuclear extracts to the NFκB oligonucleotide and this was slightly 
enhanced in hECSIT knockdown cells  (Figure 3.1B). Given that pro-inflammatory 
cytokines are primarily regulated by NFκB transcription factors we also measured 
LPS-induced expression of the cytokines IL-6 and IL-8 that are strongly regulated by 
NFκB.  However knockdown of hECSIT resulted in no significant difference in LPS 
and IL-1 induced production of IL-6 (Figure 3.2). 
 A recent report had shown that ubiquitination of mECSIT by TRAF6 promotes 
accumulation of mECSIT at the outer mitochondrial membrane to promote the 
production of mROS during TLR4 and TLR2 signalling. Since murine and human 
ECSIT appear to have different functions in the NFκB pathway we investigated if 
hECSIT could mimic the ability of mECSIT to regulate Mitochondrial Reactive 
Oxygen Species (mROS) production. Human Peripheral Blood Mononuclear Cells 
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(PBMCs) were transfected with control or hECSIT specific siRNA and stimulated 
with LPS to promote production of mROS. Stimulation of human PBMCs with LPS 
resulted in a slight increase in mROS production in  hECSIT  knockdown cells 
(Figure 3.3A) as confirmed by an increase in mean fluorescent intensity in cells 
positively stained with the mROS specific stain MitoSox (Figure 3.3B). Knockdown 
of hECSIT was confirmed in whole cell lysates (Figure 3.3C). These results again 
suggest contrasting functions for murine and human ECSIT in that whereas the 
murine form mediates the production of mROS, hECSIT appears to counter-regulate 
its production. 
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Figure 3.1 Knockdown effect of hECSIT on LPS induced NFκB activation 
 
(A) U373 cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm) for 48 
hrs. Cells were then treated with LPS (100ng/ml) for the indicated times. Cells lysates were prepared 
and separated by SDS-PAGE followed by Immunoblotting for phosphorylated and total levels of IκB-
α. Lysates were also probed for levels of ECSIT and β-Actin to confirm knockdown and equal loading. 
(B) U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT 
specific shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably 
integrated shRNA constructs. Selected cells were treated with LPS (100ng/ml) for the indicated times. 
Nuclear extracts were prepared and subsequently incubated with an Infra-Red labelled oligonucleotide 
containing an NFκB-binding motif and separated by native PAGE. Cytosolic extracts were probed for 
levels of hECSIT and β-Actin to confirm knockdown and equal loading respectively. Data shown is 
representative of 3 independent experiments. 
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Figure 3.2 Knockdown effect of hECSIT on LPS and IL-1 induced IL-6 production 
 
U373 Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hours 
after transfection cells were stimulated with (A) LPS (100ng/ml) or (B) IL-1β (10ng/ml) for 24 hrs. 
Media from NT and LPS and IL-1β treated cells were analysed for levels of IL-6 by ELISA. Data 
shown represents the mean of 3 independent experiments; p<0.05. 
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Figure 3.3 Knockdown of hECSIT enhances LPS-induced production of mROS  
 
Healthy donor PBMCs were isolated by Ficoll -paque method and transfected with hECSIT specific 
siRNA (30nm) or Control siRNA (30nm). 24 hours later cells were re-transfected with siRNA as 
before. 48 hours after the first transfection cells were stimulated with LPS (100ng/ml) for 6hr. Cells 
were subsequently stained with MitoSox and analysed by flow cytometry (A) with data also displayed 
as mean fluorescent intensity (MFI) (B) Data represent mean +/- SD from triplicate samples from 3 
independent experiments (C) Cell lysates were generated and probed for hECSIT and β-Actin to 
confirm knockdown and equal loading respectively; p<0.05. 
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3.2.2 hECSIT interacts with and regulates TRAF6 ubiquitination  
 
Given that hECSIT appears to have roles that contrast to those of mECSIT we decided 
to probe the molecular basis to the hECSIT function by initially focussing on its 
protein interaction partners.  mECSIT was initially described as a TRAF6 interacting 
protein in a yeast two hybrid study and was subsequently shown to promote the 
polyubiquitination of hECSIT during TLR signalling. Overexpression studies were 
initially performed to compare the ability of murine and human ECSIT to interact 
with TRAF6 with co-immunoprecipitation analysis showing that both forms of ECSIT 
are capable of interacting with TRAF6 (Fig. 3.4C). Co-immunoprecipitation studies 
were carried out to further investigate the possible interaction between hECSIT and 
TRAF6 at an endogenous level in response to TLR ligands using different cell lines. 
U373 cells treated with LPS resulted in a time-dependent interaction between hECSIT 
and TRAF6 as demonstrated by co-immunoprecipitation of TRAF6 with hECSIT 
(Figure 3.4A). IL-1 showed a similar ability to promote the interaction of TRAF6 and 
hECSIT in HeLa cells (Figure 3.4B). TRAF6 is an important E3 ligase in the 
activation of NFκB and mutation of the C70 residue in its RING domain results in 
loss of its E3 ligase activity and its ability to activate NFκB. TRAF6 can also undergo 
auto-ubiquitination at K124. We next assessed if these sites are important for the 
interaction between TRAF6 and hECSIT. Co-immunoprecipitation analysis showed 
that mutation of the C70 residue of TRAF6 resulted in reduced interaction between 
hECSIT and TRAF6 (Figure 3.5). However mutation of the K124 residue, the site for 
auto-ubiquitination, failed to affect this interaction (Figure 3.5). Interestingly the co-
expression of hECSIT with TRAF6 leads to increased levels of hECSIT and the 
appearance of faster migrating anti-ECSIT immunoreactive bands possibly indicative 
of TRAF6-induced processing of hECSIT. However expression of hECSIT with the 
TRAF6 E3 ligase mutant, C70A, resulted in impaired phosphorylation and processing 
of hECSIT (Figure 3.5). Interestingly this was not apparent with mECSIT. In addition 
the putative processed form of hECSIT is less apparent when hECSIT is coexpressed 
with the TRAF6 mutant that lacks E3 ligase activity.    
 Given the interaction of hECSIT with TRAF6 in an E3 ligase dependent 
manner we next assessed if hECSIT could regulate the ubiquitination status of 
TRAF6. Thus hECSIT was knocked down in HEK293 cells with hECSIT-specific 
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siRNA and the ability of LPS to promote ubiquitination of TRAF6 was examined 
(Figure 3.6).  LPS promoted the ubiquitination of TRAF6 in a time dependent manner 
However in knockdown cells TRAF6 ubiquitination was more prolonged. The 
increased ubiquitination of TRAF6 under conditions of ECSIT knockdown correlates 
with the observed enhanced activation of NFκB, and thus the regulatory effects of 
hECSIT on NFκB might be associated with its regulatory effects on the ubiquitination 
of TRAF6.   
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Figure 3.4 hECSIT interacts with TRAF6 
 
(A) U373 cells were treated with LPS (100ng/ml). (B) HeLa cells were treated with IL-1β (10ng/ml) 
for the indicated times. Cell lysates were generated and a sample for whole cell lysates analysis was 
retained. The remaining lysates was immunoprecipitated using an anti-ECSIT antibody. 
Immunoprecipitates were subsequently assayed for co-precipitated TRAF6. The expression levels of 
ECSIT and TRAF6 in whole cell lysates (Input) were also assessed by western blotting. Cell lysates 
were generated and a sample for whole cell lysates analysis was retained. The remaining lysates was 
immunoprecipitated using an anti-ECSIT antibody. Immunoprecipitates were subsequently assayed for 
co-precipitated TRAF6. The expression levels of ECSIT and TRAF6 in whole cell lysates (Input) were 
also assessed by western blotting. (C) HEK293 cells were co-transfected with Empty vector (EV) 
pcDNA3.1 (1µg), myc-tagged hECSIT (1µg) or myc-tagged mECSIT (1µg) with or without FLAG-
tagged TRAF6 (1µg). EV was used to normalize total amount of DNA transfected. 24 hrs post-
transfection cell lysates were generated and immunoprecipitated with anti-myc antibody. 
Immunoprecipitates were then subject to SDS-PAGE and subsequently to western blotting using anti-
FLAG antibody. Whole cell lysates were also analysed by western blotting using anti-FLAG and anti-
Myc antibodies to confirm expression of TRAF6 and ECSIT constructs, respectively. Results are 
representative of 3 independent experiments. 
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 Figure 3.5 Mutation of the RING domain of TRAF6 reduces its interaction with hECSIT 
 
HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1µg) or with or without FLAG-tagged TRAF6 (1µg), TRAF6C70A (1μg) or TRAF6K124A (1μg). EV 
was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were 
generated and immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject to 
SDS-PAGE and subsequently to western blotting using anti-FLAG antibody. Whole cell lysates were 
also analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of 
TRAF6 and ECSIT constructs, respectively. Results are representative of 3 independent experiments. 
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Figure 3.6 Knockdown of hECSIT prolongs LPS induced ubiquitination of TRAF6 in HEK293 
cells  
 
HEK293-TLR4 Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 
48 hrs after transfection cells were then treated with LPS (100 ng/ml) for the indicated times. Cell 
lysates were generated and immunoprecipitated using anti-TRAF6 antibody. The immunoprecipitates 
were then assayed for ubiquitination and TRAF6 by immunoblotting using anti-ubiquitin and TRAF6 
antibodies respectively. Expression levels of TRAF6, ECSIT and β-Actin were also assessed in cell 
lysates to confirm knockdown and equal loading, respectively of input samples prior to 
immunoprecipitation. Data shown is representative of 3 independent experiments. 
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3.2.3 TRAF6 and TAK1 promote, ubiquitination and processing of hECSIT 
The identification of processed forms of hECSIT, when co-expressed with wild type 
TRAF6,  led us to investigate if other signalling components in the NFκB pathway 
could similarly promote processing of hECSIT. TAK1 is an important kinase in the 
activation of NFκB and is a downstream effector of TRAF6 and, therefore we 
compared the ability of TRAF6 and TAK1 to induce processing of hECSIT. TAK1 
activity requires the presence of its protein interaction partner TAB1, and when 
investigating the effects of TAK1, we also co-expressed TAB1. Expression of 
hECSIT with TAK1/TAB1 resulted in the appearance of a number of fast migrating 
anti-ECSIT immunoreactive bands and the profile of these bands was similar to when 
hECSIT was co-expressed with TRAF6 (Figure 3.7A). Furthermore, in these studies 
the co-expression of hECSIT with TRAF6 or TAK1 resulted in the appearance of a 
slower migrating form of hECSIT, and this may possibly represent modification by 
phosphorylation. In order to evaluate the physiological relevance of such putative 
phosphorylation or processing of ECSIT by signalling molecules like TRAF6 and 
TAK1, we immunoblotted for endogenous ECSIT in U373 cells that have been 
stimulated with LPS for various time periods. Stimulation with LPS resulted in a 
time-dependent increase in intensity of fast migrating anti-ECSIT immunoreactive 
bands (Fig 3.7B). We also provide further support that these bands represent 
processed forms of hECSIT since they are absent or greatly reduced in hECSIT 
knockdown cells (Figure 3.7B). Furthermore the hECSIT construct is tagged with a 
myc tag at the C-terminal end of the protein. Given the appearance of a faster 
migrating band when probed with an anti-myc antibody we concluded that the 
processed form of hECSIT is the C-terminal section of the protein and the potential 
processing sites lie in the N-terminal region of the sequence. Given that a previous 
report indicated TRAF6 to promote ubiquitination of mECSIT and that ubiquitination 
is sometimes a pre-requisite to protein processing, we next examined if TRAF6 can 
promote ubiquitination of hECSIT by measuring the ubiquitination status of 
immunoprecipitated hECSIT.  The co-expression of hECSIT with increasing amounts 
of expression constructs encoding TRAF6 resulted in strong ubiquitination of hECSIT 
(Fig. 3.8B). Given that TAK1 can also promote processing of hECSIT we also 
demonstrate that TAK1 stimulates very strongly the ubiquitination of hECSIT (3.8A). 
It is also notable that TAK1 promotes the appearance of an ECSIT form that migrates 
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closely above the full length form and it is tempting to speculate that might be the 
result of TAK1 promoting the phosphorylation of hECSIT.   
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Figure 3.7 TRAF6 and TAK1 promote processing of hECSIT 
 
(A) HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1µg) with or without FLAG-tagged TRAF6 or TAK1 (1µg). EV was used to normalize total amount of 
DNA transfected. 24 hrs post-transfection cell lysates were analysed by western blotting using anti-
FLAG and anti-Myc antibodies to assess levels of TAK1, TRAF6 and ECSIT , respectively. Results are 
representative of 3 independent experiments. (B) U373 Cells were infected with Lentivirus containing 
constructs encoding control or hECSIT specific shRNA. Cells were grown in the presence of 
puromycin (8µg/ml) to select cells with stably integrated shRNA constructs. Selected cells were treated 
with LPS (100ng/ml) for the indicated times. Cell lysates were subsequently generated and probed for 
processed hECSIT by western blotting using anti-ECSIT antibody. Data shown is representative of 3 
independent experiments. 
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Figure 3.8 TAK1 and TRAF6 promote the ubiquitination of hECSIT 
 
HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq (1µg), myc-tagged hECSIT 
(1µg) with or without FLAG-tagged TAK1 (1µg) and TAB1 (1μg). EV was used to normalize total 
amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated using an anti-myc antibody. Immunoprecipitates were then subject to SDS-PAGE 
and subsequently to western blotting using anti-HA antibody. Whole cell lysates were also analysed by 
western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of TAK1 and ECSIT 
constructs, respectively. (B) HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq 
(1µg), and myc-tagged hECSIT (1µg) with or without increasing concentrations of FLAG-tagged 
TRAF6 (0.025-1µg). EV was used to normalize total amount of DNA transfected. 24 hrs post-
transfection cell lysates were generated and immunoprecipitated using an anti-myc antibody. 
Immunoprecipitates were then subject to SDS-PAGE and subsequently to western blotting using anti-
HA antibody. Whole cell lysates were also analysed by western blotting using anti-FLAG and anti-Myc 
antibodies to confirm expression of TRAF6 and ECSIT constructs, respectively. Data shown is 
representative of 3 independent experiments. 
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3.2.4 hECSIT interacts with TAK1 
 
Given the ability of TAK1 to potentially regulate the phosphorylation, ubiquitination 
and processing of hECSIT, we characterised  the potential interaction between 
hECSIT and TAK1 using co-immunoprecipitation analysis. The interaction of TAK1 
with hECSIT and mECSIT was initially investigated after transient transfection of 
expression constructs encoding both proteins in HEK293T cells. Myc-tagged hECSIT 
or mECSIT was co-expressed with FLAG-tagged TAK1/TAB1, immunoprecipitated 
with anti-myc antibody and probed for the presence of co-precipitated FLAG-tagged 
TAK1. As shown in Figure 3.9C both hECSIT and mECSIT interacted with TAK1. 
We next aimed to confirm interaction of endogenous forms of these proteins and 
characterise the potential regulatory effects of TLR signalling on such interactions. 
U373 cells were treated with LPS and immunoprecipitated with anti-ECSIT antibody. 
The subsequent precipitate was then analyzed for the presence of co-precipitated 
TAK1 by western blotting. LPS promoted the interaction of TAK1 with hECSIT in a 
time-dependent manner, as demonstrated by the co-immunoprecipitation of the two 
proteins (Figure 3.9A). Treatment of HeLa cells with IL-1β also resulted in the co-
immunoprecipitation of hECSIT with TAK1 in a time dependent manner (Figure 
3.9B). These data confirm that pro-inflammatory signalling pathways such as TLR4 
and IL-1 promote the association of TAK1 with hECSIT and this may lead to the 
phosphorylation, ubiquitination and processing of hECSIT. 
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Figure 3.9 hECSIT interacts with TAK1 
 
(A) U373 cells were treated with LPS (100ng/ml) for the indicated times. (B) HeLa cells were treated 
with IL-1β (10ng/ml) for the indicated times.  Cell lysates were generated and a sample for whole cell 
lysates analysis was retained. The remaining lysates was immunoprecipitated using an anti-ECSIT 
antibody. Immunoprecipitates were subsequently assayed for co-precipitated TAK1. The expression 
levels of ECSIT and TAK1 in whole cell lysates (Input) were also assessed by western blotting. (C) 
HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1µg) or myc-tagged mECSIT (1µg) with or without FLAG-tagged TAK1 (1µg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject to SDS-PAGE and 
subsequently to western blotting using anti-FLAG antibody. Whole cell lysates were also analysed by 
western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of TAK1 and ECSIT 
constructs, respectively. Data shown are representative of 3 independent experiments. 
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3.2.5 The Kinase activity and ubiquitination of TAK1 is required for the      
phosphorylation, ubiquitination and processing of hECSIT 
We next began to investigate the direct role of TAK1 in regulating the various 
modifications of hECSIT. TAK1 facilitates the activation of NFκB and the MAP 
kinases via its kinase activity. The ubiquitination of TAK1 is also required in the 
activation of NFκB in response to IL-1β and TNF-α (Fan et al, 2009). We first 
analysed the role of, if any, the kinase activity of TAK1  in regulating the various 
modifications of hECSIT. To this end we employed the TAK1 inhibitor 5z-7-
oxozeanol to block the kinase activity of TAK1. LPS stimulation of U373 cells 
resulted in hECSIT processing and  this was dramatically reduced when cells were 
pre-treated with the TAK1 inhibitor (Figure 3.10A). Similarly HeLa cells, treated with 
IL-1β, also showed time-dependent processing of hECSIT and pre-treatment of cells 
with a TAK1 inhibitor blocked this IL-1β induced processing of hECSIT. The 
efficacy of the inhibitor was confirmed by demonstrating its ability to block IL-1-
induced degradation of  IκB-α in HeLa cells (Figure 3.10B). To further probe the 
moleclar basis to the importance of TAK1 kinase activity for ECSIT processing, an 
expression construct encoding a kinase dead form of TAK1 was assessed for its 
potential to interact with hECSIT. Kinase dead TAK1 failed to mimic its wild type 
counterpart in interacting with hECSIT (Figure 3.11A) and thus unsurprisingly did not 
induce the putative phosphorylation, processing (Figure 3.11A) or ubiquitination of 
hECSIT (Figure 3.11B). Both K158 and K209 have been described as putative 
ubiquitination sites in TAK1 (Fan et al, 2011) with the former identified as an 
important ubiquitination site for the activation of NFκB. Introduction of the TAK1-
K158R mutation resulted in the loss of binding of TAK1 to hECSIT and lack of effect 
on the  phosphorylation, processing (3.12A) and ubiquitination (3.12B) of hECSIT. 
Ubiquitination of K209 is dispensable for TAK1 mediated activation of NFκB and 
interestingly the K209R mutant form of TAK1 retained the ability, albeit to a slightly 
lesser effect, to interact with hECSIT and promote its various modifications. In order 
to confirm the potential phosphorylation of hECSIT by TAK1, lysates containing 
over-expressed hECSIT and TAK1 were incubated with or without the phosphatase 
CIP. However CIP treatment had no effect on this modification (Figure 3.13). 
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Figure 3.10 Inhibition of TAK1 blocks LPS and IL-1β induced processing of hECSIT  
 
(A) U373 cells were pre-treated with 5Z-7-oxozeanol (20Mm) or DMSO (Vehicle) for 2hrs followed 
by treatment with LPS (100ng/ml) for the indicated times. Cell lysates were subsequently generated 
and probed for hECSIT using an anti-ECSIT antibody. (B)  HeLa cells were pre-treated with 5Z-7-
oxozeanol (20Mm) or DMSO (Vehicle) for 2hrs followed by treatment with IL-1β (10ng/ml) for the 
indicated times. Cell lysates were subsequently generated and probed for hECSIT using an anti-ECSIT 
antibody. Processed forms of hECSIT are indicated by arrows. 
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Figure 3.11 The kinase activity of TAK1 is required for its interaction with hECSIT and to 
manifest putative phosphorylation, processing and ubiquitination of hECSIT 
 
(A) HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1μg) with or without FLAG-tagged TAK1 (1µg) or Kinase dead TAK1 (1μg) and TAB1 (1μg). EV 
was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were 
generated and immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject to 
SDS-PAGE and subsequently to western blotting using anti-FLAG antibody. Whole cell lysates were 
also analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of 
TAK1 and ECSIT constructs, respectively. (B) HEK293 cells were co-transfected with Empty vector 
(1µg), HA-Ubq (1µg), myc-tagged hECSIT (1µg) with or without FLAG-tagged TAK1 (1µg) and 
TAB1 (1μg). EV was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell 
lysates were generated and immunoprecipitated using an anti-myc antibody. Immunoprecipitates were 
then subject to SDS-PAGE and subsequently to western blotting using anti-HA antibody. Whole cell 
lysates were also analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm 
expression of TAK1 and ECSIT constructs, respectively. Data shown is representative of 3 independent 
experiments 
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Figure 3.12 The K158 ubiquitination site of TAK1 is required for its binding to and modification 
of hECSIT  
 
(A) HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1μg) with or without FLAG-tagged TAK1 (1µg), TAK1-K158R or TAK1-K209R (1μg) and TAB1 
(1μg). EV was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates 
were generated and immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject 
to SDS-PAGE and subsequently to western blotting using anti-FLAG antibody. Whole cell lysates 
were also analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm 
expression of TAK1 and ECSIT constructs, respectively. (B) HEK293 cells were co-transfected with 
Empty vector (1µg), HA-Ubq (1µg), myc-tagged hECSIT (1µg) with or without FLAG-tagged TAK1, 
TAK1-K158R or TAK1-K209R (1µg) and TAB1 (1μg). EV was used to normalize total amount of 
DNA transfected. 24 hrs post-transfection cell lysates were generated and immunoprecipitated using an 
anti-myc antibody. Immunoprecipitates were then subject to SDS-PAGE and subsequently to western 
blotting using anti-HA antibody. Whole cell lysates were also analysed by western blotting using anti-
FLAG and anti-Myc antibodies to confirm expression of TAK1 and ECSIT constructs, respectively. 
Data shown is representative of 3 independent experiments. 
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Figure 3.13 Phosphatase treatment of TAK1 induced hECSIT modification 
HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1μg) with or without FLAG-tagged TAK1 and TAB1 (1µg) or TRAF6 (1µg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
incubated at 37°C for 30 minutes with Calf Intestinal phosphatase (CIP). 4X sample buffer was then 
added to terminate the reaction. Samples were then subject to SDS-PAGE and subsequently to western 
blotting using anti-FLAG antibody. Whole cell lysates were also analysed by western blotting using 
anti-FLAG and anti-Myc antibodies to confirm expression of TAK1 and ECSIT constructs, 
respectively 
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3.2.6 Caspase 8 promotes the phosphorylation, ubiquitination and processing of 
hECSIT 
 
From the previous results it was established that hECSIT is subjected to various forms 
of modification including extensive processing. The identification of TAK1 as the 
potential kinase and TRAF6 as the E3 ligase led us to search for a protease that could 
potentially process hECSIT. Caspase 8 is a widely studied protease that functions in 
most TLR  pathways and has been shown to directly process proteins such as RIP1 
and IRF3. Caspase 8 was initially shown to co-immunoprecipitate with hECSIT and 
this was independent of its caspase catalytic activty since the C360S point mutant 
form of caspase 8 was also capable of interacting with hECSIT . Caspase 8 also 
promoted the phosphorylation and processing of hECSIT however the Caspase 8-
C360s mutant was unable to process hECSIT, although phosphorylation was not 
affected (Figure 3.14A). As Caspase 8 promoted phosphorylation of hECSIT we next 
addressed if caspase 8 could induce ubiquitination of hECSIT. Co-expression of 
hECSIT with Caspase 8 resulted in the ubiquitination of hECSIT. However, while 
Caspase 8-C360s retained its ability to promote phosphorylation of hECSIT it failed 
to induce the ubiquitination of hECSIT (Figure 3.14B). Bioinformatic analysis was 
also performed on the hECSIT protein sequence in order to identify possible Caspase 
recognition sites (Table 3.1) however the corresponding processed fragments did not 
correspond in size to any of the predicted processing sites. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 Results 
_____________________________________________________________________ 
95 
 
 
 
 
 
 
Figure 3.14 Caspase 8 promotes the phosphorylation, processing and ubiquitination of hECSIT 
through its catalytic cysteine residue 
 
(A) HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1μg) with or without HA-tagged Caspase 8 (1µg) or Caspase 8-C360S (1μg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subjected to SDS-PAGE 
and subsequently to western blotting using anti-HA antibody. Whole cell lysates were also analysed by 
western blotting using anti-HA and anti-Myc antibodies to confirm expression of TAK1 and ECSIT 
constructs, respectively. (B) HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq 
(1µg), myc-tagged hECSIT (1µg) with or without HA-tagged Caspase 8 (1µg) or Caspase 8-C360S 
(1μg). EV was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates 
were generated and immunoprecipitated using an anti-myc antibody. Immunoprecipitates were then 
subject to SDS-PAGE and subsequently to western blotting using anti-HA antibody. Whole cell lysates 
were also analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm 
expression of Caspase 8 and ECSIT constructs, respectively. 
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Table 3.1 Bioinformatic analysis of hECSIT sequence for Caspase cleavage site 
 
The sequence for hECSIT was analysed using the Uni-prot sortware for potenital  caspase  Aspartic 
Acid and Glutamic Acid recognition sites. 
 
 
Sequence Name ECSIT 
Sequence MSWVQ...QQGQS 
Length of Sequence 431 residues 
Predicted Sites (P4-P1) DPVE-225 
DNYE-345 
DINE-350 
DHQE-418 
Predicted Sites (P4-P2') YGVE-123 
VERD-125 
EQME-169 
KETE-180 
DPVE-225 
MEPD-237 
EERE-316 
REVE-318 
ETPE-322 
DNYE-345 
YEFD-347 
DINE-350 
NEVE-352 
STRE-399 
DHQE-418 
QEED-420 
EEDD-421 
Predicted Sites (P14-P10') DPVE-225 
MEPD-237 
VFVE-288 
SGWD-342 
DNYE-345 
YEFD-347 
DINE-350 
EVEE-353 
STRE-399 
EEDD-421 
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3.2.8 The C-terminus of hECSIT is inhibitory and contains both E3 ligase and 
DUB activity  
 
We next aimed to characterise the processed forms of hECSIT that are apparent in 
response to TLR/IL-1R signalling or when co-expressed with TRAF6 or TAK1. As 
before, co-expression of myc-hECSIT with TAK1/TAB1 resulted in the migration of 
a number of processed hECSIT bands on a western blot (Figure 3.15A). An anti-myc 
antibody was used to immunoprecipitate the various forms of ECSIT and these were 
resolved by SDS-PAGE and  Coomassie stained (Figure 3.15B). The processed form 
of hECSIT, represented by the band of highest intensity, was then excised and 
tryptically  digested for LC/MS mass spectrometry analysis. Peptides corresponding 
to amino acids in the C-terminal section of hECSIT were identified (Figure 3.15C). 
Protein marker and mass spec coverage of the hECSIT sequence identified processed 
hECSIT to be a C-terminal  myc tagged fragment ,  ~ 40kDa in size.  
In order to understand the functional consequence of hECSIT processing 
truncation  mutants incorporating processed hECSIT were generated. A previous 
study demonstrated that truncation of the N-terminus of mECSIT results in a 
dominant negative form that negatively regulates the NFκB pathway (Kopp et al, 
1999). Thus a corresponding C-terminal (residues 266-431) mutant of hECSIT was 
generated and the residual N-terminal fragment (residues 1-265) was also made.  In 
order to investigate the inhibitory effects of both truncation mutants NFκB luciferase 
reporter assays were used. Transfection of TRAF6 resulted in NFκB activation. While 
full length hECSIT slighly inhibited this activation, the C-terminal truncation mutant 
showed greater inhibitory effects whereas the N-terminal truncation mutant failed to 
affect TRAF6 induced activation of NFκB (Figure 3.16A). In order to confirm this 
effect a semi-rescue experiment was carried out using hECSIT specific siRNA. 
Treatment of HEK293-TLR4 cells with LPS resulted in an augmented NFκB response 
when hECSIT was knocked down however reconstitution of hECSIT with the C-
terminal truncation mutated rescued the inhibitory effect resulting in decreased NFκB 
activation in response to LPS. In keeping with our previous data the N-terminal 
fragment failed to reconstitute the inhibitory effect (Figure 3.16B). These results 
suggested that hECSIT exerts its regulatory effect via its C-terminus and that the 
processing of hECSIT is required for it to inhibit TRAF6. 
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We next probed the molecular basis to the inhibitory effects of the C-terminal 
fragment. Given that ECSIT knockdown leads to enhanced TLR-induced 
ubiquitination of TRAF6 we hypothesised that the C-terminal fragment may possess 
deubiquitinating activity.  In order to analyse  deubiquitinating activity a recombinant 
protein encoding the C-terminal truncation mutant was generated and its  purity and 
identify was confirmed by, coomassie staining, western blotting  and mass 
spectrometry  (Figure 3.17).  DUB activity was analysed using a luciferase tagged 
DUB substrate. Incubation of recombinant full length hECSIT with the DUB substrate 
failed to show any DUB activity. However the recombinant  C-terminal fragment of 
hECSIT exhibited strong DUB activity over the indicated incubation time-points 
(Figure 3.18A). As other DUB enzymes such as A20 also posess E3 ligase activity we 
assessed hECSIT for E3 ligase activity. Recombinant full length hECSIT or 
recombinant c-terminal hECSIT were incubated with the indicated ubiquitination 
reaction mix and assessed for their ability to generate polyubiquitin chains by probing 
for ubiquitin. Both full length and the C-terminal mutant of hECSIT had E3 ligase 
activity (Figure 3.18B). This indicated that the C-terminal processed fragment of 
hECSIT contains both E3 ligase and a cryptic DUB function that is only active when 
processed.  
In order to confirm TRAF6 as a possible substrate for the DUB activity of 
processed hECSIT an in vitro ubiquitination reaction was carried out and the C-
terminal fragment of hECSIT was assayed for its ability to deubiquitinate TRAF6. 
Recombinant TRAF6 was incubated with or without full length recombinant hECSIT 
or recombinant C-terminal hECSIT in the indicated ubiquitin reaction mix. Following 
a 2hr reaction TRAF6 was immunoprecipitated and levels of TRAF6 ubiquitination 
were analysed by probing the immuno-precipitates with an anti-ubiquitin antibody 
(Figure 3.19). Incubation of TRAF6 with C-terminal hECSIT resulted in the 
deubiquitination of TRAF6. This suggested that hECSIT is processed in order to 
activate the DUB activity of hECSIT and target TRAF6 for deubiquitination. 
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Figure 3.15 Identification of processed hECSIT  
 
HEK293T cells were co-transfected with myc-tagged hECSIT (50μg) FLAG-tagged TAK1 (25μg) and 
TAB1 (25μg). 24 hrs post-transfection cell lysates were generated and immunoprecipitated with anti-
myc antibody. Immunoprecipitates and whole cell lysates were then subject to SDS-PAGE and 
subsequently to western blotting using Coomassie staining (A) and anti-myc antibody (B).  Processed 
hECSIT (Indicated by arrow) was then excised from the coomassie gel and subjected to tryptic 
digestion followed by LC-MS/MS. Mascot searches were determined using Swiss-Prot databases for 
the human genome. 
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Figure 3.16 The C-terminus of hECSIT is more inhibitory than full length hECSIT   
 
(A) HEK293 cells were co-transfected with NFκB firefly luciferase reporter construct (80ng), TK 
renilla (20ng) and myc-tagged hECSIT or mECSIT or the C-terminal or N-terminal of hECSIT (50ng) 
with or without FLAG-tagged TRAF6 (100ng). Empty Vector (EV) pcDNA3.1 was used to normalise 
total amount of DNA whilst TK Renilla was used to normalise for transfection efficiency. 24hr post-
transfection cell lysates were generated the following day and assayed for firefly luciferase activity. (B) 
HEK293 cells were co-transfected with NFκB firefly luciferase reporter construct (80ng), TK Renilla 
(20ng) and hECSIT specific siRNA or Lamin control siRNA (10nM).  24 hrs post transfection the cells 
were transfected with EV, C-terminal or N-terminal hECSIT. 24 hours later cells were treated with LPS 
for 6 hrs. Cell lysates were then generated and assayed for firefly luciferase and renilla luciferase 
activity. Results represent mean +/- SD of triplicate determinations and is a representative of 3 
independent experiments. 
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Figure 3.17 Generation and purification of recombinant C-terminus hECSIT 
 
(A) His-tagged C-terminal hECSIT was purified from BL21 E.coli competent cells using Ni-NTA 
resin. Eluted protein was then subjected to SDS-PAGE followed by western blotting and Coomassie 
staining to determine protein purity (B). Bands from the Coomassie gel were then excised and trypticly 
digested and analysed using LC-MS/MS Agilent 6510 Ion trap technologies. Swiss-Prot database 
searches recovered 60% coverage of the C-terminus of hECSIT (C). 
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Figure 3.18 The C-terminus of hECSIT contains both DUB and E3 ligase activity  
 
(A) Recombinant TRAF6, hECSIT and C-terminal hECSIT (1μg) were incubated with the DUB-Glo 
protease assay substrate. Luciferase activity was then measured after the indicated times to assess for 
DUB activity. (B) Increasing concentrations of recombinant hECSIT or recombinant c-term hECSIT 
(0.02-1μg) was incubated in a reaction mix containing Ubiquitin (2μg), E1 (50ng), E2 UbcH13/Uev1a 
(400ng), MgCl2 (2mM), ATP (2Mm), protease inhibitor cocktail and H20. Reactions were incubated at 
37◦C for 2hrs and terminated with 4x SDS sample buffer. Samples were then subjected to western 
blotting to analyse poly-ubiquitin chains and expression of hECSIT. 
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Figure 3.19 The C-terminus of hECSIT deubiquitinates TRAF6 in vitro 
 
Recombinant TRAF6 was incubated with or without the indicated concentrations of recombinant 
hECSIT (0.5-1μg) or C-terminal hECSIT (0.5-1μg) in a reaction mix containing Ubiquitin (2μg), E1 
(50ng), E2 UbcH13/Uev1a (400ng), MgCl2 (2mM), ATP (2Mm), protease inhibitor cocktail and H20. 
Reactions were incubated at 37◦C for 2hrs and subsequently immunoprecipitated using anti-TRAF6 
antibody. The immunoprecipitate was then assayed for TRAF6 ubiquitination by Immunoblotting for 
ubiquitin. Levels of TRAF3, ECSIT and ubiquitin were also assessed in the input by western blotting. 
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3.2.10 Mutation of a PEST-like sequence enhances the inhibitory effect of 
hECSIT  
Analysis of the hECSIT sequence revealed a putative conserved PEST like sequence 
in the C-terminus. PEST sequence is a peptide sequence which is rich 
in Proline (P), Glutamic acid (E), Serine (S), and Threonine (T). This sequence is 
associated with proteins that have a short intracellular half-life; hence, the PEST 
sequence acts as a signal peptide for protein degradation. Given that this PEST 
sequence was located in the C-terminus we examined how mutation of the PEST 
sequence would affect the inhibitory capacity of hECSIT. Myc-tagged hECSIT 
E322A and myc-tagged hECSIT-E323A were assessed for their ability to interact with 
TRAF6. Co-immunoprecipitation experiments revealed that mutation of the hECSIT 
PEST sequence did not affect the interaction between hECSIT and TRAF6 with a 
comparable interaction observed between wild type hECSIT and hECSIT-E322 and 
hECSIT-E323 (Figure 3.20A). Given that mutation of the PEST sequence did not 
affect the interaction of TRAF6 and hECSIT we next sought to examine the capacity 
of the wild type hECSIT and the PEST mutants to deubiquitinate TRAF6. Co-
transfection of TRAF6 with hECSIT resulted in greatly reduced ubiquitination of 
TRAF6 and this is consistent with the C-terminal region of hECSIT displaying DUB 
activity. Point mutant forms of the PEST sequences showed slightly greater levels of 
processing, at least for the E322A mutant, and this was associated with augmented 
inhibitory effects on the ubiquitination of TRAF6 (Figure 3.20B) further supporting 
an inhibitory role for the processed hECSIT forms.  
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Figure 3.20 Mutation of a hECSIT PEST sequence enhances processing and TRAF6 
deubiquitination  
 
HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq (1µg), FLAG-tagged TRAF6 
(1µg) with or without myc-tagged hECSIT (1μg) or hE-E322a (1μg) or hE-E323a (1μg). EV was used 
to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated using an anti-FLAG antibody. Immunoprecipitates were then subject to SDS-
PAGE and subsequently to western blotting using anti-HA antibody. Whole cell lysates were also 
analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of 
TRAF6 and ECSIT constructs, respectively. 
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3.2.11 Generation, genotyping and phenotyping of Humanised ECSIT mice 
 
The embryonic lethality of Ecsit -/- mice has seriously hampered the elucidation of the 
physiological roles of ECSIT. Consequently heterozygous Ecsit +/- mice have been 
used that show  ~ 40% reduction in ECSIT expression in some cells relative to their 
wildtype counterparts. Given our initial findings that hECSIT appears to act as  a 
negative regulator of TLR signalling and differs functionally from murine ECSIT we 
were keen to establish a model to allow for delineation of the physiological role of 
human ECSIT. To this end and towards the completion of the work for this thesis, we 
were successful in generating a knockin mouse in which the murine Ecsit gene was 
replaced by the human ECSIT gene. Such  a humanised mouse was generated by 
Taconic Artemis using their homologous recombination technology and the Flpe 
transgene (Figure 3.21C). The Flpe transgene was subsequently removed by breeding 
the resulting ECSIT +/- mice with  C57BL/6 mice during colony expansion. Mice were 
genotyped by PCR analysis of DNA isolated from ear punches.  
Confirmation of gene-replacement was confirmed by RT-PCR   and western 
blotting. Primers specific to both hECSIT and mECSIT were used to amplify ECSIT 
DNA isolated from MEFs. The use of genomic DNA from WT mice as template  
resulted in the amplification of a 241 bp fragment from the murine Ecsit allele whilst 
the presence of the human ECSIT allele generates a fragment of 349 bp. (Figure 
3.21A). Protein expression was determined by generating cell lysates from MEF cells. 
Probing of lysates with an ECSIT specific polyclonal antobody showed expression of 
mECSIT in WT mice and expression of hECSIT in homozygote mice. Heterozygote 
mice expressed both mECSIT and hECSIT as indicated by arrows (Figure 3.21B).  
Both heterozygous and homozygous ECSIT mice were viable however 
homozygote females were unable to carry a litter to full term and pregnancy in female 
mice resulted in miscarriage or fatality. 
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Figure 3.21 Generation and genotyping of Humanised ECSIT mice  
 
(A) Genotyping was performed by PCR on genomic DNA from ear punches. Primers for the ECSIT 
gene differentiate between the wild type allele (WT) from the human allele in homozygote mice (-/- 
(Hum)) based on different fragment size. CD79b was used as the control allele. (B) MEFs were isolated 
from WT, ECSIT+/- and ECSIT+/+ (Hum) embryos. Cell lysates were prepared and subjected to western 
blotting using anti-ECSIT and anti-β-Actin antibodies. (C) Diagram shows: the mouse ECSIT gene 
exons that were replaced with the hECSIT exons through homologous recombination.  
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3.2.11 Replacement of Ecsit with human ECSIT in a Humanised mouse model 
does not effect LPS and IL-1 induced activation of  NFκB  
As demonstrated previously siRNA and shRNA knockdown of hECSIT resulted in 
modest augmentation of NFκB in response to IL-1 and LPS indicating a potential 
negative inhibitory role for hECSIT in the NFκB pathway and an opposing function 
from its murine counterpart. In order to further assess the role of hECSIT in regulating 
NFκB primary MEF cells were isolated from WT and ECSIT+/+ (Hum) embryos and 
treated with LPS and levels of IL-6 and Keratinocyte Chemoattractant (KC) were 
measured by ELISA. Replacement of Ecsit with ECSIT failed to effect LPS induced 
IL-6 and KC production (Figure 3.22). To further confirm this we analysed the 
intracellular activation markers of NFκB activation. Stimulation of MEF cells with 
LPS again failed to alter the NFκB response in humanised MEFs in comparison to 
their WT counterparts as demonstrated by normal levels of p-IκB-α and p-p65 in our 
humanised MEF cells (Figure 3.23). As hECSIT had been previously shown to also 
negatively regulate IL-1R signalling we analysed NFκB activation in response to IL-
1β. As with LPS, no difference in levels of p-p65 and p-IκB-α were observed  in 
humanised MEF cells treated with IL-1β in comparison to WT MEF cells (Figure 
3.24). We next examined other intra-cellular read-outs in order to gain a functional 
understanding of hECSIT’s mechanism of action. 
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Figure 3.22 Replacement of Ecsit with ECSIT does not impair LPS induced expression of IL-6 
and KC  
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and treated with or without LPS (100ng/ml) 
for 24 hrs. NT and treated media were then assayed for levels of IL-6 (A) and KC (B) by ELISA. Data 
represents the mean +/- S.D of 3 independent experiments.  
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Figure 3.23 Replacement of Ecsit with ECSIT does not affect LPS induced NFκB activation 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and treated with or without LPS (100ng/ml) 
for the indicted times. Cell lysates were then prepared and immunoblotted for phosphorylated and total 
levels of P65 and IκB-α. Lysates were also probed for levels of ECSIT and β-Actin.  
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Figure 3.24 Replacement of Ecsit with ECSIT does not affect IL-1 induced NFκB activation 
 
MEFs were isolated from WT and -/- (Hum) embryos and treated with or without IL-1 (10ng/ml) for 
the indicted times. Cell lysates were then prepared and immunoblotted for phosphorylated and total 
levels of P65 IκB-α and IKK-α. Lysates were also probed for levels of ECSIT and β-Actin.  
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3.2.12 hECSIT inhibits Inflammasome mediated IL-1β production 
As discussed previously knockdown of hECSIT resulted in modest increases in 
NFκB, however production of mROS in response to LPS was also significantly 
enhanced when hECSIT was knocked down. As no difference in the IL-1/LPS NFκB 
response in our humanised model was observed we further analysed the effect of 
hECSIT on mROS production. mROS has been shown to function as a second signal 
for inflammasome assembly and IL-1β processng. In order to analyse the effect of 
hECSIT on this MEF cells were  treated with LPS and ATP to drive inflammasome 
activation. WT MEFs treated with LPS and ATP for the indicated times resulted in 
induction of IL-1β production, however this was significantly attenuated in our ECSIT 
+/+(Hum) cells as demonstrated by lower levels of IL-1β measured by ELISA (Figure 
3.25). 
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Figure 3.25 Replacement of Ecsit with ECSIT impairs Inflammasome induced IL-1β production 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and treated with or without LPS (100ng/ml) 
for 3hrs followed by ATP (100mM) for 1hr. NT and treated media were then assayed for levels of  IL-
1β by ELISA. Data represents the mean +/- S.D of 3 independent experiments; p=<0.01 
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Figure 3.26 Schematic representation of hECSIT’s regulatory effect in TLR4 signalling 
Activation of TLR4 by LPS results in ECSIT phosphorylation, ubiquitination and processing. 
Processing of hECSIT results in an active DUB enzyme which can deubiquitinate TRAF6 in an auto-
regulatory fashion. 
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3.3 Discussion  
 
During infection TLRs function as the immune system’s first line of defence. 
Activation of TLRs leads to the nuclear translocation of transcription factors such as 
NFκB and the IRFs which promote the production of pro-inflammatory cytokines and 
type 1 IFN. NFκB is a highly regulated transcription factor and many  intracellular 
signalling intermediates promote or inhibit activation of NFκB. ECSIT was originally 
identified as a TRAF6 interacting protein in a yeast two hybrid study that positively 
regulated the activation of NFκB. Subsequent studies highlighted the importance of 
ECSIT in development as ECSIT knockout mice displayed a lethal embryonic 
phenotype. The production of heterozygote mice in a recent report identified ECSIT 
as a positive regulator of mROS production and showed ECSIT as a mitochondrial 
protein that linked TLR signalling to the outer membranes of the mitochondria. 
Currently there exists no published information on the role of the human orthologue 
of hECSIT in TLR signalling. The present study aimed to build on early findings from 
the author’s host laboratory and especially focus on the mechanistic basis to the 
effects of hECSIT and an explanation for the functional differences between mECSIT 
and hECSIT.  
  As previously discussed knockdown of hECSIT modestly augmented NFκB 
activation in response to LPS. However the recently available information on 
mECSIT’s role in mROS production prompted us to examine the potential role of 
hECSIT in mROS production. Knockdown of hECSIT in primary human cells 
resulted in augmented LPS induced mROS production. As hECSIT's effect on NFκB 
activation is marginal we speculate that augmented mROS may explain the indirect 
effect on NFκB as previous studies have shown that ROS can activate NFκB during 
cell stress responses (Ghosh and Karin, 2002).  Given that over-expression of hECSIT 
results in the deubiquitination of TRAF6 we next looked at TRAF6 ubiquitination at 
an endogenous level. Knockdown of hECSIT resulted in prolonged ubiquitination of 
TRAF6 in response to LPS. However this effect was not mirrored by proinflammatory 
cytokine production. The ubiquitination of TRAF6 has been associated with other 
intracellular signalling pathways regulated by LPS, such as mROS (West et al, 2011) 
and autophagy (Shi and Kehrl, 2010). Also it has been suggested that free ubiquitin 
chains are sufficient to activate NFκB suggesting that TRAF6 may be dispensable for 
NFκB activation. As mentioned ECSIT has primarily been studied in the context of 
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mitochondrial function (Vogel et al 2007; West et al, 2011) and for the most part 
localises in the outer mitochondrial membranes. When TLRs are activated TRAF6 
ubiquitination of mECSIT leads to its accumulation at the outer mitochondrial 
membrane (West et al, 2011). Therefore hECSIT may only temporally target a small 
proportion of TRAF6 at certain sub-cellular locations and hence no direct downstream 
effect is seen as a result of this. However the exact sub-cellular location of hECSIT in 
response to TLR ligands has yet to be analysed. This will need to be examined to 
confirm the latter hypothesis.  
The conserved interaction shown between hECSIT and TRAF6 led us to 
investigate the post-translational modifications of hECSIT. TRAF6 over-expression 
induced various modifications of hECSIT, including putative phosphorylation and 
ubiquitination and processing of hECSIT, and we were keen to see if these various 
modifications were related and possibly regulated in a sequential manner. Given that 
TRAF6 triggers TAK1 activation we were especially keen to assess if TAK1 could 
reproduce the modifications of hECSIT that were effected by co-expression of 
TRAF6. We initially showed that both LPS and IL-1 induced a time-dependent 
interaction between TAK1 and hECSIT, and that co-expression of TAK1 was 
sufficient to trigger the various modifications of hECSIT. Mutational analysis 
revealed that both the kinase activity of TAK1 and ubiquitination of TAK1 are 
required for the processing of hECSIT. Kinase dead TAK1 is unable to activate NFκB 
and the MAP kinases and mutation of TAK1 at K158 also abrogates NFκB activation 
(Fan et al, 2011). This raised the possibility that processing of hECSIT first required 
the activation of NFκB to induce the auto-regulatory processing of hECSIT. To 
confirm this we utilised the pharmacological inhibitor 5z-7-oxozeanol to inhibit 
TAK1 kinase activity. In keeping with the previous data inhibition of TAK1 kinase 
activity impaired LPS and IL-1β induced processing of hECSIT. TAK1 inhibition also 
inhibited NFκB as demonstrated by reduced IκB-degradation in response to IL-1β. 
This indicated that the activation of NFκB was possibly required to drive the 
formation of the regulatory complex that was mediating the activation of hECSIT.  
Many similar negative feedback loops have been described previously and it is not 
unprecedented that hECSIT exerts its inhibitory effect in such a manner. Other 
kinases such as IKK-α have been attributed to inhibition of NFκB by activating 
negative regulators such as A20 (Shembade et al, 2010). Despite many attempts we 
were unable to show direct phosphorylation of hECSIT by recombinant TAK1 in an 
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in vitro system. This might be due to recombinant TAK1 lacking some pre-requisite 
for modification or an ancillary protein to manifest its kinase activity towards 
hECSIT. Furthermore, incubation of lysates containing phosphorylated hECSIT with 
the phosphatase CIP had no effect on levels of phosphorylated hECSIT. As this was 
done using an over-expression approach the levels of CIP used may not have been at a 
high enough threshold to reduce the overall level of phosphorylated hECSIT. 
However the possibility of another form of modification must also be considered and 
different approaches to identify the TAK1 mediated modification will be investigated 
in future experiments. An endogenous approach may give a clearer result. Given that 
TRAF6 had been previously described to ubiquitinate hECSIT we next aimed to 
identify a protease that was being recruited to process hECSIT. Caspase 8 induced 
processing of hECSIT; however the Caspase 8 catalytic mutant was unable to induce 
processing of hECSIT. The protease activity of Caspase 8 has a number of targets in 
TLR signalling including IRF3 (Sears et al, 2011), RIP1 (Rajput et al, 2011) and 
CYLD (O’Donnell et al, 2012). Bioinformatic analysis was also performed on the 
hECSIT sequence in order to find potential caspase recognition sites in the sequence. 
Whilst the Uni-Prot software predicted a number sites, the relative sizes of the 
processed site would not correspond to the processed ECSIT bands we have 
identified. Furthermore mutation of sites D74, D85, D108 and D125 to serine residues 
did not affect the ability of Caspase 8 to induce hECSIT processing (data not shown).  
A direct processing site will need to be determined in order to confirm the 
requirement for Caspase 8 in hECSIT processing.  
We next aimed to understand the functional consequence of hECSIT 
processing. ECSIT has been shown to contain an N-terminal mitochondrial 
localisation sequence. It is possible that processing of hECSIT allows it to leave the 
mitochondrial membranes and exhibit its inhibitory effect on TRAF6. In support of 
this it has been previously shown that a truncated form of mECSIT lacking its N-
terminus promotes a dominant negative effect on NFκB (Kopp et al, 1999). We 
therefore generated a truncated hECSIT construct based on the mECSIT truncation 
sequence to analyse its inhibitory function and enzymatic activity. The N-terminal 
truncation mutant, coding amino acids 261-431, exhibited a stronger inhibitory effect 
than the full length protein indicating that processing is required for hECSIT to carry 
out its inhibitory function. To confirm this we measured DUB activity and also E3 
ligase activity of recombinant full length and C-terminal hECSIT.  Surprisingly the C-
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terminus of hECSIT contained both E3 ligase and DUB activity and the C-terminal 
hECSIT mutant was able to directly deubiquitinate TRAF6 in vitro. Such roles have 
also been extensively described for A20 where both E3 ligase and activity are utilised 
by A20 to inhibit TLR and TNF signalling. It is possible that the processing of 
hECSIT results in it exiting the mitochondria thereby allowing it deubiquitinate 
TRAF6. As hECSIT is also heavily ubiquitinated it is possible that multiple linkages 
such as K63 and K48 ubiquitination, control the stability of hECSIT and hence its 
functional effects. Identification of a direct catalytic residue required for this DUB 
activity or ubiquitinated lysine residues will confirm the latter. Also sub-cellular 
localisation studies utilising confocal microscopy or protein fractionation after 
stimulation with TLR ligands would give us a greater understanding of hECSIT’s 
function. As mentioned, hECSIT also exhibited E3 ligase activity. Thus far we have 
not identified a substrate for this. However, analysis of hECSIT in other signalling 
pathways may reveal targets for its E3 ligase function.  
Analysis of the hECSIT sequence also revealed a PEST-like sequence in the 
C-terminus of hECSIT. Given the importance of these sequences in signalling for 
protein degradation we were interested in what effects mutation of this domain would 
have on the stability of processed hECSIT. Mutation of two glutamic acid residues 
increased the stability and expression of processed hECSIT. And as a result the PEST 
mutant was more efficient at deubiquitinating TRAF6. Identification of these sites 
may prove useful in the development of any hECSIT based therapeutics and it will be 
of interest to analyse hECSIT peptides containing these mutants in vivo to assess their 
half- life and therapeutic potential. 
Given our data appears to show that hECSIT plays a functionally opposing 
role to its murine orthologue in conjunction with the lethal phenotype of ECSIT-
deficient mice, the use of ECSIT knockout mice is of limited value in studying the 
role of hECSIT at a physiological level. To overcome this limitation, mice were 
humanised at the Ecsit locus. Unfortunately these mice were generated towards the 
end of the present study and thus with time limitations, it is only possible to present 
early studies from these mice. The humanised mice were viable and displayed normal 
development. However upon colony expansion homozygote female mice were unable 
to carry a litter to full term. All homozygote pregnancies resulted in miscarriage or 
death which suggests that hECSIT cannot completely compensate for the loss of 
mECSIT during gestation. However heterozygous female mice crossed with 
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homozygote male mice display no defect in reproducing. Further pathological analysis 
of the humanised mice will be required to identify the exact problem. We are now 
continuing to analyse this phenotype through pathology and histology. In keeping 
with previous data on Ecsit +/- mice, our humanised model also displayed no effect on 
NFκB in response to LPS. As mROS has been linked to inflammasome activation 
(Menu et al, 2012), we next examined IL-1β production. As IL-1β production in our 
humanised cells was impaired we can speculate that this is perhaps as a result of lower 
mROS production in response to LPS. The difficulty in breeding the humanised mice 
has imposed many limitations on the number of experiments performed. mROS 
production is primarily associated with macrophages and low animal numbers has 
thus far limited us to ex-vivo experiments in MEF cells. Analysis of mROS in 
macrophages from our humanised mice will need to be conducted to further confirm 
this finding.  
This study further highlights hECSIT as a negative regulator of TLR signalling 
and has identified a novel intricate mechanism to explain the difference in function 
observed between hECSIT and mECSIT. Further in vivo work and analysis of 
hECSIT in other innate signalling pathways will help in further elucidation of the 
physiological and pathological roles of hECSIT. It will also be of interest to explore if 
any natural occurring defective forms or expression of hECSIT may provide a genetic 
basis to some cases of chronic inflammatory diseases and cancer observed through 
dysregulated TLR signalling.
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4.1 Introduction 
 
TLRs represent the immune systems first defence to invading pathogens by activating 
downstream transcription factors such as NFκB that promotes the production of pro-
inflammatory cytokines and IFNs to trigger an immune response to eliminate 
infection (Moynagh, 2005). Most TLRs use the MyD88-dependent pathway to 
activate NFκB but TLR4 can additionally deploy other protein adaptors, TRIF and 
TRAM, to trigger a MyD88-independent pathway that also activates NFκB 
(Yammamoto et al, 2002). Uniquely TLR3, an endosomal anti-viral TLR, uses TRIF 
as its exclusive adaptor protein. TRIF recruits the adaptor kinase RIP1 to trigger 
downstream TAK1 and IKK-mediated activation of NFκB (Cusson-Hermance et al, 
2005; Meylan et al, 2004). TRAF6 has also been reported to play a role in TRIF 
mediated activation of NFκB (Sasai et al, 2010). However other studies have 
concluded that TRAF6 is dispensable for TLR3 signalling (Jiang et al, 2004). Such a 
discrepancy in relation to the role of TRAF6 may be due to cell specific roles for 
TRAF6 and/or functional redundancy of TRAF6 with other members of the TRAF 
family (Sato et al, 2003).  Alternatively TLR3 can also activate the transcription of 
type 1 IFN through the multifunctional adaptor TRAF3 (Liu and Chen, 2011). TRAF3 
has been extensively studied in the regulation of TLR3 signalling. TRAF3 forms a 
complex with TANK, NEMO and TBK1 (Oganesyan et al, 2006). NEMO is required 
for the activation of both IKK and TBK1 in response to viral infection, and mutations 
disrupting the binding of NEMO to polyubiquitin chains impair the activation of the 
latter kinases (Zhao et al, 2007). It has been proposed that auto-ubiquitination of 
TRAF3 is required for downstream activation of TBK1 however TRAF3 deficient 
cells only exhibit a partial defect in producing IFNβ following viral infection (Zeng et 
al, 2009). However a recent study revealed a loss of function mutation (R118W) in 
patients which resulted in impaired IFN production in response to viral infection 
(Perez de Diego et al, 2010). Such a discrepancy in the role of TRAF3 can perhaps be 
attributed to its range of functions which vary dependent on cell type, its subcellular 
localization and its modification by ubiquitin. Many studies are now utilizing 
conditional knock-out models to study the role of TRAF3 in a cell specific manner. 
The activation of TLR4 results in the degradation of TRAF3 which is facilitated by 
the K48 ubiquitination of TRAF3 by cIAP1. When TRAF3 is degraded it releases 
TAK1 and the MAP kinase pathway is activated (Tseng et al, 2009).The ability of 
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TRAF3 to positively regulate IFN production and negatively regulate P38 and JNK 
activation is attributed to the compartmentalization of the activated TLR. TRAF3 
dependent activation of the IFN response is initiated from signalling complexes that 
are assembled by the adaptor TRIF at an endosomal location. Signalling complexes 
assembled by MyD88 are located at the plasma membrane. In the endosome TRAF3 
is able to positively regulate the production of type 1 IFN however at plasma 
membrane locations, TRAF3 negatively regulates MAP kinase signalling by 
sequestering TAK1 (Barton et al, 2009). 
 In addition to the negative regulation of the MAP kinases TRAF3 also 
functions as a negative regulator of non-canonical NFκB activation. TRAF3 is 
constitutively bound to NIK in resting cells and upon de novo synthesis; NIK is 
immediately bound by TRAF3 and targeted for ubiquitin-proteasome mediated 
degradation (Liao et al, 2004). Further investigation also revealed a role for cIAPs and 
TRAF2 in TRAF3 regulation of NIK. Following stimulation of the non-canonical 
pathway cIAP is K63 ubiquitinated by TRAF2 which enhances cIAPs E3 ligase 
affinity for TRAF3 which results in its K48 ubiquitination and subsequent degradation 
(Xiao et al, 2004). It was later shown that TRAF3 acts a molecular bridge between 
cIAP and NIK which allows NIK to interact with cIAP (Vallabhapurapu et al, 2008).  
When TRAF3 is degraded newly synthesized NIK is no longer able to interact with 
the cIAP-TRAF2 complex and is free to autophosphorylate and activate the IKK 
complex (Zarnegar et al, 2008) followed by the processing of p100 (Cheng et al, 
2008).  This mechanism is highlighted in TRAF3 -/- B-cells which contain high levels 
of NIK and exhibit constitutive p100 processing which can be blocked in a TRAF3 
NIK double -/- (Gardam et al, 2008).   
A recent study has implicated mECSIT as a positive regulator of IRF3/7 
activation however as this study was carried out independent of any pathway specific 
ligand or endogenous analysis the precise role of mECSIT in this pathway has yet to 
be established. The present study aimed to analyse the role of hECSIT in anti-viral 
signalling by studying the TLR3 pathway. Through a combination of knockdown 
methods and our humanised mouse model we show an evolutionary diverged role for 
hECSIT and mECSIT in TLR3 signalling and provide a mechanistic basis for this 
difference. Activation of TLR3 signalling induces the phosphorylation and subsequent 
processing of hECSIT in a TAK1 dependent manner. This critical activation step 
allows hECSIT to associate with and facilitate the polyubiquitination of TRAF3 thus 
Chapter 4 Results 
_____________________________________________________________________ 
123 
 
inhibiting the ability of the latter to promote activation of NFκB and the IRFs. These 
findings reveal hECSIT as an important regulator of TLR3 signalling limiting the 
activation of NFκB and IRFs.  
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4.2 Results 
4.2.1 hECSIT negatively regulates TLR3 signalling  
Following on from our initial study of the role of hECSIT in TLR4 signalling we were 
interested to explore the role of hECSIT in other innate immune signalling pathways, 
in particular anti-viral signalling pathways. As previously discussed we have 
identified hECSIT as a negative regulator of TLR4/IL-1R signalling. To investigate 
the potential regulatory role of hECSIT in TLR3 signalling an initial combination of 
siRNA and over-expression studies in HEK293-TLR3 cells were performed. Gene 
reporter assays using IRF3, IRF7 and RANTES driven luciferase tagged promoters 
were used to investigate the possibility of divergent roles between hECSIT and 
mECSIT and their functional role in TLR3 signalling. Over-expression of hECSIT 
resulted in inhibition of polyriboinosinic: polyribocytidylic acid (Poly (I:C)), the 
TLR3 agonist, induced expression of  reporter gene constructs regulated by IRF3, 
IRF7 and the RANTES promoter. In contrast over-expression of mECSIT augmented 
the ability of Poly (I:C) to active these transcription factors and promoter (Figure 4.1). 
To further confirm the divergent inhibitory roles of hECSIT and mECSIT in TLR3 
signalling that were indicated from these overexpression studies, these pathways were 
also studied in hECSIT knockdown cells. Co-transfection of an IRF3-dependent 
luciferase reporter construct with hECSIT specific siRNA, to suppress the expression 
of hECSIT resulted in enhanced IRF3 activation in response to Poly (I:C) (Figure 
4.2A). A similar augmentation of TLR signalling was observed with reporter gene 
constructs regulated by IRF7 (Figure 4.2B) and NFκB (Figure 4.2D). Given these 
effects on IRFs and NFκB we also probed the effect of hECSIT on a naturally 
occurring promoter that is regulated by both NFκB and IRFs and show that hECSIT 
knockdown potentiates TLR3-induced activation of the RANTES promoter (Figure 
4.2C). 
We next examined the role of hECSIT in regulating the expression of type 1 
IFNs since they are strongly regulated by TLR3 and the downstream activation of 
NFκB and IRFs. Using a type 1 IFN-reporter cell line as a bioassay system, the TLR3 
agonist Poly (I:C), induced increased levels of type 1 IFN when hECSIT was knocked 
down (Figure 4.3A).The knockdown of hECSIT in these studies was confirmed by 
western blot (Figure 4.3C).  
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We were keen to confirm that the above enhancing effects of hECSIT 
knockdown on Poly (I:C) signalling was not an artifact of HEK293-TLR3 cells or of 
the siRNA-mediated knockdown approach. To this end U373 cells were transduced 
with lenti-virus to stably express hECSIT-specific shRNA and knockdown hECSIT 
expression. Knockdown of hECSIT was confirmed by RT-PCR (Figure 4.3C). Cells 
were stimulated with Poly (I:C) for the indicated time and assayed for the induction of 
IFNβ and RANTES mRNA. Again, the expression levels of these IRF- regulated 
genes, in response to Poly (I:C) were significantly enhanced under conditions of 
hECSIT knockdown consistent with our earlier findings from over-expression and 
siRNA knockdown analysis that indicated hECSIT to be a negative regulator of 
expression of type 1 IFN and related genes in response to Poly(I:C).  
We next addressed if the regulatory effects of hECSIT on expression of type 1 
IFNs and related genes also applied in our humanised murine model. MEF cells from 
ECSIT +/+ (Hum) were stimulated with Poly (I:C) for the various times and assayed for 
mRNA levels of IL-6 (Figure 4.5A), RANTES (Figure 4.5B) and IFNβ (Figure 4.5C). 
The efficacy of Poly (I:C) in inducing IL-6, RANTES and IFNβ was lower in cells 
from mice containing human ECSIT alleles relative to cells from mice containing the 
murine counterparts. ELISA analysis to assay protein levels of IL6 and IFNβ further 
confirmed this reduced efficacy of Poly (I:C) in cells from mice humanized at the 
ECSIT locus Poly (I:C) (Figure 4.6). From the data above it is clear that hECSIT is 
effecting the transcriptional activation of Poly (I:C) induced NFκB and IRF 
responsive genes. To further analyse these effects levels of phosphorylated 
intracellular signalling mediators were analysed in response to Poly (I:C).  As 
mentioned TLR3 signalling results in the activation of NFκB and the IRFs mediated 
by the adaptors RIP1 and TRAF3, respectively. The TAK1 and IKK complex are the 
major drivers of MAP kinase and NFκB activation whereas TBK1 and IKKi mediate 
the activation of the transcription factors IRF3 and IRF7. Suppression of hECSIT in 
HEK293-TLR3 cells resulted in increased levels of Poly (I:C) induced phosphorylated 
TBK1 and IRF3 (Figure 4.7). In keeping with these findings MEF cells derived from 
our -/- (Hum) mice exhibited a lower level of phosphorylated TBK1 and IRF3. Lower 
levels of Poly (I:C) induced p-IκB-α were also observed in response to Poly (I:C) 
(Figure 4.8). These ex vivo studies are consistent with the earlier cell-based 
approaches demonstrating an important role for hECSIT in limiting type 1 IFN and 
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pro-inflammatory gene expression. Thus hECSIT serves an important regulatory 
function in controlling anti-viral signalling. 
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Figure 4.1 Differential effects of hECSIT and mECSIT on TLR3 signalling  
 
HEK293-TLR3 cells were co-transfected with pFA (30ng) IRF3 (A) or pFA IRF7 (30ng) (B) with pFR 
luciferase reporter construct (60ng) or RANTES promoter-regulated firefly luciferase reporter construct 
(C) (80ng), TK renilla (20ng) and myc-tagged hECSIT or mECSIT (1μg). Empty Vector (EV) 
pcDNA3.1 was used to normalise total amount of DNA whilst TK renilla was used to normalise for 
transfection efficiency.  24 hrs post transfection the cells were treated with Poly (I:C) (25μg/ml) for a 
further 24 hr. Cell lysates were generated 48 hrs after transfection and assayed for firefly luciferase and 
renilla luciferase activity. Results represent mean +/- SD of triplicate determinations and is 
representative  of 3 independent experiments.   
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Figure 4.2 Knockdown of hECSIT enhances Poly (I:C) induced activation of IRF3, IRF7,  NFκB 
and the RANTES promoter 
HEK293-TLR3 cells were co-transfected with pFA (30ng) IRF3 (A) or pFA IRF7 (30ng) (B) with pFR 
luciferase reporter construct (60ng) or RANTES (C) or NFκB (D) firefly luciferase reporter construct 
(80ng) and TK renilla (20ng) reporter construct with  hECSIT specific siRNA or Lamin control siRNA 
(10nM).  24 hrs post transfection the cells were treated with Poly (I:C) (25μg/ml) for a further 24 hr. 
Cell lysates were generated 24 hrs later and assayed for firefly luciferase and renilla luciferase activity. 
Results represent mean +/- SD of triplicate determinations and is an average of 3 independent 
experiments. 
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Figure 4.3 siRNA-mediated knockdown of hECSIT enhances Poly (I:C) induced expression of 
IFN and RANTES in HEK-TLR3 cells.  
 
HEK293-TLR3 Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 
48 hours after transfection cells were stimulated with Poly (I:C) (205μg/ml) for 24 hrs. Media from 
Non-treated and TNF treated cells were analysed for (A)  type 1 IFN by bioassay and (B) RANTES 
levels by ELISA. Data shown represents the mean of 3 independent experiments. *p< 0.05. (C) Cell 
lysates were probed for expression levels of hECSIT and β-Actin by western blot.  
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Figure 4.4 shRNA-mediated knockdown of hECSIT enhances Poly (I:C) induced expression of  
IFNβ and RANTES mRNA in U373 cells  
 
U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT specific 
shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably integrated 
shRNA constructs. Selected cells were treated with Poly (I:C) (25μg/ml) for 6 hrs. mRNA expression 
levels of IFNβ (A) and RANTES (B) were measured by quantitative RT-PCR and expressed relative to 
expression levels in unstimulated control siRNA cells. Data represents the average of 3 independent 
experiments; p<0.05. (C) mRNA expression levels of hECSIT were measured by quantitative RT-PCR 
to confirm knockdown. 
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Figure 4.5 Replacement of Ecsit with ECSIT inhibits Poly (I:C) induced production of IL-6, 
RANTES and IFNβ 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with Poly (I:C) (25μg/ml) 
for the indicated times. mRNA expression levels of IL-6 (A) RANTES (B) and IFNβ (C) were 
measured by quantitative RT-PCR and expressed relative to expression levels in unstimulated WT 
cells. Data represents the average of 3 independent experiments; p<0.05 
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Figure 4.6 Replacement of Ecsit with ECSIT inhibits Poly (I:C) induced IL-6 and IFNβ 
production  
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with Poly (I:C) (25μg/ml) 
for 24 hrs. Media from Non-treated and Poly (I:C) (25μg/ml) treated cells were analysed for levels of  
IL-6 (A) and IFNβ (B) by ELISA. Data represents the average of 3 independent experiments; p<0.05 
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Figure 4.7 Knockdown of hECSIT increases Poly (I:C) induced IRF3 and TBK1 phosphorylation 
 
HEK293-TLR3 cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm) 
for 48 hrs. Cells were then treated with Poly (I:C) (25μg/ml) for the indicated times. Cells lysates were 
prepared and separated by SDS-PAGE followed by Immunoblotting for phosphorylated and total levels 
of IRF3 and TBK1. Lysates were also probed for levels of TRAF3, ECSIT and β-Actin to confirm 
knockdown and equal loading. 
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Figure 4.8 Replacement of Ecsit with ECSIT inhibits Poly (I:C) induced IRF3 and TBK1 
phosphorylation 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with Poly (I:C) (25μg/ml) 
for the indicated times. Cells lysates were prepared and separated by SDS-PAGE followed by 
Immunoblotting for phosphorylated and total levels of IRF3, TBK1 and IκB-α. Lysates were also 
probed for levels of TRAF3, TRAF6 and RIP1. Levels of ECSIT and β-Actin were analysed to confirm 
genotyping and equal loading. 
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4.2.2 hECSIT interacts with TRAF3  
We next probed the mechanism by which hECSIT can target the TLR3 pathway. As 
discussed TRAF3 is a multi-functional signalling adaptor in the TLR3 pathway and 
regulates both the IFN response and non-canonical activation of NFκB. The 
ubiquitination of TRAF3 plays important roles in the activation of the IRFs and the 
auto-ubiquitination of TRAF3 has been described as a prerequisite for 
phosphorylation of TBK1. Given the importance of TRAF3 in TLR3 signalling, 
coupled to our previous data demonstrating the E3 ligase activity and DUB activity of 
hECSIT, TRAF3 was examined as a potential target for hECSIT. Co-
immunoprecipitation studies were carried out to investigate the possible interaction 
between hECSIT and TRAF3. HEK293-TLR3 cells were treated with Poly (I:C) for 
the indicated times and immunoprecipitated with anti-ECSIT. The subsequent 
precipitate was then analysed for the presence of co-precipitated TRAF3 by western 
blotting. Poly (I:C) promoted the interaction of TRAF3 with hECSIT in a time-
dependent manner, as demonstrated by the co-immunoprecipitation of the two 
proteins (Figure 4.9A). We next investigated the regions of hECSIT that are important 
in facilitating its interaction with TRAF3. Myc-tagged hECSIT or the previously 
described N- and C-terminal truncation mutants were co-expressed with FLAG-
tagged TRAF3, immunoprecipitated with anti-myc antibody and probed for the 
presence of co-precipitated FLAG-tagged TRAF3. As shown in Figure 4.9B hECSIT 
interacted with TRAF3 and this appears to be mediated by its C-terminal region since 
the C-terminal but not N-terminal truncation mutant of hECSIT interacted with 
TRAF3. Interestingly mECSIT also showed association with TRAF3.   
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 Figure 4.9 hECSIT interacts with TRAF3  
 
(A) HEK293-TLR3 cells were treated with Poly (I:C) (25μg/ml) for the indicated times. Cell lysates 
were generated and a sample for whole cell lysates analysis was retained. The remaining lysates was 
immunoprecipitated using an anti-ECSIT antibody. Immunoprecipitates were subsequently assayed for 
co-precipitated TRAF3. The expression levels of ECSIT and TRAF3 in whole cell lysates (Input) were 
also assessed by western blotting. (B) HEK293 cells were co-transfected with Empty vector (EV) 
pcDNA3.1 (1µg), myc-tagged hECSIT (1µg) or myc-tagged mECSIT (1µg) or C-terminal hECSIT 
(1μg) or N-terminal hECSIT (1μg)  with or without FLAG-tagged TRAF3 (1µg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject to SDS-PAGE and 
subsequently to western blotting using anti-FLAG antibody. Whole cell lysates were also analysed by 
western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of RIP1 and ECSIT 
constructs, respectively. Results are representative of 3 independent experiments. 
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4.2.3 hECSIT Ubiquitinates TRAF3    
As hECSIT interacts with TRAF3 in response to Poly (I:C) stimulation we next 
probed the functional consequence of this interaction by measuring the ubiquitination 
of TRAF3. We were especially interested in the ubiquitination of TRAF3 given its 
importance in mediating the activation of the IRF transcription factors. Given that 
hECSIT possesses both E3 ligase and DUB activity the effect of hECSIT on TRAF3 
ubiquitination was investigated.  
Firstly an over-expression system was utilised to analyse the possible 
differential effects of mECSIT and hECSIT on TRAF3 ubiquitination. Myc-tagged 
hECSIT or mECSIT were co-transfected with FLAG-tagged TRAF3 and HA-
ubiquitin. FLAG-tagged TRAF3 was immunoprecipitated and probed for 
ubiquitination using an anti-HA antibody. Co-expression of hECSIT or mECSIT 
resulted in an increase in the levels of TRAF3 ubiquitination (Figure 4.10A). To 
investigate this effect at an endogenous level TRAF3 ubiquitination was measured in 
cells where hECSIT expression was suppressed. Poly(I:C) induced strong 
ubiquitination of TRAF3 in a time-dependent manner but knockdown of hECSIT with 
hECSIT-specific siRNA resulted in greatly reduced  ubiquitination of TRAF3 in 
response to Poly (I:C) compared with cells transfected with control siRNA (Figure 
4.10B). These findings suggest that ECSIT acts as important mediator of TRAF3 
ubiquitination in the TLR3 pathway.   
We next compared the TLR3-induced ubiquitination of TRAF3  in MEF cells 
from ECSIT humanized mice and wild type mice. Stimulation of humanised MEF 
cells with Poly (I:C) resulted in an increase in TRAF3 ubiquitination when compared 
with WT cells (Figure 4.11).  We next examined the capacity of hECSIT to directly 
ubiquitinate TRAF3 by using an in vitro ubiquitination assay and measuring the 
ubiquitination of recombinant TRAF3 in the presence of recombinant hECSIT. 
Incubation of recombinant TRAF3 with increasing concentrations of recombinant 
hECSIT and the indicated E1 and E2 enzymes resulted in a dose-dependent increase 
in TRAF3 ubiquitination as indicated by the appearance of high molecular weight 
forms of TRAF3 in anti-TRAF3 immunoblotting of reactions (Figure 4.12). To further 
confirm this TRAF3 was immunoprecipitated from the reaction to remove all 
associated reaction components. Immunoprecipitated TRAF3 was then assayed for 
levels of ubiquitination, which also showed increased levels of TRAF3 ubiquitination 
Chapter 4 Results 
_____________________________________________________________________ 
138 
 
when hECSIT was present (Figure 4.12). In conjunction with the earlier cell line and 
ex vivo approaches these findings provide strong support for hECSIT acting as a 
novel, direct E3 ligase for TRAF3. 
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Figure 4.10 hECSIT promotes the ubiquitination of TRAF3   
 
HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq (1µg), myc-tagged hECSIT 
(1µg) or myc-tagged mECSIT (1µg) with or without FLAG-tagged RIP1 (1µg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated using an anti-FLAG antibody. Immunoprecipitates were then subject to SDS-
PAGE and subsequently to western blotting using anti-HA antibody. Whole cell lysates were also 
analysed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of RIP1 
and ECSIT constructs, respectively. (B) HEK293-TLR3 Cells were transfected with hECSIT specific 
siRNA (30nm) or Control siRNA (30nm). 48 hrs after transfection cells were then treated with Poly 
(I:C) (25μg/ml) for the indicated times. Cell lysates were generated and immunoprecipitated using anti-
TRAF3 antibody. The immunoprecipitate was then assayed for TRAF3 ubiquitination and 
immunoprecipitated TRAF3 by Immunoblotting for ubiquitin and TRAF3 respectively. Expression 
levels of TRAF3, ECSIT and β-Actin were also assessed in the input by western blotting. Data shown 
is representative of 3 independent experiments. 
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Figure 4.11 Replacement of mECSIT with hECSIT enhances Poly (I:C) induced TRAF3 
ubiquitination 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with Poly (I:C) (25μg/ml) 
for the indicated times. Cell lysates were generated and immunoprecipitated using anti-TRAF3 
antibody. The immunoprecipitate was then assayed for TRAF3 ubiquitination and immunoprecipitated 
TRAF3 by immunoblotting for Ubiquitin and TRAF3 respectively. Expression levels of TRAF3, 
ECSIT and β-Actin were also assessed in the input by western blotting. Data shown is representative of 
3 independent experiments. 
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Figure 4.12 hECSIT Ubiquitinates TRAF3 in vitro 
 
Recombinant TRAF3 was incubated with or without the indicated concentrations of recombinant 
hECSIT (0.5-1μg) in a reaction mix containing Ubiquitin (2μg), E1 (50ng), E2 UbcH13/Uev1a 
(400ng), MgCl2 (2mM), ATP (2Mm), protease inhibitor cocktail and H20. Reactions were incubated at 
37◦C for 2hrs and subsequently immunoprecipitated using anti-TRAF3 antibody. The 
immunoprecipitate was then assayed for TRAF3 ubiquitination by immunoblotting for ubiquitin. 
Levels of TRAF3, ECSIT and ubiquitin were also assessed in the input by western blotting. Data 
shown is representative of 3 independent experiments. 
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4.2.4 hECSIT is processed in response to Poly (I:C) 
As previously demonstrated TAK1 promotes the formation of modified and processed 
forms of hECSIT in response to IL-1 and LPS that possesses both E3 ligase and DUB 
activity. In order to determine if hECSIT is similarly regulated by TAK1 in the 
context of TLR3 signalling we initially assessed if hECSIT can associate with TAK1 
upon TLR3 stimulation. Poly (I:C) promoted the interaction of TAK1 and hECSIT in 
a time dependent manner in HEK293-TLR3 cells as shown by co-
immunoprecipitation of TAK1 and hECSIT (Figure 4.13A). As hECSIT interacted 
with TAK1 in response to Poly (I:C) we next assessed the ability of Poly (I:C) to 
induce TAK1 dependent phosphorylation and processing of hECSIT using the 
pharmacological TAK1 inhibitor 5Z-7-oxozeanol. THP1 cells stimulated with Poly 
(I:C) resulted in putative phosphorylation and processing of hECSIT. However pre-
treatment of THP1 cells with the TAK1 inhibitor resulted in inhibition of hECSIT 
phosphorylation and processing (Figure 4.13B).  In order to determine the functional 
consequence of hECSIT processing in response to Poly (I:C) a truncated expression 
construct encoding the C-terminus of hECSIT was used as a model to represent the 
processed form of hECSIT. IFNβ-luciferase reporter assays revealed that in response 
to Poly (I:C) the C-terminus of hECSIT was more inhibitory than the full length 
hECSIT and the N-terminus of hECSIT (Figure 4.19A).  
These data are consistent with a model where Poly (I:C) induces TAK1 
dependent phosphorylation and processing of hECSIT to enhance its E3 ligase activity  
and facilitate the ubiquitination of TRAF3 to inhibit TLR3 signalling. This represents 
a novel mechanism by which hECSIT can exert its inhibitory effect on innate immune 
signalling and identifies TRAF3 as the first substrate for the E3 ligase function of 
hECSIT. 
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Figure 4.13 TAK1 promotes phosphorylation and processing of hECSIT in response to Poly (I:C) 
 
(A) HEK293-TLR3 cells were treated with Poly (I:C) (25μg/ml) for the indicated times. Cell lysates 
were generated and a sample for whole cell lysates analysis was retained. The remaining lysates was 
immunoprecipitated using an anti-ECSIT antibody. Immunoprecipitates were subsequently assayed for 
co-precipitated RIP1 and ECSIT. The expression levels of ECSIT and RIP1 in whole cell lysates were 
also assessed by western blotting. (B) THP1 cells were pre-treated for 2 hrs with vehicle DMSO and 
5z-7-oxozeanol (20Mm).  Cells were then treated with Poly (I:C) (25μg/ml) for the indicated times. 
Cell lysates were generated and subjected to SDS-PAGE and probed by Immunoblotting for expression 
levels of ECSIT and β-Actin. Processed ECSIT is indicated by arrows. 
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Figure 4.14 The C-terminus of hECSIT inhibits Poly (I:C) induced IFNβ activation 
 
HEK293-TLR3 cells were co-transfected with IFNβ firefly luciferase reporter construct (80ng), TK 
renilla (20ng) and myc-tagged hECSIT or mECSIT or the C-terminal amino acids 261-435 (CT) or N-
terminal of hECSIT amino acids 1-260 (NT) (100ng). Empty Vector (EV) pcDNA3.1 was used to 
normalise total amount of DNA whilst TK renilla was used to normalise for transfection efficiency. 
24hr post-transfection the cells were treated with Poly (I:C) (25μg/ml). Cell lysates were generated the 
following day and assayed for firefly luciferase activity. Results represents mean +/- SD of triplicate 
determinations and is representative of 3 independent experiments.  
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Figure 4.15 Schematic representation of hECSIT’s regulatory effect in the TLR3 
pathway 
 
Activation of the TLR3 pathway results in the processing of hECSIT activating its E3 ligase activity. 
Direct ubiquitination of TRAF3 by hECSIT results in inhibition of the IRFs and NFκB 
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4.3 Discussion 
 
In the previous chapter it was shown that the induction of TLR4 and IL-1R signalling 
results in the likely processing of hECSIT into an inhibitory form which reveals a 
cryptic DUB activity leading to the deubiquitination of TRAF6 and negative 
regulatory effects on the NFκB pathway and mROS production. It was also shown 
that the C-terminus of hECSIT also possessed E3 ligase activity. To investigate the 
role of hECSIT in anti-viral signalling we assessed its potential regulatory function in 
TLR3 signalling. The production of Type 1 IFN is tightly regulated to prevent 
excessive inflammation and auto-immunity after viral infection is eliminated (Gao et 
al, 2011). Many DUB enzymes and E3 ligases regulate this response such as A20, 
CYLD and DUBA (Zhang et al, 2008; Mankouri et al, 2010) the latter targeting the 
deubiquitination of TRAF3.  In this study we have identified hECSIT as a novel 
regulator of TLR3 signalling. We propose that TLR3 signalling results in the 
activation of the E3 ligase function of hECSIT via a TAK1-dependent cross-
regulatory mechanism, thus facilitating its interaction with TRAF3 and the 
ubiquitination of the latter. We propose that this ubiquitination step results in 
inhibition of TRAF3 in the cell leading to inhibition of type 1 IFN expression. In 
addition to uncovering a new regulatory mechanism in TLR3 signalling the findings 
also highlight TRAF3 as the first substrate for the E3 ligase function of hECSIT.  
mECSIT has recently been identified as a positive regulator of IRF3 and IRF7 
pathways (Kondo et al, 2012) although no definitive mechanistic role has been 
attributed to mECSIT in the TLR3 pathway. However, consistent with previous 
positive regulatory roles for mECSIT we demonstrate a positive role for mECSIT in 
Poly (I:C) induced activation of IRFs. However, hECSIT negatively regulates this 
pathway as demonstrated in our knockdown systems and our animal model. The 
availability of our humanised model allowed us to assess the physiological role of 
hECSIT in the TLR3 pathway. Replacing mECSIT with hECSIT resulted in 
attenuated IFN but also NFκB responses. Whilst TRAF3 had been our lead target thus 
far, the abrogated NFκB response shown in our primary cells cannot be explained by 
the targeting of TRAF3. However as hECSIT has dual DUB/E3 ligase activity it may 
also have dual targets in this pathway. As TRAF6 has been previously identified as a 
target for hECSIT and is required for both Poly (I:C) induced NFκB and IRF7 
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activation (Sasai et al, 2010; Siednienko et al, 2012) it will be interesting to examine 
the possibility of hECSIT also regulating TRAF6 in response to Poly (I:C). 
A number of studies have identified various E3 ligases that target TRAF3 for 
ubiquitination to either inhibit or enhance the function of the latter. cIAP1/2 have 
been implicated in TRAF3 ubiquitination in TLR3 and TLR4 signalling as has 
Triad3a in RIG-I signalling. TRAF3 undergoes biphasic ubiquitination following viral 
infection. Early after infection, K63-linked polyubiquitination of TRAF3 contributes 
to IFN signalling while at later times after infection, TRAF3 undergoes K48-linked 
polyubiquitination mediated by Triad3a which results in the degradation of TRAF3. 
Here we propose hECSIT as a novel E3 ligase for TRAF3 in controlling the 
production of type 1 IFN. As we were unable to determine the exact ubiquitin linkage 
owing possibly due to E2 specificity further experimentation using a wider range of 
E2 enzymes will perhaps uncover the exact mechanism. TRAF3 ubiquitination is an 
important factor in TRAF3-mediated signalling as demonstrated by the number of E3 
ligases that target TRAF3. However the specific lysine residues in TRAF3 that act as 
ubiquitination sites have yet to be identified. Mutational analysis of these sites and 
precise genetic models utilising knock-in site-specific mutations on putative 
ubiquitination sites, will be necessary for unequivocal conclusions about the exact 
role of TRAF3 ubiquitination. Furthermore the identification of a direct lysine residue 
where hECSIT ubiquitinates TRAF3 will be required to further understand this 
mechanism. 
Consistent with our previous data hECSIT is also processed in response to 
Poly (I:C) in a TAK1 dependent manner. Such cross-regulation is not unprecedented 
as the TLR3 pathway is also targeted by the TIR adaptors Mal and MyD88 to inhibit 
IFNβ and RANTES production (Siednienko et al, 2010; Siednienko et al, 2011). 
Additionally the NFκB subunits Rel B and c-Rel can also induce the transcriptional 
repressor YY1 to inhibit TLR3 induced IFNβ production (Siednienko et al, 2011b). It 
is likely that TAK1-induced phosphorylation of hECSIT serves as an important pre-
requisite for hECSIT processing as evident by the C-terminus containing both the E3 
and DUB activity. Similarly the DUB enzyme DUBA also requires a phosphorylation 
event to manifest its DUB activity (Huang et al, 2012). Phosphorylation-dependent E3 
ligase function has also been described. The catalytic activity of the Pellino proteins is 
strongly enhanced by phosphorylation (Ordureau et al, 2008) and in the context of 
anti-viral signalling Pellino 1 is activated by the kinases TBK1 and IKKi (Smith et al, 
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2010). As hECSIT can negatively regulate the TLR3 pathway it will also be of 
interest to examine its role, if any, in RIG-I signalling. It was been recently shown 
that mECSIT can interact with MAVS when over-expressed (Kondo et al, 2012). 
Given its mitochondrial localisation ECSIT could also be an important regulator of 
RLR signalling. Although more studies will be required to delineate the precise 
molecular mechanisms involved, this present study shows that TAK1 co-operates with 
hECSIT to restrict the TLR3 pathway. 
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Chapter 5 
 
Investigating the role of hECSIT in TNF-α 
Signalling 
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5.1 Introduction 
 
 Inflammation is an essential component of innate immunity and the host 
response to infection. In response to viral or bacterial infection innate cells produce 
potent pro-inflammatory cytokines such as TNF-α and IL-1ß which trigger the 
inflammatory response (Serhan et al, 2008).  TNF-α initiates a complex cascade of 
signaling events that lead to the induction of proinflammatory cytokines, cell 
proliferation, and differentiation or programmed cell death (Chen and Goeddel, 2002). 
The binding of TNF to its receptor TNFR1 leads to association of TNF-R1 associated 
death domain protein (TRADD) (Hsu et al, 1995) with the receptor complex  followed 
by recruitment of FAS associated death domain protein (FADD), TRAF2 and RIP1 
(Hsu et al, 1996). Whilst FADD can trigger activation of Caspase 8 leading to cell 
apoptosis (Wilson et al, 2009) TRAF2, cIAP1 and RIP1 mediate the activation of 
NFκB and MAP kinase in response to TNF-α (Karin and Gallagher, 2009) 
Alternatively inhibition of caspase activity can lead to the formation of the 
necroptosome, or programmed necrosis via the interaction of RIP1 and RIP3 to form 
the ’Ripoptosome’ (Imre et al, 2011). The ubiquitination of RIP1 facilitates the 
recruitment of IKK complexes (Ea et al, 2006). The subject of RIP1 ubiquitination has 
been under much scrutiny in recent years and a number of E3 ligases have been 
implicated in the ubiquitination of RIP1 including TRAF2 (Lee et al, 2004, Wertz et 
al, 2004) (Yammato et al, 2006), the cellular inhibitor of apoptosis proteins (cIAPs) 
(Bertrand et al, 2005) and more recently LUBAC (Haas et al, 2009).  K63-linked 
ubiquitination of RIP1 functions as a major cytoprotective effect. Linear 
ubiquitination of RIP1 has also been shown to inhibit the induction of apoptosis 
(Tokunaga and Iwai, 2011).  Conversely disruption of RIP1 ubiquitination converts 
RIP1 into a death inducing protein via its interaction with Caspase 8 (O’Donnell and 
Ting 2010). Caspase 8 mediated cleavage of RIP1 prevents RIP1 induced NFκB 
activation, biasing the TNF pathway towards cell apoptosis (Lin et al, 1999). In the 
absence of caspase activity the phosphorylation of RIP1 by RIP3 promotes the 
assembly of the ripoptosome to induce necrosis. RIP1 has also been implicated in 
TLR signaling and IKK activation in response to signaling by the TLR3 and TLR4 
adaptor TRIF (Cusson-Hermance et al., 2005; Meylan et al., 2004). A recent study has 
also described RIP1 as dual positive and negative regulator of RIG-I signaling (Rajput 
et al, 2011). RIP1 was shown to promote the activation of IRF3 downstream of RIG-I.  
Chapter 5 Results 
_____________________________________________________________________ 
152 
 
However this action was blocked following cleavage of RIP1 by Caspase-8 which 
converted RIP1 into an inhibitor of RIG-I signalling. This cleavage of RIP1 by 
Caspase-8 is ubiquitin dependent and Caspase 8 fails to cleave a form of RIP1 in 
which the ubiquitination site of lysine 377 has been mutated (Rajput et al, 2011).   
A number of negative regulators of TNF signaling target RIP1 to inhibit NFκB 
activation and apoptosis. A20 is one such negative regulator and functions as a dual 
ubiquitin editing enzyme towards RIP1 (Wertz et al, 2004). RIP1 ubiquitination is 
also regulated by Triad3a (Fearns et al, 2006), Cezanne (Enesa et al, 2008) and CYLD 
(Wright et al, 2007) which all serve to inhibit NFκB. From these studies it is evident 
that RIP1 is a central target in the inhibition of the TNF-α signal. To this end it 
seemed appropriate to investigate if hECSIT, a novel E3 ligase/DUB enzyme, plays a 
regulatory role in the TNF-α pathway. The function of murine ECSIT has been 
previously demonstrated not to be involved in the regulation of TNF-α signalling. 
However the emergence of hECSIT being functionally different to its murine 
orthologue in TLR/IL-1R signalling prompted us to investigate other pathways 
activated during innate immune signalling. During TLR/IL-1R signalling hECSIT 
becomes activated via processing into an active form. This processed form is induced 
by the co-operative kinase activity of TAK1 and the protease activity of caspase 8, 2 
proteins which are critical in the activation of NFκB and induction of apoptosis in the 
TNF-α pathway. Following on from our study in TLR/IL-1R signalling we decided to 
investigate the role of ECSIT and the processed subunit in the TNF-α pathway 
utilizing siRNA/shRNA methods in conjunction with our humanised animal model. 
As discussed mECSIT has been shown not to function in the TNF pathway. However 
no role for hECSIT in TNF signaling has been reported. This chapter aimed to 
characterize the role of hECSIT in the TNF-α pathway and to investigate the 
mechanistic basis of any such regulatory effects.   
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5.2 Results  
5.2.1 hECSIT negatively regulates TNF-α induced NFκB activation and 
Apoptosis  
Previous reports had indicated that mECSIT failed to play a role in the TNF pathway. 
To investigate the potential regulatory role of hECSIT in TNF-α signalling an initial 
combination of siRNA and over-expression studies in HEK293 cells were used.  Co-
transfection of an NFκB-dependent luciferase reporter construct with control siRNA 
or hECSIT-specific siRNA to suppress hECSIT expression resulted in enhanced 
NFκB activation in response to TNF-α (Figure 5.1A). To analyse this further hECSIT 
or mECSIT expression constructs were co-transfected with an NFκB-dependent 
luciferase reporter construct. Over-expression of hECSIT inhibited TNF-α induced 
NFκB activation whereas mECSIT promoted the activation of NFκB (Figure 5.1B) 
 To further analyse the role of hECSIT in regulating this pathway the HeLa cell 
system was used, a cell line well documented for potent TNF-α responses. HeLa cells 
were transfected with hECSIT specific siRNA. Knockdown was confirmed at a 
protein and mRNA level (Figure 5.2B, C). Activation of NFκB by TNF-α promotes 
the production of cytokines such as IL-6 and IL-8. Knockdown of hECSIT in HeLa 
cells enhanced the production of IL-6 after TNF-α treatment, as measured by ELISA 
(Figure 5.2C). This was further confirmed at an mRNA level by quantitative RT-
PCR(Figure 5.3). The regulatory of hECSIT on TNF-α signalling was also assessed in 
primary MEF cells where mECSIT had been replaced with hECSIT. Replacing 
mECSIT with hECSIT resulted in decreased levels of IL-6 and KC in response to 
TNF-α (Figure 5.4). These data indicated that hECSIT has the capacity to negatively 
regulate TNF-induced expression of pro-inflammatory genes. To probe the target for 
such a regulatory role, the effects of hECSIT knockdown on TNF induced 
intracellular signalling were examined. siRNA-mediated suppression of hECSIT 
expression in HeLa cells resulted in increased levels of phosphorylated TAK1, IKK 
and IκB-α in response to TNF-α relative to cells transfected with control siRNA 
(Figure 5.5). This was also confirmed in U373 cells in which shRNA-mediated 
knockdown of hECSIT resulted in enhanced TNF-induced phosphorylation of TAK1, 
IKK and IκB-α, the latter being coincident with prolonged degradation of IκB (Figure 
5.6). TNF-α is also a potent activator the MAP kinases P38 and JNK and whilst 
suppression of hECSIT in HeLa cells failed to enhance TNF-α induced 
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phosphorylation of p38, reduced levels of hECSIT were associated  with modest 
enhancement of TNF-induced phosphorylation of JNK (Figure 5.7) 
In addition to its widely characterised role in activating NFκB, TNF is also 
well known to regulate various forms of cell death. Again the HeLa cell and U373 cell 
systems were used in conjunction with siRNA and shRNA-mediated knockdown of 
hECSIT to assess it potential regulatory role in TNF-α induced apoptosis. TNF is 
cytoprotective under circumstances in which it activates NFκB to induce anti-
apoptotic genes. However in the presence of protein synthesis inhibitors, like 
cyclohexamide, these anti-apoptotic genes are not expressed leading to caspase-
mediated activation of the apoptotic programme. Thus treatment of U373 cells with 
TNF-α and cyclohexamide caused the cells to become rounded and detach from the 
cell culture plate and this was associated with increased apoptosis as measured by 
increases cleavage of PARP (Fig. 5.8A). However the number of rounded and 
detached cells and levels of cleaved PARP increased when hECSIT expression was 
suppressed by hECSIT specific shRNA (Figure 5.8A). This was further confirmed in 
HeLa cells where reduced expression of hECSIT led to increased cleavage of PARP 
in response to co-treatment of TNF-α and cyclohexamide. Furthermore an increase in 
RIP1 ubiquitination was also observed (Figure 5.8B). 
The above findings, utilizing independent approaches to suppress hECSIT 
function in different cell lines in combination with a murine model to address the 
functional difference between hECSIT and its murine orthologue, provide strong 
evidence to suggest that hECSIT plays a key role in regulating the various signalling 
pathways that are triggered by TNF-α. 
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Figure 5.1 Differential effects of hECSIT and mECSIT on TNF induced activation of  NFκB  
 
(A) HEK293 cells were co-transfected with NFκB firefly luciferase reporter construct (80ng), TK 
renilla (20ng) and hECSIT specific siRNA or Lamin control siRNA (10nM).  24 hrs post transfection 
the cells were treated with TNF-α (50ng) for a further 24 hr. Cell lysates were generated 48 hrs after 
transfection and assayed for firefly luciferase and renilla luciferase activity. Results represent mean +/- 
SD of triplicate determinations and is an average of 3 independent experiments. (B) HEK293 cells were 
co-transfected with NFκB firefly luciferase reporter construct (80ng), TK renilla (20ng) and myc-
tagged hECSIT or mECSIT (100ng). Empty Vector (EV) pcDNA3.1 was used to normalise total 
amount of DNA whilst TK renilla was used to normalise for transfection efficiency. 24hr post-
transfection the cells were treated with TNF-α (50ng). Cell lysates were generated the following day 
and assayed for firefly luciferase activity. Data shown represents the mean of 3 independent 
experiments. *p< 0.05. 
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Figure 5.2 hECSIT knockdown enhances TNF induced expression of  IL-6 
 
U373 Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hours 
after transfection cells were stimulated with TNF-α (50ng/ml) for 24 hrs. (A) Media from Non-treated 
and TNF treated cells were analysed for IL-6 levels by ELISA. Data shown represents the mean of 3 
independent experiments. **p< 0.01. (B) Cell lysates were probed for expression levels of hECSIT and 
β-Actin. (C)  RNA was extracted 48 hrs post-transfection and analysed by quantitative RT-PCR for 
levels of hECSIT mRNA. 
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Figure 5.3 hECSIT knockdown enhances TNF induced IL-6 and IL-8 mRNA 
 
HeLa Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hrs 
after transfection cells were stimulated with TNF-α (50ng/ml) for 6 hrs. (A,B) mRNA expression levels 
of IL-6 and IL-8 were measured by quantitative RT-PCR and expressed relative to expression levels in 
unstimulated control siRNA cells. Data represents the average of 3 independent experiments; p<0.01. 
(C) mRNA expression levels of hECSIT were measured my quantitative RT-PCR. 
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Figure 5.4 Replacement of Ecsit with ECSIT inhibits TNF induced production of IL-6 and KC 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with murine TNF-α 
(25ng/ml) for 24 hrs. Media from non-treated and treated cells were assayed for levels of IL-6 (A) and 
KC (B) by ELISA. Data represent the mean of 3 independent experiments; p<0.05. 
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Figure 5.5 hECSIT knockdown enhances TNF induced NFκB activation in HeLa cells  
 
HeLa cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm) for 48 hrs. 
Cells were then treated with TNF-α (50ng/ml) for the indicated times. Cells lysates were prepared and 
separated by SDS-PAGE followed by Immunoblotting for phosphorylated and total levels of TAK1, 
IκB-α and IKK-α. Lysates were also probed for levels of ECSIT and β-Actin to check knockdown and 
equal loading. 
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Figure 5.6 Knockdown of hECSIT enhances TNF induced NFκB activation in U373 cells 
 
U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT specific 
shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably integrated 
shRNA constructs. Selected cells were treated with TNF-α (50ng/ml) for the indicated times. Cell 
lysates were prepared separated by SDS-PAGE followed by Immunoblotting for phosphorylated and 
total levels of TAK1, IκB-α and IKK-α. Lysates were also probed for levels of ECSIT and β-Actin to 
check knockdown and equal loading. 
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Figure 5.7 Knockdown of hECSIT enhances TNF induced JNK activation 
 
U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT specific 
shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably integrated 
shRNA constructs. Selected cells were treated with TNF-α (50ng/ml) for the indicated times. Cell 
lysates were prepared separated by SDS-PAGE followed by Immunoblotting for phosphorylated and 
total levels of P38 and JNK. Lysates were also probed for levels of ECSIT and β-Actin to check 
knockdown and equal loading. 
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Figure 5.8 Knockdown of hECSIT sensitizes cells to TNF-α induced apoptosis  
 
(A) U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT 
specific shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably 
integrated shRNA constructs. Selected cells were treated with or without TNF-α (50ng/ml) and CHX 
(10µg/ml) for the indicated times. Cells were then photographed using a phase contrast microscope 
(20µm). (B) HeLa Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA 
(30nm). 48 hrs after transfection cells were then treated with TNF-α (50ng/ml) and CHX (10µG/ml) for 
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the indicated times. Cell lysates were generated and separated by SDS-PAGE and were probed by 
Immunoblotting for expression levels of RIP1, cleaved PARP, ECSIT and β-Actin. 
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5.2.2 hECSIT interacts with RIP1  
 
Given the ability of hECSIT to regulate TNF-α induced NFκB activation, we next 
characterized the ability of hECSIT to interact with the individual protein components 
of the TNF-α pathway.  RIP1 acts as a central signalling adaptor in the TNF pathway 
and regulates both the NFκB and apoptotic arms of the pathway. RIP1 function is 
heavily regulated by its ubiquitination status. Given the earlier data indicating that 
hECSIT contains both E3 ligase and DUB activity, RIP1 was examined as a potential 
target for hECSIT. Co-immunoprecipitation studies were carried out to investigate the 
possible interaction between hECSIT and RIP1. U373 cells were treated with TNF-α 
and immunoprecipitated with anti-ECSIT antibody. The subsequent precipitate was 
then analyzed for the presence of co-precipitated RIP1 by western blotting. TNF-α 
promoted the interaction of RIP1 with hECSIT in a time-dependent manner, as 
demonstrated by the co-immunoprecipitation of the two proteins (Figure 5.9A). 
Treatment of HEK293 cells also resulted in the co-immunoprecipitation of hECSIT 
with RIP1 in a time dependent manner (Figure 5.9B). The interaction of RIP1 with 
hECSIT and mECSIT was also investigated after transient transfection in HEK293T 
cells. Myc-tagged hECSIT or mECSIT was co-expressed with FLAG-tagged RIP1, 
immunoprecipitated with anti-myc antibody and probed for the presence of co-
precipitated FLAG-tagged RIP1. As shown in Figure 5.9C both hECSIT and mECSIT 
interacted with RIP1. These data suggests the regulatory role of hECSIT on TNF-α 
induced NFκB activation is achieved by targeting RIP1. 
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Figure 5.9 hECSIT Interacts with RIP1 
 
HeLa cells (A), HEK293 cells (B) were treated with TNF-α (50ng/ml) for the indicated times. Cell 
lysates were generated and a sample for whole cell lysates analysis was retained. The remaining lysates 
was immunoprecipitated using an anti-ECSIT antibody. Immunoprecipitates were subsequently 
assayed for co-precipitated RIP1 and ECSIT. The expression levels of ECSIT and RIP1 in whole cell 
lysates (Input) were also assessed by western blotting. (C) HEK293 cells were co-transfected with 
Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT (1µg) or myc-tagged mECSIT (1µg) with or 
without FLAG-tagged RIP1 (1µg). EV was used to normalize total amount of DNA transfected. 24 hrs 
post-transfection cell lysates were generated and immunoprecipitated with anti-myc antibody. 
Immunoprecipitates were then subject to SDS-PAGE and subsequently to western blotting using anti-
FLAG antibody. Whole cell lysates were also analyzed by western blotting using anti-FLAG and anti-
Myc antibodies to confirm expression of RIP1 and ECSIT constructs, respectively. Results are 
representative of 3 independent experiments. 
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4.2.3 hECSIT negatively regulates the ubiquitination of RIP1  
As hECSIT interacts with RIP1 in response to TNF-α we next probed the functional 
consequence of this interaction by measuring the ubiquitination of RIP1. We were 
especially interested in the ubiquitination of RIP1 given that it is prone to an array of 
ubiquitin modifications and is tightly regulated by a number of deubiquitinating 
enzymes. Given that hECSIT possesses both E3 ligase and DUB activity the effect of 
hECSIT on RIP1 ubiquitination was examined. Analysis of the effect of hECSIT and 
mECSIT on RIP1 ubiquitination was initially investigated in HEK293T cells by 
transient transfection. Myc-tagged hECSIT or mECSIT were co-transfected with 
FLAG-tagged RIP1 and HA-ubiquitin. Immunoprecipitated RIP1 was probed for 
ubiquitination using an anti-HA antibody. Expression of hECSIT resulted in inhibition 
of RIP1 ubiquitination whereas expression of mECSIT resulted in enhanced RIP1 
ubiquitination (Figure 5.10). This suggested hECSIT was negatively regulating the 
pathway at the level of ubiquitination. To investigate this effect at an endogenous 
level RIP1 ubiquitination was measured in cells where hECSIT expression was 
suppressed. Knockdown of hECSIT with hECSIT-specific siRNA resulted in 
increased ubiquitination of RIP1 in response to TNF-α in HEK293 cells (Figure 5.11). 
This was also observed in HeLa cells (Figure 5.12). To further validate the above 
conclusion that hECSIT knockdown enhanced TNF-induced RIP1 ubiquitination we 
used U373 cells stably expressing hECSIT specific shRNA to demonstrate the effect 
was independent of cell line or knockdown method. Knockdown of hECSIT in U373 
cells also showed an increase in RIP1 ubiquitination in response to TNF-α (Figure 
5.13). Since K63 linked polyubiquitination of RIP1 is usually associated with 
triggering of downstream activation of NFκB we especially focused on the potential 
of hECSIT to regulate K63-linked ubiquitination of RIP1. Knockdown of hECSIT in 
HeLa cells resulted in enhanced TNF-induced K63-linked ubiquitination of RIP1 and 
this is consistent with the earlier described augmentation of TNF-induced activation 
of NFκB under these conditions (Figure 5.14) 
 Given the differential effects of murine and human ECSIT in the TNF 
pathway we next characterised the ubiquitination of RIP1 in MEFs from WT mice and 
in ECSIT humanized mice. TNF induced ubiquitination of RIP1 in wild type MEFs 
but the efficacy of TNF was reduced in corresponding ECSIT humanised MEFs. 
Stimulation of ECSIT humanised MEF cells resulted in a decrease in RIP1 
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ubiquitination when compared to WT MEFs (Figure 5.15). In conjunction with the 
earlier cell line approaches these findings provides strong support for hECSIT acting 
as a novel regulator of RIP1 ubiquitination. As mentioned RIP1 is ubiquitinated by a 
number of E3 ligases such as TRAF2 and cIAP1. We assessed if hECSIT was capable 
of targeting any of these E3 ligases.  HEK293T cells were transiently transfected with 
myc-tagged hECSIT or mECSIT or FLAG-tagged TRAF2 or cIAP1. The latter 2 
proteins were immunoprecipitated using an anti-FLAG antibody and 
immuoprecipitates were probed for co-precipitated ECSIT by western blot. However 
both hECSIT and mECSIT did not interact with TRAF2 (Figure 5.16A) or cIAP1 
(Figure 5.16B) and thus hECSIT might act directly on RIP1 to effect its de-
ubiquitination. 
These findings, employing independent approaches to suppress hECSIT 
expression in different cell lines, over-expression studies and primary humanised cells 
provide strong evidence that hECSIT plays a key role in regulating RIP1 
ubiquitination in response to TNF-α. 
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Figure 5.10 Differential effects of hECSIT and mECSIT on RIP1 ubiquitination 
 
HEK293 cells were co-transfected with Empty vector (1µg), HA-Ubq (1µg), myc-tagged hECSIT 
(1µg) or myc-tagged mECSIT (1µg) with or without FLAG-tagged RIP1 (1µg). EV was used to 
normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were generated and 
immunoprecipitated using an anti-FLAG antibody. Immunoprecipitates were then subject to SDS-
PAGE and subsequently to western blotting using anti-HA antibody. Whole cell lysates were also 
analyzed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of RIP1 
and ECSIT constructs, respectively. Results are representative of 3 independent experiments. 
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Figure 5.11 Knockdown of hECSIT enhances TNF induced RIP1 ubiquitination in HEK293 cells 
 
HEK293 Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hrs 
after transfection cells were then treated with TNF-α (50ng/ml) for the indicated times. Cell lysates 
were generated and immunoprecipitated using anti-RIP1 antibody. The immunoprecipitate was then 
assayed for RIP1 ubiquitination and immunoprecipitated RIP1 by Immunoblotting for ubiquitin and 
RIP1 respectively. Expression levels of RIP1, ECSIT and β-Actin were also assessed in the input by 
western blotting. 
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Figure 5.12 Knockdown of hECSIT enhances TNF induced RIP1 ubiquitination in HeLa cells 
 
HeLa Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hrs 
after transfection cells were then treated with TNF-α (50ng/ml) for the indicated times. Cell lysates 
were generated and immunoprecipitated using anti-RIP1 antibody. The immunoprecipitate was then 
assayed for RIP1 ubiquitination and immunoprecipitated RIP1 by Immunoblotting for ubiquitin and 
RIP1 respectively. Expression levels of RIP1, ECSIT and β-Actin were also assessed in the input by 
western blotting. 
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Figure 5.13 Knockdown of hECSIT enhances TNF induced RIP1 ubiquitination in U373 cells 
 
U373 Cells were infected with Lentivirus containing constructs encoding control or hECSIT specific 
shRNA. Cells were grown in the presence of puromycin (8µg/ml) to select cells with stably integrated 
shRNA constructs. Selected cells were treated with TNF-α (50ng/ml) for the indicated times. Cell 
lysates were generated and immunoprecipitated using anti-RIP1 antibody. The immunoprecipitate was 
then assayed for RIP1 ubiquitination and immunoprecipitated RIP1 by Immunoblotting for ubiquitin 
and RIP1 respectively. Expression levels of RIP1, ECSIT and β-Actin were also assessed in the input 
by western blotting.. 
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Figure 5.14 Knockdown of hECSIT enhances TNF induced K63-linked ubiquitination of RIP1 
 
HeLa Cells were transfected with hECSIT specific siRNA (30nm) or Control siRNA (30nm). 48 hrs 
after transfection cells were then treated with TNF-α (50ng/ml) for the indicated times. Cell lysates 
were generated and immunoprecipitated using anti-K63 antibody. The immunoprecipitate was then 
assayed for K63- linked RIP1 ubiquitination and immunoprecipitated K63 ubiquitin chains by 
Immunoblotting for RIP and K63 respectively. Expression levels of RIP1, ECSIT and β-Actin were 
also assessed in the input by western blotting. 
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Figure 5.15 Replacement of Ecsit with ECSIT inhibits TNF induced RIP1 ubiquitination 
 
MEFs were isolated from WT and ECSIT +/+ (Hum) embryos and were treated with murine TNF-α 
(25ng/ml) for the indicated times. Cell lysates were generated and immunoprecipitated using anti-RIP1 
antibody. The immunoprecipitate was then assayed for RIP1 ubiquitination and immunoprecipitated 
RIP1 by Immunoblotting for Ubq and RIP1 respectively. Expression levels of RIP1, ECSIT and β-
Actin were also assessed in the input by western blotting. 
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Figure 5.16 hECSIT and mECSIT do not interact with TRAF2 and cIAP1  
 
HEK293 cells were co-transfected with Empty vector (EV) pcDNA3.1 (1µg), myc-tagged hECSIT 
(1µg) or myc-tagged mECSIT (1µg) with or without FLAG-tagged TRAF2 (1µg) (A) or cIAP1 (B). 
EV was used to normalize total amount of DNA transfected. 24 hrs post-transfection cell lysates were 
generated and immunoprecipitated with anti-myc antibody. Immunoprecipitates were then subject to 
SDS-PAGE and subsequently to western blotting using anti-FLAG antibody. Whole cell lysates were 
also analyzed by western blotting using anti-FLAG and anti-Myc antibodies to confirm expression of 
TRAF2 and ECSIT constructs, respectively. Results are representative of 3 independent experiments. 
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4.2.4 hECSIT is processed in response to TNF-α  
We next addressed the potential mechanism by which hECSIT was mediating its 
regulatory effect on RIP1 ubiquitination. We have earlier shown data that suggest that 
in context of TLR4 and IL-1 signalling, hECSIT is processed in a TAK1 kinase-
dependent manner to produce a C terminal fragment(s) with DUB activity. We 
assessed if hECSIT undergoes similar TAK1-dependent processing in response to 
TNF-α. Thus hECSIT protein expression was assayed by Western blotting in lysates 
from cells that had been treated with TNF-α in the absence or presence of the TAK1 
inhibitor 5Z-7-oxozeanol and the caspase inhibitor Z-VAD-FMK. Treatment of THP1 
cells with TNF-α resulted in the appearance of fast migrating forms of hECSIT 
consistent with hECSIT processing (Figure 5.17A). However upon pre-treatment of 
these cells with 5Z-7-oxozeanol or Z-VAD-FMK, the levels of processed hECSIT in 
response to TNF were greatly decreased (Figure 5.17A). Since under conditions of 
protein synthesis blockade, TNF-α can induce apoptosis we were also keen to 
characterise hECSIT processing under conditions of TNF induced apoptosis.  Co-
treatment of HeLa cells with TNF-α and CHX resulted in increased processing of 
hECSIT when compared to TNF-α treatment alone. However pre-treatment with 5Z-
7-oxozeanol also resulted in decreased levels of processed hECSIT during apoptosis. 
The latter was confirmed by increased levels of cleaved PARP (Figure 5.17B). As 
shown previously hECSIT interacts with TAK1 in response to LPS and IL-1.We thus 
probed the association of hECSIT with TAK1 in response to TNF-α. Using co-
immunoprecipitation hECSIT was found to associate with TAK1 in response to TNF-
α in both U373 (Figure 5.18A) and HeLa cells (Figure 5.18B). Interestingly the co-
precipitated forms of TAK1 manifested as multiple bands and a laddering pattern 
potentially indicative of varying levels of ubiquitination and the possibility that 
ubiquitinated forms of TAK1 interact with hECSIT.  In order to determine the 
functional consequence of hECSIT processing in response to TNF-α a truncated 
expression construct encoding processed  hECSIT was used as a model to analyse the 
inhibitory function of processed hECSIT in TNF signalling. NFκB reporter assays 
reveled that in response to TNF-α  the C-terminus of hECSIT was more inhibitory 
than full length hECSIT (Figure 5.19A). This was further confirmed by a semi-rescue 
approach whereby HEK293T cells knocked down with hECSIT specific siRNA 
followed by transfection of the C-terminus or N-terminus revealed that only the C-
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terminus, representing the processed form could rescue the inhibitory effect (Figure 
5.19B) 
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Figure 5.17 TNF-α promotes the processing of ECSIT in a TAK1 and Caspase dependent manner 
 
(A) THP1 cells were pre-treated for 2 hrs with vehicle DMSO and 5z-7-oxozeanol (20Mm) or Z-VAD-
FMK (10Mm).  Cells were then treated with TNF-α (50ng/ml) for the indicated times. Cell lysates were 
generated and subjected to SDS-PAGE and probed by Immunoblotting for expression levels of ECSIT, 
IκB-α and β-Actin. Processed ECSIT is indicated by arrows. (B) HeLa cells were pre-treated for 2 hrs 
with vehicle DMSO or 5z-7-oxozeanol (20mM). Cells were then treated with TNF-α (50ng/ml) with or 
without cyclohexamide (10ug/ml) for the indicated times.  Cell lysates were generated and subjected to 
SDS-PAGE and probed by Immunoblotting for expression levels of ECSIT, cleaved PARP and β-
Actin. Processed ECSIT is indicated by arrows.  
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Figure 5.18 hECSIT interacts with TAK1 in response to TNF-a 
 
U373 cells (A) and HeLa cells (B) were treated with TNF-α (50ng/ml) for the indicated times. Cell 
lysates were generated and a sample for whole cell lysates analysis was retained. The remaining lysates 
was immunoprecipitated using an anti-ECSIT antibody. Immunoprecipitates were subsequently 
assayed for co-precipitated RIP1 and ECSIT. The expression levels of ECSIT and RIP1 in whole cell 
lysates were also assessed by western blotting. 
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Figure 5.19 The C-terminus of hECSIT inhibits TNF induced NFκB activation 
 
 (A) HEK293 cells were co-transfected with NFκB firefly luciferase reporter construct (80ng), TK 
renilla (20ng) and myc-tagged hECSIT or mECSIT or the C-terminal or N-terminal of hECSIT 
(100ng). Empty Vector (EV) pcDNA3.1 was used to normalise total amount of DNA whilst TK renilla 
was used to normalise for transfection efficiency. 24hr post-transfection the cells were treated with 
TNF-α (50ng). Cell lysates were generated the following day and assayed for firefly luciferase activity. 
(B) HEK293 cells were co-transfected with NFκB firefly luciferase reporter construct (80ng), TK 
renilla (20ng) and hECSIT specific siRNA or Lamin control siRNA (10nM).  24 hrs post transfection 
the cells were transfected with EV, C-terminal or N-terminal hECSIT.24 hours later cells were treated 
with TNF-α for 6 hrs. Cell lysates were then generated and assayed for firefly luciferase and renilla. 
luciferase activity. Results represent mean +/- SD of triplicate determinations and is a representative of 
3 independent experiments. 
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Figure 5.20 Schematic representation of hECSIT’s regulatory effect in TNF 
signalling  
 
Activation of the TNF pathway results in the ubiquitination of RIP1 for the downstream activation of 
NFκB. Processing of hECSIT results in an active deubiquitinating enzyme which targets RIP1 for  
deubiquitination to inhibit NFκB. 
 
 
 
 
 
 
 
Chapter 5 Results 
_____________________________________________________________________ 
181 
 
5.3 Discussion 
 
This study highlights a critical role for hECSIT in the regulation of TNF-α induced 
NFκB activation and apoptosis. The initial suggestion of such a role arose from our 
cell line studies in which hECSIT knockdown augmented NFκB activation and 
sensitised cells to apoptosis in response to TNF-α. The physiological relevance of 
hECSIT in the TNF-α pathway was confirmed by the generation of humanised mice, 
where mECSIT was replaced with hECSIT, with cells from these mice displaying 
reduced activation of NFκB in response to TNF-α relative to wild type cells. 
Furthermore the differential effects of murine and human ECSIT function were also 
seen in TNF signalling. 
 hECSIT was initially assessed for its ability to regulate NFκB in response to 
TNF-α. mECSIT and hECSIT had opposing effects on NFκB where the latter strongly 
inhibited the TNF-α pathway. The murine orthologue mECSIT has been previously 
shown not to function in TNF signalling (Kopp et al, 1999) however our data would 
suggest a positive role for mECSIT in the pathway, a role consistent with functions in 
other pathways.  Knockdown of hECSIT resulted in an enhanced NFκB response in 
cell lines as demonstrated by higher levels of cytokine production and 
phosphorylation of p-IκB-α and pIKK-β. This effect on NFκB was also observed in 
our animal model when mECSIT was replaced by hECSIT.  Given that NFκB acts to 
counter regulate the apoptotic pathway by the induction of anti-apoptotic proteins it 
was of interest to examine if hECSIT could exert its regulatory effects on NFκB by 
affecting apoptosis. However the increased levels of apoptosis that are observed in 
hECSIT-knockdown cells cannot be attributed to impaired NFκB function and the 
augmented NFκB response in these cells does not provide any protective effect 
against TNF-α induced apoptosis. A similar effect has been shown in A20 deficient 
cells which have uncontrolled NFκB response whilst also being highly sensitive to an 
apoptotic stimulus (Shembade et al, 2009). Polymorphisms in A20 have also been 
linked to many inflammatory autoimmune diseases in humans (Coornaert et al, 2008) 
and expression of A20 is also upregulated in many forms of cancer and has been 
shown to have an important survival function in breast cancer (Vendrell et al, 2007). 
A20 has also been identified as a susceptibility locus for rheumatoid arthritis, SLE, 
type 1 diabetes, inflammatory bowel disease, celiac disease, psoriasis and coronary 
heart disease (Harhaj and Dixit, 2012). Given the similarities in function between A20 
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and hECSIT it would be interesting to investigate the expression levels of hECSIT in 
tumour cells and tissue from patients from the aforementioned conditions which 
would perhaps help explain the discrepancy between augmented NFκB activation and 
increased cell death when hECSIT is absent. However further analysis of the 
apoptotic response will need to be assessed and quantified  in our knockdown systems 
and  humanised model before a definitive role for  hECSIT can be fully established in 
the apoptotic arm of the TNF-α pathway. 
In order to further examine the negative role of hECSIT in the TNF pathway 
we looked for hECSIT interaction partners in response to TNF-α. We show that 
hECSIT can interact with RIP1 in a TNF dependent manner resulting in the decreased 
ubiquitination of RIP1 as evidenced by the complementary approaches of hECSIT 
knockdown and overexpression. Furthermore reduced levels of RIP1 ubiquitination in 
response to TNF-α were also observed in cells from our humanised mice. The 
ubiquitination of RIP1 by E3 ligases, such as TRAF2 and cIAP1, has traditionally 
been associated with promoting the activation of NFκB and blocking DISC formation 
by inhibiting the binding of RIP1 to FADD and Caspase 8 (Bertrand et al, 2008). We 
thus considered the possibility that the deubiquitination of RIP1 by hECSIT may 
allow RIP1 to interact with caspase 8 and FADD to promote apoptosis. However 
knockdown of hECSIT in HeLa and U373 cells resulted in increased levels of 
apoptosis in response to TNF-α and CHX indicating a role for hECSIT in suppressing 
apoptosis. As well as deubiquitination A20 can also mediate the K48-linked 
ubiquitination of RIP1 following TNF activation. As hECSIT has both E3 and DUB 
activity it is also possible hECSIT regulates RIP1 via K48 ubiquitination or another 
obscure linkage. Furthermore it is also possible that like A20, hECSIT has the ability 
to interchange K63 linked ubiquitin chains for K48 linked ubiquitin chains. A more 
comprehensive screen of E2 enzymes in vitro may give a better understanding for the 
types of ubiquitin chains hECSIT can produce and regulate. However as expression or 
knockdown of hECSIT had no effects on the expression levels of RIP1 it is more 
likely deubiquitination. RIP1 is subject to multiple forms of ubiquitination and 
regulators such as A20 and CYLD control these modifications via ubiquitination and 
deubiquitination. Like these regulators hECSIT exerts its regulatory effect via the 
deubiquitination of RIP1 however a direct catalytic residue in the sequence of 
hECSIT will need to be determined in order to confirm this DUB effect and eliminate 
the possibility of another mechanism. 
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In the previous chapter hECSIT was shown to mediate its regulatory effects in 
TLR signalling in a manner  involving TRAF6, TAK1 and caspase 8 resulting in the 
possible phosphorylation, ubiquitination and processing of hECSIT into a functional 
inhibitory protein. The formation of such a complex in the TNF pathway is not 
unprecedented and many examples of similar regulatory complexes in this signalling 
pathway have been described. Such studies have highlighted a number of regulatory 
complexes in the TNF-α pathway involving the deubiquitinating enzymes A20 
(Shembade et al, 2009) and CYLD (Ahmed et al, 2011).  A20 functions in the context 
of a multi-protein complex consisting of A20, TAX1BP1 and the E3 ligases Itch and 
RNF11 (Harhaj and Dixit, 2012) whose interactions are formed through conserved 
PPxY and WW domains. CYLD also utilises the E3 ligase Itch through conserved 
PPxY domains to mediate the deubiquitination and subsequent K48-linked 
ubiquitination of TAK1 (Ahmed et al, 2011). The assembly of the A20 complex is 
dependent on a critical phosphorylation step whereby IKK-α directly phosphorylates 
TAX1BP1. In a similar manner hECSIT also forms a complex with TAK1 and 
caspase 8 and undergoes phosphorylation and processing during TNF-α signalling. 
While we propose hECSIT is phosphorylated in response to TNF-α we were unable to 
show this at an endogenous level owing possibly to cell responses and relative 
abundance. However as phosphorylation might be a pre-requisite for hECSIT 
processing, lower levels of TNF-α induced processing are seen in the presence of a 
TAK1 inhibitor. Identification of the hECSIT phosphorylation sites and generation of 
a phospho antibody will allow us to further study this modification in a ligand 
dependent manner. A similar result was observed with the caspase 8 inhibitor Z-
VAD-FMK. Caspase 8 has been widely studied in the TNF-α pathway and has 
regulatory functions in apoptosis, necrosis but also functions in the RIG-I pathway 
(Rajput et al, 2011). Caspase 8 cleaves RIP1 during apoptosis and also inhibits 
necrosis by blocking the interaction of RIP1 and RIP3. The protease activity of 
caspase 8 also extends to the RIG-I pathway where processing of RIP1 by caspase 8 
inhibits pathway activation and converts RIP1 into an inhibitor. As previously shown 
the catalytic mutant is unable to process hECSIT. Defining A direct caspase 8 
processing site in the hECSIT sequence will give a greater understanding of the 
interaction between Caspase 8 and hECSIT during TNF signalling.  
In summary the present findings highlight hECSIT as a new regulator of TNF-
α signalling and strongly indicate it may play an important role in terminating both the 
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NFκB and apoptotic response to TNF-α. The present study also further confirms a key 
functional difference between two evolutionary conserved proteins, hECSIT and 
mECSIT and sheds more light on the complex system of TNF-α signalling by 
proposing a novel regulatory complex within the pathway. Whilst most studies have 
focused on the role of ECSIT in TLR mitochondrial signalling this present study 
extends the role of ECSIT beyond these pathways. 
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6.1 Concluding Remarks 
 
The current study has identified hECSIT as a negative regulator of TLR and TNF-α 
signalling. Through the targeting of TRAF6, TRAF3 and RIP1, hECSIT utilises its 
DUB and E3 activity to attenuate innate immune signalling pathways. In addition to 
its dual ubiquitin editing function hECSIT under-goes a unique activation step 
through the co-operation of 3 multi-functional signalling intermediates, TAK1, 
TRAF6, and Caspase 8 which results in its processing. Whilst ECSIT’s regulatory 
function centres on ubiquitination of its targets, its E3 ligase function and DUB 
function add additional complexity to elucidating its complete role. As discussed 
TLR4 signalling results in the processing of hECSIT into an active DUB enzyme 
which can negatively regulate TRAF6. Similarly TNF signalling also promotes 
processing of hECSIT in order to regulate RIP1 ubiquitination. Conversely during 
anti-viral responses hECSIT directly ubiquitinates TRAF3 resulting in inhibition of 
the type 1 IFN response. Thus far in this study we have been unable to identify a 
direct catalytic domain of hECSIT to explain these dual roles; however truncation 
experiments have demonstrated that the E3 ligase domain and DUB domain are both 
found in the C-terminal section of the protein. Given that hECSIT contains an N-
terminal mitochondrial localisation sequence is possible that processing of hECSIT 
allows translocation of hECSIT to the cytoplasm where it can engage with its targets. 
Further work characterising its subcellular localisation and more specifically 
expression levels within different organs will allow us to understand the definitive in 
vivo role of hECSIT. Whilst no large scale studies have been carried out in patient 
disease cohorts, some screening studies have identified novel interactions for ECSIT. 
The complexity of ECSIT function has been demonstrated by the lethal 
phenotype and the evolutionary functional difference we have shown between 
hECSIT and mECSIT. These complexities have slowed down the elucidation of the 
exact physiological role of ECSIT. The subcellular localisation of ECSIT has to date 
been the focus of the majority of ECSIT based studies. Many studies analysing the 
role of ECSIT have focussed on mitochondrial function. The mitochondrion is the 
energy centre of the cell and many diseases have impaired mitochondrial function. 
Parkinson’s disease, diabetes, ataxia, multiple sclerosis and Alzheimer’s disease all 
have impaired mitochondrial function. The lethal phenotype of the ECSIT mouse and 
the inability of hECSIT to completely compensate for the loss of mECSIT is perhaps 
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testament to the function of the mitochondria and the importance of ECSIT in 
development and the life cycle of the mitochondria. A recent study has flagged ECSIT 
as a potential dysregulated protein in the onset of Alzheimer’s disease. Although an 
altered ECSIT gene expression has not been reported in AD patients to date, its 
expression is significantly up-regulated in Huntington's patients (Borovecki et al, 
2005). This gives further support to the hypothesis that ECSIT might modulate the 
energetic requirements upon inflammatory response by regulating the rate of complex 
I synthesis (Vogel et al, 2007). Analysis of the expression levels of ECSIT in patients 
suffering from these diseases and potential protein interaction within these pathways 
would possibly highlight novel roles for ECSIT in the cell and lead to the targeting of 
ECSIT therapeutically. 
TLR signalling is dependent on negative regulators to prevent excessive 
signalling and cytokine production. Exacerbated immune system activation has been 
attributed to cancer progression and auto-immune diseases such as Lupus. It will be of 
interest to identify possible SNPs and loss of function mutations in the hECSIT gene 
from patients suffering from these diseases. Furthermore utilisation of our humanised 
animal model to study the exact roles of hECSIT and mECSIT in these disease states 
will give us a greater understanding of ECSIT’s physiological role.   
The presented findings thus highlight a new novel regulator of innate immune 
signalling. Activation of these pathways promotes an auto-regulatory mechanism 
which results in the processing of hECSIT into an active protein. Through the 
targeting of TRAF6, RIP1 and TRAF3 hECSIT can attenuate signalling via its dual 
ubiquitin editing function. These effects promote hECSIT as a potential therapeutic 
target for diseases caused by dysregulated innate immune signalling pathways. 
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